image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
4db2732eef4b8d962cebf218a5ecb13b48ee4bc3c57dfcf4ba194b6695a00a6d.png
|
complex
|
<table><tr><td></td><td colspan="4">Mean percentage density (95% confidence interval)<sup>a,b</sup></td></tr><tr><td>Chemical</td><td>Nondetected</td><td>Below median<sup>d</sup></td><td>Above median<sup>d</sup></td><td><i>P</i><sub>trend</sub><sup>c</sup></td></tr><tr><td></td><td><i>n </i>= 225</td><td><i>n </i>= 19</td><td><i>n </i>= 18</td><td></td></tr><tr><td>Mono-ethyl phthalate</td><td>13.1 (11.9, 14.3)</td><td>13.0 (9.1, 17.7)</td><td>18.2 (13.4, 23.7)</td><td>0.07</td></tr><tr><td></td><td><i>n </i>= 88</td><td><i>n </i>= 88</td><td><i>n </i>= 87</td><td></td></tr><tr><td>Propyl paraben</td><td>12.7 (10.9, 14.8)</td><td>13.3 (11.4, 15.4)</td><td>13.9 (12.0, 16.1)</td><td>0.41</td></tr><tr><td></td><td><i>n </i>= 121</td><td><i>n </i>= 72</td><td><i>n </i>= 71</td><td></td></tr><tr><td>Butyl paraben</td><td>14.4 (12.7, 16.3)</td><td>12.4 (10.4, 14.7)</td><td>12.4 (10.4, 14.7)</td><td>0.13</td></tr><tr><td></td><td><i>n </i>= 228</td><td><i>n </i>= 19</td><td><i>n </i>= 16</td><td></td></tr><tr><td>Octylphenol</td><td>13.5 (12.3, 14.7)</td><td>11.3 (7.6, 15.6)</td><td>14.5 (9.9, 19.9)</td><td>0.93</td></tr><tr><td></td><td><i>n </i>= 155</td><td><i>n </i>= 55</td><td><i>n </i>= 54</td><td></td></tr><tr><td>Nonylphenol</td><td>14.1 (12.6, 15.6)</td><td>12.1 (9.8, 14.7)</td><td>12.5 (10.1, 15.1)</td><td>0.21</td></tr><tr><td></td><td><i>n </i>= 193</td><td><i>n </i>= 35</td><td><i>n </i>= 34</td><td></td></tr><tr><td>Bisphenol A</td><td>12.6 (11.4, 14.0)</td><td>13.7 (10.7, 17.1)</td><td>17.6 (14.1, 21.5)</td><td>0.01</td></tr></table>
|
952491fbe388a9568e1174ee38203ba059127841afb1dbb612212c780380ccfd.png
|
complex
|
<table><tr><td></td><td colspan="2">Intra-assay</td><td colspan="2">Inter-assay</td></tr><tr><td>Specimens</td><td>Mean (U/L)</td><td>CV (%)</td><td>Mean (U/L)</td><td>CV (%)</td></tr><tr><td>Low</td><td>40.3</td><td>2.00</td><td>33.4</td><td>2.60</td></tr><tr><td>Medium</td><td>160.0</td><td>2.27</td><td>130.0</td><td>1.38</td></tr><tr><td>High</td><td>765.7</td><td>1.27</td><td>656.3</td><td>3.47</td></tr></table>
|
9bc188d43376affc481c570d1e95486797329b381bf5b21c7d9299e91a6f97f2.png
|
complex
|
<table><tr><td></td><td colspan="2">Linear probability models</td><td colspan="2">Maximum likelihood proceduresb</td></tr><tr><td></td><td>OLS</td><td>2SLS</td><td>Probit</td><td>Bivariate probit</td></tr><tr><td>Land rental</td><td>0.365 (0.142) <sup>**</sup></td><td>0.135 (0.033) <sup>**</sup></td><td>0.277 (0.063) <sup>**</sup></td><td>0.151 (0.038) <sup>**</sup></td></tr><tr><td>Plot size</td><td>0.033 (0.007) <sup>**</sup></td><td>0.040 (0.011) <sup>**</sup></td><td>0.044 (0.014) <sup>**</sup></td><td>0.044 (0.009) <sup>**</sup></td></tr><tr><td>Soil fertility</td><td>−0.037 (0.039)</td><td>−0.016 (0.023)</td><td>−0.012 (0.030)</td><td>−0.021 (0.041)</td></tr><tr><td>Soil slope</td><td>0.039 (0.020) <sup>*</sup></td><td>0.033 (0.021)</td><td>0.030 (0.025)</td><td>0.015 (0.025)</td></tr><tr><td>Soil depth</td><td>0.067 (0.019) <sup>**</sup></td><td>0.060 (0.017) <sup>**</sup></td><td>0.079 (0.020) <sup>**</sup></td><td>0.073 (0.022) <sup>**</sup></td></tr><tr><td>Dist. from home</td><td>0.000 (0.001)</td><td>0.001 (0.000)</td><td>0.000 (0.000)</td><td>0.001 (0.001)</td></tr><tr><td>Cropping season</td><td>0.122 (0.036) <sup>**</sup></td><td>0.141 (0.042) <sup>**</sup></td><td>0.154 (0.051) <sup>**</sup></td><td>0.136 (0.039) <sup>**</sup></td></tr><tr><td>Household size</td><td>0.012 (0.008)</td><td>0.006 (0.005)</td><td>0.002 (0.005)</td><td>0.006 (0.004)</td></tr><tr><td>Total asset</td><td>−0.000 (0.000)</td><td>0.000 (0.000)</td><td>−0.000 (0.000)</td><td>0.000 (0.000)</td></tr><tr><td>Head age</td><td>−0.001 (0.001)</td><td>−0.002 (0.001)</td><td>−0.002 (0.001) <sup>**</sup></td><td>−0.002 (0.001)</td></tr><tr><td>Head gender</td><td>0.062 (0.055)</td><td>0.033 (0.057)</td><td>0.075 (0.066)</td><td>0.096 (0.062)</td></tr><tr><td>Head marital status</td><td>0.041 (0.061)</td><td>0.050 (0.072)</td><td>0.070 (0.041)</td><td>0.050 (0.034)</td></tr><tr><td>Head education</td><td>0.002 (0.003)</td><td>0.003 (0.002) <sup>*</sup></td><td>0.004 (0.003)</td><td>0.003 (0.002) <sup>*</sup></td></tr><tr><td>Main market dist.</td><td>−0.002 (0.000) <sup>**</sup></td><td>−0.002 (0.000) <sup>**</sup></td><td>−0.002 (0.000) <sup>**</sup></td><td>−0.002 (0.000) <sup>**</sup></td></tr><tr><td>Extension office dist.</td><td>0.000 (0.000)</td><td>−0.001 (0.000)</td><td>−0.001 (0.000)</td><td>−0.000 (0.000)</td></tr><tr><td>Total land holding</td><td>−0.001 (0.001)</td><td>−0.001 (0.001)</td><td>−0.001 (0.001)</td><td>−0.001 (0.001)</td></tr><tr><td>Unmet credit need</td><td>−0.019 (0.003) <sup>**</sup></td><td>−0.014 (0.003) <sup>**</sup></td><td>−0.008 (0.003) <sup>*</sup></td><td>−0.009 (0.001) <sup>**</sup></td></tr><tr><td>Years living in village</td><td>0.008 (0.005)</td><td>0.005 (0.014)</td><td>0.013 (0.020)</td><td>0.004 (0.014)</td></tr><tr><td>Cooperation membership</td><td>0.012 (0.015)</td><td>0.012 (0.042)</td><td>0.021 (0.018)</td><td>0.003 (0.022)</td></tr><tr><td>Constant</td><td>0.127 (0.148)</td><td>0.189 (0.095) <sup>**</sup></td><td></td><td></td></tr><tr><td><i>F</i> statistic</td><td>16.81 <sup>**</sup></td><td>16.33 <sup>**</sup></td><td></td><td></td></tr><tr><td><i>F</i> test of 1st stage IV</td><td></td><td>79.19 <sup>**</sup></td><td></td><td></td></tr><tr><td>Underidentificationc</td><td></td><td>64.95 <sup>**</sup></td><td></td><td></td></tr><tr><td>Weak identificationd</td><td></td><td>54.11</td><td></td><td></td></tr><tr><td>LR / Wald chi-square</td><td></td><td></td><td>286.26 <sup>**</sup></td><td>536.60 <sup>**</sup></td></tr><tr><td><i>ρ</i><sub>adoption and land rental</sub></td><td></td><td></td><td></td><td>0.213 <sup>**</sup></td></tr></table>
|
4ecf19a28aa2b6177f713f566120a30d7fb906382282acda7aa48e28f3736034.png
|
complex
|
<table><tr><td rowspan="2">Cpd.</td><td colspan="6">IC<sub>50</sub> (μM)</td></tr><tr><td>CDK5/p25</td><td>GSK3α/β</td><td>DYRK1A</td><td>DYRK2</td><td>CLK1</td><td>CLK2</td></tr><tr><td>3a</td><td>> 10</td><td>> 10</td><td>> 10</td><td>> 10</td><td>> 10</td><td>> 10</td></tr><tr><td>3b</td><td>> 10</td><td>> 10</td><td>> 10</td><td>> 10</td><td>> 10</td><td>> 10</td></tr><tr><td>3c</td><td>> 10</td><td>8.5</td><td>0.070</td><td>–</td><td>–</td><td>–</td></tr><tr><td>5d</td><td>> 10</td><td>> 10</td><td>0.041</td><td>0.6</td><td>0.5</td><td>7.7</td></tr></table>
|
b476f1cb658e644dc73037ffbfdc788bc6bc52fdf53f6c96192336ed08fbeb1a.png
|
simple
|
<table><tr><td>Variable</td><td><i>p</i>-Value</td><td>HR</td><td>95% CI</td></tr><tr><td>Intestinal type vs. others</td><td>0.0025</td><td>0.5156</td><td>0.3143–0.8457</td></tr><tr><td>HLR type vs. others</td><td><0.0001</td><td>2.6683</td><td>1.7298–4.1160</td></tr><tr><td>Stage I/II vs. III/IV</td><td><0.0001</td><td>2.9569</td><td>1.8946–4.6148</td></tr><tr><td>pT2/pT3 vs. pT4</td><td><0.0001</td><td>2.6042</td><td>1.4849–4.5670</td></tr><tr><td>pN0 vs. pN1/pN2/pN3</td><td>0.0021</td><td>2.2075</td><td>1.4088–3.4592</td></tr><tr><td>CD8 > 9.5 cells/HPF</td><td>0.015</td><td>0.5637</td><td>0.3358–0.9462</td></tr><tr><td>EBV<sup>+</sup>/MSI vs. MSS/EBV<sup>−</sup></td><td>0.003</td><td>1.8981</td><td>1.2207–2.9513</td></tr><tr><td>PD-L1 ≥ 5% vs. <5%</td><td>0.012</td><td>0.4102</td><td>0.2408–0.6988</td></tr></table>
|
5b94c4282545c2c2a9ce060b70df53a1dbecaa25be46fb308037c22e6e4ad084.png
|
complex
|
<table><tr><td></td><td colspan="3">One visit</td><td colspan="3">Two or more visits</td></tr><tr><td>Characteristic</td><td>N</td><td>%</td><td>HIV prev.<i><sup>a</sup></i></td><td>N</td><td>%</td><td>HIV prev.<i><sup>a</sup></i></td></tr><tr><td>Total</td><td>94020</td><td></td><td>34.1</td><td>8865</td><td></td><td>58.6</td></tr><tr><td>Sex</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Female</td><td>35083</td><td>37.3%</td><td>38.6</td><td>3486</td><td>39.3%</td><td>68.3</td></tr><tr><td> Male</td><td>58937</td><td>62.7%</td><td>31.5</td><td>5379</td><td>60.7%</td><td>52.3</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> 15-19</td><td>1784</td><td>1.9%</td><td>16.3</td><td>72</td><td>0.8%</td><td>44.4</td></tr><tr><td> 20-29</td><td>22433</td><td>23.9%</td><td>46.7</td><td>2336</td><td>26.4%</td><td>74.1</td></tr><tr><td> 30-39</td><td>28396</td><td>30.2%</td><td>48.8</td><td>3245</td><td>36.6%</td><td>71.8</td></tr><tr><td> 40-49</td><td>18901</td><td>20.1%</td><td>29.4</td><td>1727</td><td>19.5%</td><td>48.9</td></tr><tr><td> 50+</td><td>22506</td><td>23.9%</td><td>8.5</td><td>1485</td><td>16.8%</td><td>17.2</td></tr><tr><td colspan="2">Education</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> None/primary</td><td>61528</td><td>65.4%</td><td>30.4</td><td>5105</td><td>57.6%</td><td>54.5</td></tr><tr><td> Secondary/graduate</td><td>32492</td><td>34.6%</td><td>41.2</td><td>3760</td><td>42.4%</td><td>64.1</td></tr><tr><td colspan="3">Current marital status</td><td></td><td></td><td></td><td></td></tr><tr><td> Married</td><td>74800</td><td>79.6%</td><td>33.9</td><td>7502</td><td>84.6%</td><td>57.7</td></tr><tr><td> Unmarried</td><td>19220</td><td>20.4%</td><td>34.9</td><td>1363</td><td>15.4%</td><td>63.6</td></tr><tr><td colspan="2">Occupation</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Housewife</td><td>15974</td><td>17.0%</td><td>39.2</td><td>1763</td><td>19.9%</td><td>64.9</td></tr><tr><td> Other/unemployed</td><td>9006</td><td>9.6%</td><td>12.9</td><td>579</td><td>6.5%</td><td>21.6</td></tr><tr><td>Professional/manager</td><td>2642</td><td>2.8%</td><td>48.5</td><td>260</td><td>2.9%</td><td>69.2</td></tr><tr><td> Skilled</td><td>35733</td><td>38.0%</td><td>40.2</td><td>3625</td><td>40.9%</td><td>65.8</td></tr><tr><td> Student</td><td>723</td><td>0.8%</td><td>5.4</td><td>26</td><td>0.3%</td><td>23.1</td></tr><tr><td> Unskilled</td><td>29942</td><td>31.8%</td><td>30</td><td>2612</td><td>29.5%</td><td>51.8</td></tr><tr><td colspan="3">Lifetime sexual partners</td><td></td><td></td><td></td><td></td></tr><tr><td> 0 or 1</td><td>57283</td><td>60.9%</td><td>23.5</td><td>4898</td><td>55.3%</td><td>46.4</td></tr><tr><td> 2 or more</td><td>36737</td><td>39.1%</td><td>50.8</td><td>3967</td><td>44.7%</td><td>73.6</td></tr></table>
|
89c16945f49ca54e9610b0216b39bd4e4da81ddca717cd8ee3c382f20698bf1a.png
|
simple
|
<table><tr><td>Compound</td><td>Target</td><td>p-eIF2α</td><td>Disease model</td><td>Disease effect</td><td>References</td></tr><tr><td>Salubrinal</td><td>PPP1R15A(GADD34)-PP1c/PPP1R15B-PP1c</td><td>↑</td><td>ALS (SOD1G93A)Prion disease</td><td>Beneficialdetrimental</td><td>[7, 88][65]</td></tr><tr><td>Guanabenz</td><td>PPP1R15A(GADD34)-PP1c</td><td>↑</td><td>ALS (TDP-43)ALS (SOD1 G93A)</td><td>Beneficial</td><td>[110, 112, 118]</td></tr><tr><td>Sephin1</td><td>PPP1R15A(GADD34)-PP1c</td><td>↑</td><td>ALS (SOD1G93A); CMT1B</td><td>Beneficial</td><td>[21]</td></tr><tr><td>GSK2606414</td><td>PERK inhibitor</td><td>↓</td><td>Prion disease</td><td>Beneficial</td><td>[3, 64]</td></tr><tr><td>ISRIB</td><td>eIF2β</td><td>Not changed</td><td>Prion disease</td><td>Beneficial</td><td>[28, 93, 96]</td></tr></table>
|
22d5279155ec93335cfb86ed6a93e6f79cfbdb93e1a522b3c7c2d2daf8bd4ade.png
|
simple
|
<table><tr><td>Variable</td><td>Number</td><td>Weighted %<sup>a</sup></td></tr><tr><td>Total</td><td>677.0</td><td>100.0</td></tr><tr><td>Male</td><td>302.0</td><td>48.0</td></tr><tr><td>Age</td><td></td><td></td></tr><tr><td><i><=35 years</i></td><td>222.0</td><td>33.4</td></tr><tr><td><i>35 < years < =50</i></td><td>263.0</td><td>39.0</td></tr><tr><td><i>50 < years < =65</i></td><td>192.0</td><td>27.6</td></tr><tr><td>SES<sup>b</sup></td><td></td><td></td></tr><tr><td><i>Low</i></td><td>201.0</td><td>31.2</td></tr><tr><td><i>Medium</i></td><td>165.0</td><td>24.0</td></tr><tr><td><i>Medium-High</i></td><td>198.0</td><td>28.9</td></tr><tr><td><i>High</i></td><td>113.0</td><td>15.9</td></tr><tr><td>Education</td><td></td><td></td></tr><tr><td><i>Some Elementary</i></td><td>36.0</td><td>5.0</td></tr><tr><td><i>Complete Elementary</i></td><td>67.0</td><td>10.1</td></tr><tr><td><i>Some Middle School</i></td><td>23.0</td><td>3.9</td></tr><tr><td><i>Complete Middle School</i></td><td>140.0</td><td>21.1</td></tr><tr><td><i>Some High School</i></td><td>29.0</td><td>4.4</td></tr><tr><td><i>Complete Highschool</i></td><td>162.0</td><td>23.2</td></tr><tr><td><i>Some College</i></td><td>34.0</td><td>5.5</td></tr><tr><td><i>Complete College or more</i></td><td>186.0</td><td>26.8</td></tr><tr><td>Motor vehicle ownership</td><td></td><td></td></tr><tr><td><i>Car</i></td><td>363.0</td><td>53.2</td></tr><tr><td><i>Motorcycle</i></td><td>32.0</td><td>5.1</td></tr><tr><td><i>Either</i></td><td>371.0</td><td>54.7</td></tr><tr><td>Marital status</td><td></td><td></td></tr><tr><td><i>Single</i></td><td>166.0</td><td>25.0</td></tr><tr><td><i>Married or living with someone</i></td><td>438.0</td><td>65.3</td></tr><tr><td><i>Separated or Divorced</i></td><td>56.0</td><td>7.4</td></tr><tr><td><i>Widower</i></td><td>17.0</td><td>2.4</td></tr><tr><td>BMI Status</td><td></td><td></td></tr><tr><td><i>Under-nutrition (BMI < 20)</i></td><td>22.0</td><td>3.2</td></tr><tr><td><i>Normal (20 < =BMI < 25)</i></td><td>165.0</td><td>24.2</td></tr><tr><td><i>Overweight (25 < =BMI < 30)</i></td><td>278.0</td><td>40.9</td></tr><tr><td><i>Obese (BMI > =30)</i></td><td>212.0</td><td>31.7</td></tr></table>
|
e9888a4103a229f96b57cb86a33ed1374913b78f4f6cd1ff00a26806400892a5.png
|
simple
|
<table><tr><td>Hematological index </td><td>Formula </td></tr><tr><td>Mentzer index (MI) (1973)</td><td>MCV/RBC </td></tr><tr><td>RDWI (1987)</td><td>MCV × RDW/RBC</td></tr><tr><td>Shine and Lal (S and L) (1977)</td><td>MCV × MCV × MCH/100</td></tr><tr><td>Srivastava (1973)</td><td>MCH/RBC</td></tr><tr><td>Green and King (G and K) (1989)</td><td>MCV × MCV × RDW/Hb × 100</td></tr><tr><td>Sirdah (2007)</td><td>MCV − RBC − (3 × Hb)</td></tr><tr><td>Ehsani (2005)</td><td>MCV − (10 × RBC) </td></tr><tr><td>England and Fraser (E and F) (1973)</td><td>MCV − (5 × Hb) − RBC − 3.4</td></tr><tr><td>Ricerca (1987)</td><td>RDW/RBC</td></tr><tr><td>MDHL (1999)</td><td>(MCH/MCV) × RBC</td></tr><tr><td>MCHD (1999)</td><td>MCH/MCV</td></tr></table>
|
0b1169f1f2c5533a4519cd683e4adf9b2bd143398fff56bdf4012bbcf1e95bc8.png
|
simple
|
<table><tr><td>EXPREF</td><td>Total</td><td>N (case)</td><td>N (control)</td><td>Disease Case</td><td>Disease Control</td><td>Source</td><td>Detection Method</td><td>Reference</td></tr><tr><td>Exp25666440</td><td>23</td><td>11</td><td>12</td><td>naïve Fabry patients</td><td>ERT</td><td>urine</td><td>nanoLC-ESI-MS/MS</td><td>[25]</td></tr><tr><td>Exp17301227</td><td>13</td><td>N/A</td><td>N/A</td><td>6 months of ERT</td><td>before treatment (baseline)</td><td>blood</td><td>nanoLC-ESI-MS/MS</td><td>[26]</td></tr><tr><td>Exp18339188a</td><td>13</td><td>N/A</td><td>N/A</td><td>6 months of ERT</td><td>before treatment (baseline)</td><td>blood</td><td>microarray</td><td>[27]</td></tr><tr><td>Exp18339188b</td><td>13</td><td>N/A</td><td>N/A</td><td>naïve Fabry patients</td><td>healthy</td><td>blood</td><td>microarray</td><td>[27]</td></tr><tr><td>Exp20954982</td><td>30</td><td>20</td><td>10</td><td>Fabry</td><td>healthy</td><td>urine</td><td>MALDI-TOF MS</td><td>[28]</td></tr><tr><td>Exp23385635</td><td>14</td><td>8</td><td>6</td><td>Fabry</td><td>healthy</td><td>blood</td><td>MALDI-TOF MS</td><td>[29]</td></tr><tr><td>Exp23464927</td><td>10</td><td>N/A</td><td>N/A</td><td>12 months of ERT</td><td>before treatment (baseline)</td><td>urine</td><td>QTOF MS/MS</td><td>[30]</td></tr><tr><td>Exp25619383</td><td>46</td><td>32</td><td>14</td><td>Fabry</td><td>healthy</td><td>blood</td><td>LC-MS/MS</td><td>[31]</td></tr><tr><td>Exp21698285</td><td>124</td><td>35</td><td>89</td><td>naïve female Fabry</td><td>healthy</td><td>urine</td><td>CE-MS</td><td>[32]</td></tr><tr><td>Exp26490183</td><td>6</td><td>N/A</td><td>N/A</td><td>short term of ERT</td><td>before treatment (baseline)</td><td>blood</td><td>Illumina MiSeq instrument</td><td>[8]</td></tr><tr><td>Exp25582508</td><td>32</td><td>16</td><td>16</td><td>untreated Fabry males</td><td>healthy</td><td>urine</td><td>UPLC-ESI-TOF-MS</td><td>[33]</td></tr></table>
|
c2a191389cf0470932d34ad7311088df5d893f0d4065ec5bb9bd926334449203.png
|
simple
|
<table><tr><td>Technique</td><td>Type</td><td>Comments</td><td>References</td></tr><tr><td>Specific gene promoter: indicator protein fusions [i.e. beta-glucuronidase (GUS) or fluorescent proteins]</td><td>1, B</td><td>Long lead times of >2 months to get stably expressed genes, homozygous gene expression, sequences other than the promoter may control gene expression, no guarantee that promoter fragment chosen is correct, not suitable for plants that cannot be transformed.</td><td>[5]</td></tr><tr><td>Laser Capture Microdissection (LCM) and Single Cell Sampling (SiCSA)</td><td>2, A</td><td>Difficulty in isolating certain cell-types (e.g. vascular cells using SiCSA), long tissue prep (~2 weeks) for LCM, need for specialised equipment</td><td>[6,7]</td></tr><tr><td><i>in situ</i> PCR</td><td>3, B</td><td>No specialised equipment required apart from vibratome, simple and fast method. No detailed protocol for plants until this manuscript, especially for agarose- embedded vibratome- sectioned in tube PCR. Can be performed on plants that are difficult to, or cannot be transformed. We do not recommend fluorescence detection of <i>in situ</i> PCR products due to interference with autofluorescence from plant tissue. As it is possible to do separate PCRs on adjoining tissue sections or replicate tissues from other plants we see no great advantage in multiplexing <i>in situ</i> PCR as it causes multiple complications to what is a robust and relatively simple technique. We do not recommend multiplexing <i>in situ</i> PCR due to the differential abundance of transcripts in the same cell and consequently the saturation of products, generation of non-specific products and problems with signal separation.</td><td> </td></tr><tr><td><i>in situ</i> hybridisation (ISH)</td><td>3, B</td><td>High detection threshold (10–20 copies per cell for ISH vs 1–2 copies per cell for <i>in situ</i> PCR), need to design a specific probe that hybridises to RNA while <i>in situ</i> PCR uses the same primers as qPCR, much cheaper. The View RNA Assay (Affymetrix) enables automated multiple transcript detection using fluorescence by employing the principles of ISH to detect nucleic acid targets within specific cells/cell-types. Its use is limited to abundant transcripts and laboratories equipped with and/or experienced in FFPE (formalin-fixed paraffin embedded) and frozen tissue preparation.</td><td>[8]</td></tr><tr><td>Protoplasting of fluorescently labelled cells and single cell sorting (FACS)</td><td>4, A</td><td>Can assay multiple transcripts at the same time. Potential damage responses of tissue. Needs specialised sorting flow cytometer. Limited to analysis of cells that are fluorescently labelled. Cannot give detail of all cells in which a particular gene is expressed.</td><td>[9,10]</td></tr><tr><td>Nuclear sorting, INTACT (isolation of nuclei tagged in specific cell types) or ribosomal binding techniques</td><td>4, A</td><td>When combined with microarrays or RNAseq can assay multiple transcripts at the same time. Limited to analysis of cells that are fluorescently labelled. Cannot give detail of all cells in which a particular gene is expressed. Not easily replicated.</td><td>[11-13]</td></tr><tr><td><i>In situ</i> RNA sequencing</td><td>3, B</td><td>Offers the prospect of obtaining whole transcriptomes and more from single cells in tissue sections. Not yet optimised in any tissue. Has not been performed for plant tissue.</td><td>[14]</td></tr></table>
|
ed95b1193ccbd4f7ce34fb94c6415746601222d68aec0202f48112053ff605c7.png
|
complex
|
<table><tr><td>Total sample</td><td colspan="5">Soda consumption categories</td></tr><tr><td><i>N</i> = 888</td><td>None (<i>n</i> = 501)</td><td>1 or less serv/wk. (<i>n</i> = 245)</td><td colspan="2">≥ 2 serv/wk. (<i>n</i> = 142)</td><td><i>Overall Groups P</i>-value</td></tr><tr><td colspan="6">Model 1:</td></tr><tr><td> Unadjusted</td><td>Referent</td><td>1.30 (0.90–1.89)</td><td colspan="2">2.31 (1.53–3.49)*</td><td>0.005</td></tr><tr><td colspan="6">Model 2:<sup>b</sup></td></tr><tr><td> Adjusted</td><td>Referent</td><td>1.04 (0.69–1.58)</td><td colspan="2">1.94 (1.22–3.07)*</td><td>0.014</td></tr><tr><td colspan="6">Model 3:<sup>c</sup></td></tr><tr><td> Adjusted</td><td>Referent</td><td>1.04 (0.68–1.57)</td><td colspan="2">1.95 (1.22–3.11)*</td><td>0.014</td></tr><tr><td colspan="6">Model 4:<sup>d</sup></td></tr><tr><td> Adjusted</td><td>Referent</td><td>1.00 (0.65–1.53)</td><td colspan="2">1.61 (0.98–2.66)<sup>†</sup></td><td>0.136</td></tr><tr><td>Fried food consumption categories</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>N</i> = 888</td><td>None (<i>n</i> = 295)</td><td>1 serv/wk. (<i>n</i> = 353)</td><td>2–4 serv/wk. (<i>n</i> = 208)</td><td>≥ 5 serv/wk. (<i>n</i> = 32)</td><td><i>Overall Groups P</i>-value</td></tr><tr><td colspan="6">Model 1:</td></tr><tr><td> Unadjusted</td><td>Referent</td><td>1.23 (0.82–1.82)</td><td>1.99 (1.30–3.04)*</td><td>3.72 (1.74–7.96)*</td><td><0.001</td></tr><tr><td colspan="6">Model 2:<sup>b</sup></td></tr><tr><td> Adjusted</td><td>Referent</td><td>1.06 (0.69–1.63)</td><td>1.84 (1.15–2.92)*</td><td>3.38 (1.44–7.96)*</td><td>0.003</td></tr><tr><td colspan="6">Model 3:<sup>c</sup></td></tr><tr><td> Adjusted</td><td>Referent</td><td>1.12 (0.72–1.73)</td><td>1.89 (1.18–3.02)*</td><td>3.50 (1.48–8.29)*</td><td>0.003</td></tr><tr><td colspan="6">Model 4:<sup>e</sup></td></tr><tr><td> Adjusted</td><td>Referent</td><td>1.12 (0.71–1.75)</td><td>1.80 (1.08–3.00)*</td><td>3.38 (1.36–8.38)*</td><td>0.015</td></tr></table>
|
44ae74b5600fa47cb4f5ebbf1f83688864bc89525cf026197fc50a94ad79aa56.png
|
complex
|
<table><tr><td> </td><td>Breakfast eaters<sup>a</sup></td><td>Breakfast skippers<sup>b</sup></td><td><i>P</i> value<sup>c</sup></td></tr><tr><td><i>n</i>, %</td><td>4188, 90.4</td><td>443, 9.6</td><td> </td></tr><tr><td>Men, %</td><td>78.2</td><td>73.8</td><td>0.04</td></tr><tr><td>Age, year</td><td>47.8 (7.1)</td><td>46.0 (6.8)</td><td><0.001</td></tr><tr><td>Body mass index, kg/m<sup>2</sup></td><td>22.9 (2.8)</td><td>22.9 (3.0)</td><td>0.78</td></tr><tr><td>Smoking status, %</td><td> </td><td> </td><td> </td></tr><tr><td> Current</td><td>26.7</td><td>44.9</td><td><0.001</td></tr><tr><td> Former</td><td>23.4</td><td>14.2</td><td> </td></tr><tr><td> Never</td><td>49.9</td><td>40.9</td><td> </td></tr><tr><td>Leisure-time physical activity, %<sup>d</sup></td><td> </td><td> </td><td> </td></tr><tr><td> ≥3 days/week</td><td>75.5</td><td>84.2</td><td><0.001</td></tr><tr><td> <3 days/week</td><td>16.0</td><td>9.5</td><td> </td></tr><tr><td>Work-time physical activity, yes, %</td><td>5.3</td><td>7.7</td><td><0.01</td></tr><tr><td>Family history of diabetes mellitus, yes, %</td><td>14.8</td><td>17.4</td><td>0.14</td></tr><tr><td>Fasting blood glucose, mg/dL<sup>e</sup></td><td>92.3 (92.0–92.6)</td><td>92.5 (91.5–93.4)</td><td>0.74</td></tr><tr><td>Perceived stress, %<sup>d</sup></td><td> </td><td> </td><td> </td></tr><tr><td> Very much</td><td>11.0</td><td>13.8</td><td>0.02</td></tr><tr><td> Much</td><td>40.1</td><td>39.7</td><td> </td></tr><tr><td> Ordinary</td><td>43.8</td><td>39.1</td><td> </td></tr><tr><td> Little</td><td>4.9</td><td>6.8</td><td> </td></tr><tr><td>Sleep duration, %<sup>d</sup></td><td> </td><td> </td><td> </td></tr><tr><td> <7 hours/day</td><td>52.9</td><td>61.6</td><td><0.001</td></tr><tr><td> ≥7 hours/day</td><td>45.5</td><td>35.7</td><td> </td></tr><tr><td>Work schedule, %<sup>d</sup></td><td> </td><td> </td><td> </td></tr><tr><td> Without shift work or night shifts</td><td>84.6</td><td>78.3</td><td><0.001</td></tr><tr><td> With shift work but without night shifts</td><td>1.9</td><td>1.4</td><td> </td></tr><tr><td> Without shift work but with night shifts</td><td>6.8</td><td>7.9</td><td> </td></tr><tr><td> With shift work including night shifts</td><td>4.9</td><td>11.3</td><td> </td></tr><tr><td>Total energy intake, kcal/day</td><td>1942 (538)</td><td>1740 (553)</td><td><0.001</td></tr><tr><td>Alcohol consumption, g/day</td><td>13.6 (19.2)</td><td>18.1 (26.4)</td><td><0.001</td></tr><tr><td>Eating speed, %<sup>d</sup></td><td> </td><td> </td><td> </td></tr><tr><td> Very fast</td><td>11.4</td><td>12.9</td><td>0.67</td></tr><tr><td> Relatively fast</td><td>35.8</td><td>37.9</td><td> </td></tr><tr><td> Medium</td><td>38.5</td><td>35.2</td><td> </td></tr><tr><td> Slow</td><td>12.6</td><td>12.4</td><td> </td></tr><tr><td>Satiation eater, %</td><td>61.2</td><td>59.1</td><td>0.24</td></tr><tr><td>Fruits and vegetables intake, g/1000 kcal/day</td><td>142.3 (67.0)</td><td>118.7 (61.2)</td><td><0.001</td></tr><tr><td>Fish intake, g/1000 kcal/day</td><td>84.1 (41.9)</td><td>84.8 (39.4)</td><td>0.74</td></tr><tr><td>Frequency of whole-grain cereals intake, %</td><td> </td><td> </td><td> </td></tr><tr><td> Always</td><td>8.5</td><td>5.7</td><td>0.10</td></tr><tr><td> Sometimes</td><td>9.2</td><td>8.1</td><td> </td></tr><tr><td> Rarely</td><td>14.9</td><td>12.6</td><td> </td></tr><tr><td> No</td><td>67.4</td><td>73.6</td><td> </td></tr><tr><td>Frequency of coffee intake, %<sup>d</sup></td><td> </td><td> </td><td> </td></tr><tr><td> ≥4 cups/day</td><td>6.6</td><td>10.6</td><td>0.02</td></tr><tr><td> 2–3 cups/day</td><td>39.0</td><td>39.1</td><td> </td></tr><tr><td> 1 cup/day</td><td>24.3</td><td>23.7</td><td> </td></tr><tr><td> <1 cup/day</td><td>28.8</td><td>25.1</td><td> </td></tr><tr><td colspan="2">Frequency of sugar-sweetened beverages intake, %<sup>d</sup></td><td> </td><td> </td></tr><tr><td> ≥1 serving/day</td><td>5.5</td><td>9.3</td><td><0.001</td></tr><tr><td> 4–6 servings/week</td><td>5.3</td><td>7.0</td><td> </td></tr><tr><td> 1–3 servings/week</td><td>29.9</td><td>36.3</td><td> </td></tr><tr><td> Never or rarely</td><td>57.6</td><td>45.1</td><td> </td></tr><tr><td>Snack intake, yes, %</td><td>95.3</td><td>94.8</td><td>0.61</td></tr></table>
|
1692a9413c00940c4bc00958e0ca5312e8532d4e8d219118668b7f7a52243b0c.png
|
complex
|
<table><tr><td>Groups</td><td>N</td><td>Age</td><td>BMI</td><td>EBL</td><td>Duration</td><td>PreHGB</td><td>PreHCT</td><td>PostHGB</td><td>PostHCT</td></tr><tr><td>Group 1</td><td>42</td><td>24.69 ± 6.2</td><td>21.70 ± 3.8</td><td>680.95 ± 313.12</td><td>5:58 ± 1:19</td><td>12.94 ± 2.0</td><td>38.51 ± 4.8</td><td>9.76 ± 2.1</td><td>29.42 ± 5.6</td></tr><tr><td>Group 2</td><td>19</td><td>22.79 ± 6.8</td><td>21.48 ± 3.0</td><td>744.74 ± 367</td><td>6:28 ± 1:07</td><td>14.14 ± 1.8</td><td>41.54 ± 4.8</td><td>9.82 ± 1.6</td><td>29.26 ± 4.2</td></tr><tr><td>Group 3</td><td>21</td><td>20.76 ± 5.3</td><td>22.61 ± 3.9</td><td>495.24 ± 517.91</td><td>3:25 ± 2:00*</td><td>13.64 ± 2.3</td><td>40.66 ± 6.7</td><td>11.25 ± 2.6</td><td>33.58 ± 7.7*</td></tr><tr><td>Group 4</td><td>10</td><td>22.10 ± 5.0</td><td>21.59 ± 3.8</td><td>665.00 ± 456.47</td><td>6:26 ± 1:11</td><td>13.97 ± 1.2</td><td>41.61 ± 3.5</td><td>10.53 ± 2.0</td><td>31.29 ± 5.4</td></tr><tr><td>Total</td><td>92</td><td>23.12 ± 6.1</td><td>21.85 ± 3.6</td><td>650.00 ± 397.8</td><td>5:32 ± 1:52</td><td>13.46 ± 2.0</td><td>39.96 ± 5.3</td><td>10.20 ± 2.2</td><td>30.54 ± 6.1</td></tr><tr><td colspan="2">p-value</td><td>0.102</td><td>0.750</td><td>0.211</td><td><0.001*</td><td>0.119</td><td>0.100</td><td>0.059</td><td>0.050*</td></tr></table>
|
e7523389201501d8e5e3320c404fd333d3adb29f248b5e6661b689c8a296b2bc.png
|
complex
|
<table><tr><td rowspan="2">Characteristics</td><td>NASH - HCC</td><td>Non-NASH - HCC</td><td rowspan="2">P</td></tr><tr><td>(n = 45)</td><td>(n = 1074)</td></tr><tr><td>Male gender*</td><td>35 (77.8)</td><td>888 (82.7)</td><td>0.820</td></tr><tr><td>Age at time of diagnosis<sup>#</sup></td><td>67.6 (46.6-89.9)</td><td>65 (15.3-87.3)</td><td>0.007</td></tr><tr><td>Caucasian*</td><td>45 (100)</td><td>1055 (98.2)</td><td>1,000</td></tr><tr><td>Obesity*</td><td>13 (28.9)</td><td>158 (14.7)</td><td>0.046</td></tr><tr><td>BMI (kg/m<sup>2</sup>)<sup>#</sup></td><td>29 (19.4-49.6)</td><td>26.6 (16.5-48.4)</td><td>0.022</td></tr><tr><td>Type II diabetes *</td><td>30 (66.7)</td><td>406 (37.8)</td><td>0.024</td></tr><tr><td>Hypertension*</td><td>32 (71.1)</td><td>485 (45.2)</td><td>0.060</td></tr><tr><td>Hyperlipidemia*</td><td>18 (40)</td><td>211 (19.6)</td><td>0.016</td></tr><tr><td>Myocardial infarction*</td><td>6 (13.3)</td><td>52 (4.8)</td><td>0.035</td></tr><tr><td>apoplectic stroke*</td><td>4 (8.9)</td><td>23 (2.1)</td><td>0.025</td></tr><tr><td>Cirrhosis*</td><td>35 (77.8)</td><td>858 (79.9)</td><td>1,000</td></tr><tr><td>Child-Turcotte-Pugh-Score*</td><td></td><td></td><td></td></tr><tr><td> A</td><td>21 (46.7)</td><td>421 (39.2)</td><td>0.577</td></tr><tr><td> B</td><td>14 (31.1)</td><td>301 (28)</td><td>0.748</td></tr><tr><td> C</td><td>0</td><td>136 (12.7)</td><td>0.012</td></tr><tr><td>Bilirubin<sup>#</sup></td><td>0.8 (0.3-4.8)</td><td>1.2 (0.2-78.3)</td><td><0.001</td></tr><tr><td>INR<sup>#</sup></td><td>1.1 (0.8-1.4)</td><td>1.1 (0.9-3.2)</td><td><0.001</td></tr><tr><td>Creatinine<sup>#</sup></td><td>1 (0.6-7.5)</td><td>0.9 (0.3-7.2)</td><td>0.420</td></tr><tr><td>Albumin<sup>#</sup></td><td>35 (19–52.6)</td><td>34 (3–55.6)</td><td>0.173</td></tr><tr><td>Thrombocytopenia*</td><td>15 (33.3)</td><td>472 (43.9)</td><td>0.394</td></tr><tr><td>AFP<sup>#</sup></td><td>96.9 (1.5-96611)</td><td>39 (0–624094.4)</td><td>0.722</td></tr><tr><td>MELD score<sup>#</sup></td><td>9 (6–21)</td><td>10 (6–40)</td><td>0.005</td></tr><tr><td>Encephalopathy*</td><td>0</td><td>44 (4,1)</td><td>1.640</td></tr><tr><td>Ascites*</td><td>14 (31.1)</td><td>235 (21.9)</td><td>0.299</td></tr><tr><td>Varices*</td><td>10 (22.2)</td><td>342 (31.8)</td><td>0.420</td></tr><tr><td>Portal vein thrombosis*</td><td>13 (28.9)</td><td>222 (20.7)</td><td>0.290</td></tr></table>
|
17b0b2b767b3016d188ac3e424260999fdfe0326c96509060a09bd084416c079.png
|
simple
|
<table><tr><td>Recalled receiving information on:</td><td>CP<sup>a</sup>n=106n (%)</td><td>PE<sup>a</sup>n=619n (%)</td><td><i>p</i>-value</td></tr><tr><td>Appropriate amount of weight gain</td><td>89 (84.0)</td><td>473 (76.4)</td><td>0.085</td></tr><tr><td>Exercise or active living during pregnancy</td><td>83 (78.3)</td><td>434 (70.1)</td><td>0.085</td></tr><tr><td>Nutrition</td><td>92 (86.8)</td><td>453 (73.2)</td><td>0.003</td></tr><tr><td>Taking vitamins or mineral supplements</td><td>92 (86.8)</td><td>543 (87.7)</td><td>0.789</td></tr><tr><td>Taking prescription or non-prescription drugs</td><td>75 (70.8)</td><td>430 (69.5)</td><td>0.790</td></tr><tr><td>Alcohol consumption during pregnancy</td><td>77 (72.6)</td><td>350 (56.5)</td><td>0.002</td></tr><tr><td>Cigarette smoking and second hand smoke</td><td>71 (67.0)</td><td>299 (48.3)</td><td><0.001</td></tr><tr><td>Working during pregnancy</td><td>65 (61.3)</td><td>343 (55.4)</td><td>0.257</td></tr></table>
|
ba02770e2159d42c5e0793cdf3956b3b01103e7840cb651df9eafb523a9fe1ce.png
|
simple
|
<table><tr><td>Batch Code</td><td>Mean particle size(μm) mean ± SEM</td><td>% yield = (Practical yield / Theoretical yield) × 100</td><td>Drug Entrapment (%)</td><td>Drug Encapsulation Efficiency (%)</td></tr><tr><td>K1</td><td>290.54± 6.52</td><td>90</td><td>1.33</td><td>02.39</td></tr><tr><td>K2</td><td>378.88± 8.73</td><td>97</td><td>2.70</td><td>07.84</td></tr><tr><td>K3</td><td>395.86±10.21</td><td>85</td><td>8.82</td><td>29.98</td></tr><tr><td>K4</td><td>542.85± 9.60</td><td>78</td><td>9.38</td><td>36.58</td></tr><tr><td>K5</td><td>216.84± 6.48</td><td>55</td><td>3.17</td><td>03.49</td></tr><tr><td>K6</td><td>314.32± 8.44</td><td>60</td><td>5.04</td><td>15.92</td></tr><tr><td>K7</td><td>321.06± 8.39</td><td>80</td><td>6.85</td><td>21.91</td></tr><tr><td>K8</td><td>432.57± 9.68</td><td>76</td><td>8.84</td><td>22.15</td></tr></table>
|
e70a0965aca63e5bef9e9dedf4b502b150d24e042d66c11224e53e533a33ee90.png
|
simple
|
<table><tr><td>Population</td><td>Sample</td><td>Average</td><td>Standard deviation</td><td>Percentile 25%</td><td>Percentile 50%</td><td>Percentile 75%</td></tr><tr><td>General population</td><td>4176</td><td>59.3125</td><td>30.99565</td><td>40</td><td>70</td><td>80</td></tr><tr><td>General population (men)</td><td>1739</td><td>64.64347</td><td>29.17882</td><td>50</td><td>75</td><td>85</td></tr><tr><td>General population(women)</td><td>2437</td><td>55.50841</td><td>31.69165</td><td>30</td><td>60</td><td>80</td></tr><tr><td>General populationAge 16-44</td><td>2128</td><td>65.04229</td><td>31.28681</td><td>50</td><td>80</td><td>90</td></tr><tr><td>General populationAge 45-65</td><td>1130</td><td>56.4177</td><td>30.0071</td><td>40</td><td>65</td><td>80</td></tr><tr><td>General populationAge ≥ 65</td><td>918</td><td>49.59368</td><td>28.5296</td><td>25</td><td>50</td><td>70</td></tr><tr><td>General populationSeniors IAge 65-74</td><td>568</td><td>50.27641</td><td>28.75174</td><td>30</td><td>55</td><td>70</td></tr><tr><td>General populationSeniors IIAge 75-84</td><td>300</td><td>49.15</td><td>28.46545</td><td>20</td><td>55</td><td>70</td></tr><tr><td>General populationSeniors IIIAge ≥ 85</td><td>50</td><td>44.5</td><td>26.25172</td><td>20</td><td>50</td><td>63</td></tr></table>
|
45bc18f85c71b74abd973b635fac8a802dd4b593fbadcdbb282e5c43b13b7dcb.png
|
complex
|
<table><tr><td rowspan="2">Spirometry variable</td><td rowspan="2">Puncture approach</td><td>T<sub>0</sub></td><td></td><td></td><td>T<sub>30</sub></td><td></td><td></td></tr><tr><td>Median (Q1, Q3)</td><td>Median difference<sub>anterior-posterior</sub> (95 % CI)</td><td><i>p</i>-value (two-sided)</td><td>Median (Q1, Q3)</td><td>Median difference<sub>anterior-posterior</sub> (95 % CI)</td><td><i>p</i>-value (two-sided)</td></tr><tr><td>VC [l]</td><td>anterior</td><td>5.09 (3.98, 5.58)</td><td>0.38 (−0.15, 0.88)</td><td>0.167</td><td>3.98 (3.31, 4.67)</td><td>0.40 (−0.08, 0.88)</td><td>0.088</td></tr><tr><td></td><td>posterior</td><td>4.46 (3.90, 5.37)</td><td></td><td></td><td>3.46 (2.90, 4.34)</td><td></td><td></td></tr><tr><td>FEV1 [l/s]</td><td>anterior</td><td>3.80 (3.34, 4.33)</td><td>0.25 (−0.16, 0.63)</td><td>0.174</td><td>3.05 (2.41, 3.44)</td><td>0.34 (−0.09, 0.72)</td><td>0.103</td></tr><tr><td></td><td>posterior</td><td>3.57 (3.01, 4.11)</td><td></td><td></td><td>2.58 (2.05, 3.22)</td><td></td><td></td></tr><tr><td>Sniff PmaxPeak [kPa]</td><td>anterior</td><td>6.24 (4.84, 7.67)</td><td>−0.24 (−1.24, 0.83)</td><td>0.655</td><td>5.13 (4.21, 7.22)</td><td>−0.23 (−1.04, 0.56)</td><td>0.582</td></tr><tr><td></td><td>posterior</td><td>6.25 (5.09, 8.63)</td><td></td><td></td><td>5.70 (4.54, 6.83)</td><td></td><td></td></tr></table>
|
3550ae2e0807a7c8e8bfc302f10bb939d35fbda1993be9ad109930fc14ebc0c1.png
|
simple
|
<table><tr><td>Activity</td><td>Annual average E (mSv/yr)</td><td>Radiation source</td></tr><tr><td>Natural background due to external exposure (cosmic rays; terrestrial radionuclides)</td><td>0.9 (0.4; 0.5)</td><td>Cosmic rays, terrestrial radionuclides</td></tr><tr><td>Natural background due to internal exposure (inhalation; ingestion)</td><td>1.5 (1.2; 0.3)</td><td>Terrestrial radionuclides</td></tr><tr><td>Total natural background, worldwide</td><td>2.4</td><td>Cosmic rays, terrestrial radionuclides</td></tr><tr><td>Natural background due to cosmic rays, world average</td><td>0.380</td><td>Cosmic rays</td></tr><tr><td>Natural background due to cosmic rays, sea level</td><td>0.270</td><td>Cosmic rays</td></tr><tr><td>Natural background due to cosmic rays, 1600 m amsl</td><td>0.570</td><td>Cosmic rays</td></tr><tr><td>Natural background due to cosmic rays, 2200 m amsl</td><td>0.820</td><td>Cosmic rays</td></tr><tr><td>Natural background due to cosmic rays, 3900 m amsl</td><td>2.020</td><td>Cosmic rays</td></tr><tr><td>8 hours of flight (London-New York)</td><td>0.030 – 0.045 per flight</td><td>Cosmic rays</td></tr></table>
|
19f5ad244144b7c3469fd698d6b3389a9804082b8d939c65a5babafd30d09bd8.png
|
simple
|
<table><tr><td>Negative Papers</td><td>Positive Papers</td><td>Paper Score</td></tr><tr><td>10</td><td>100</td><td>0.60</td></tr><tr><td>20</td><td>100</td><td>0.63</td></tr><tr><td>30</td><td>100</td><td>0.63</td></tr><tr><td>40</td><td>100</td><td>0.64</td></tr><tr><td>10</td><td>200</td><td>0.56</td></tr><tr><td>20</td><td>200</td><td>0.59</td></tr><tr><td>30</td><td>200</td><td>0.58</td></tr><tr><td>40</td><td>200</td><td>0.60</td></tr><tr><td>10</td><td>300</td><td>0.60</td></tr><tr><td>20</td><td>300</td><td>0.63</td></tr><tr><td>30</td><td>300</td><td>0.64</td></tr><tr><td>40</td><td>300</td><td>0.66</td></tr><tr><td>10</td><td>400</td><td>0.61</td></tr><tr><td>20</td><td>400</td><td>0.65</td></tr><tr><td>30</td><td>400</td><td>0.66</td></tr><tr><td>40</td><td>400</td><td>0.66</td></tr></table>
|
43f534bae26dea69ba822d00ed3a60f88aff1ffc5c497402d9c6a6a412b25c05.png
|
complex
|
<table><tr><td rowspan="2">Feature</td><td colspan="4">Value</td></tr><tr><td><i>D. rotundata</i> (v0.1)</td><td><i>A. thaliana</i> (TAIR10)</td><td><i>B. distachyon</i> (v3.1)</td><td><i>O. sativa</i> (v7_JGI 323)</td></tr><tr><td>Total length (Mbp)</td><td>594.23</td><td>119.67</td><td>271.16</td><td>374.47</td></tr><tr><td>GC (%)</td><td>35.83</td><td>36.06</td><td>46.40</td><td>43.57</td></tr><tr><td>Number of scaffolds (≥ 0 bp)</td><td>4723</td><td>7</td><td>10</td><td>14</td></tr><tr><td>Number of scaffolds (≥ 1000 bp)</td><td>4704</td><td>7</td><td>10</td><td>14</td></tr><tr><td>Largest scaffold (Mbp)</td><td>13.61</td><td>30.43</td><td>75.07</td><td>43.27</td></tr><tr><td>N50 (Mbp)</td><td>2.12</td><td>23.46</td><td>59.13</td><td>29.96</td></tr><tr><td>N75 (Mbp)</td><td>0.77</td><td>19.70</td><td>48.59</td><td>28.44</td></tr><tr><td>Number of Ns per 100 kb</td><td>282.45<sup>a</sup></td><td>155.60</td><td>155.85</td><td>44.13</td></tr><tr><td>Ambiguous bases</td><td>1,413,029</td><td>–</td><td>–</td><td>–</td></tr><tr><td>Number of genes</td><td>26,198</td><td>27,416</td><td>34,310</td><td>42,189</td></tr><tr><td colspan="5">Exons</td></tr><tr><td> Number</td><td>158,059</td><td>141,044</td><td>154,104</td><td>178,353</td></tr><tr><td> Average number per gene</td><td>6.03</td><td>5.14</td><td>4.49</td><td>4.25</td></tr><tr><td> Total length (Mbp)</td><td>42.43</td><td>33.49</td><td>39.01</td><td>46.85</td></tr><tr><td> Average size (bp)</td><td>268.43</td><td>237.46</td><td>253.15</td><td>262.70</td></tr><tr><td> Average GC (%)</td><td>44.08</td><td>43.70</td><td>51.02</td><td>51.12</td></tr><tr><td colspan="5">Introns</td></tr><tr><td> Number</td><td>105,663</td><td>86,212</td><td>85,484</td><td>94,345</td></tr><tr><td> Average number per gene</td><td>4.03</td><td>3.14</td><td>2.49</td><td>2.25</td></tr><tr><td> Total length (Mbp)</td><td>83.12</td><td>17.87</td><td>47.70</td><td>53.34</td></tr><tr><td> Average size (bp)</td><td>630.33</td><td>157.25</td><td>398.18</td><td>391.23</td></tr><tr><td> Average GC (%)</td><td>32.37</td><td>32.45</td><td>38.29</td><td>37.20</td></tr><tr><td colspan="5">Transposable elements<sup>b</sup></td></tr><tr><td> % Total interspersed</td><td>46.07</td><td>13.32</td><td>37.39</td><td>44.40</td></tr><tr><td> Total interspersed total length (Mbp)</td><td>274.51</td><td>15.94</td><td>101.39</td><td>166.27</td></tr><tr><td> % Short interspersed nuclear elements (SINEs)</td><td>0.02</td><td>0.17</td><td>0.38</td><td>0.88</td></tr><tr><td> SINEs total length (Mbp)</td><td>0.13</td><td>0.20</td><td>1.02</td><td>3.31</td></tr><tr><td> % Long interspersed nuclear elements (LINEs)</td><td>2.43</td><td>1.07</td><td>2.91</td><td>1.29</td></tr><tr><td> LINEs total length (Mbp)</td><td>14.46</td><td>1.29</td><td>7.90</td><td>4.83</td></tr><tr><td> % Long terminal repeat (LTR) elements</td><td>22.82</td><td>6.35</td><td>19.31</td><td>21.09</td></tr><tr><td> LTR elements total length (Mbp)</td><td>135.71</td><td>7.61</td><td>52.36</td><td>78.98</td></tr><tr><td> % DNA elements</td><td>6.70</td><td>3.08</td><td>7.11</td><td>16.7</td></tr><tr><td> DNA elements total length (Mbp)</td><td>39.83</td><td>3.69</td><td>19.27</td><td>62.82</td></tr><tr><td> % Unclassified</td><td>14.20</td><td>2.64</td><td>7.68</td><td>4.36</td></tr><tr><td> Unclassified total length (Mbp)</td><td>84.38</td><td>3.16</td><td>20.84</td><td>16.32</td></tr></table>
|
a04baeebd08700d4c39d877ea51861fadf91ba98bf0abde5dc804fed8e6da154.png
|
complex
|
<table><tr><td>Characteristics</td><td>Hazard Ratio (95% Confidence Interval)<sup>a</sup></td></tr><tr><td>Age (continuous)</td><td>1.01 (1.001–1.02)*</td></tr><tr><td>Sex, female (versus male)</td><td>1.05 (0.80–1.37)</td></tr><tr><td colspan="2">Charlson Comorbidity Index</td></tr><tr><td> 0</td><td>Reference</td></tr><tr><td> 1</td><td>0.90 (0.62–1.29)</td></tr><tr><td>≥ 2</td><td>0.94 (0.68–1.31)</td></tr><tr><td colspan="2">Observation period<sup>b</sup></td></tr><tr><td> Period 1 in Pre-Campaign Year (weeks 1–5)</td><td>3.22 (0.88–11.7)</td></tr><tr><td> Period 2 in Pre-Campaign Year (weeks 6–10)</td><td>0.97 (0.20–4.80)</td></tr><tr><td> Period 3 in Pre-Campaign Year (weeks 11–15)</td><td>2.27 (0.59–8.77)</td></tr><tr><td> Period 4 in Pre-Campaign Year (weeks 16–20)</td><td>0.98 (0.20–4.85)</td></tr><tr><td> Period 5 in Pre-Campaign Year (weeks 21–25)</td><td>0.98 (0.20–4.85)</td></tr><tr><td> Period 6 in Pre-Campaign Year (weeks 26–30)</td><td>2.29 (0.59–8.87)</td></tr><tr><td> Period 7 in Pre-Campaign Year (weeks 31–35)</td><td>0.99 (0.20–4.89)</td></tr><tr><td> Period 8 in Pre-Campaign Year (weeks 36–40)</td><td>3.31 (0.91–12.0)</td></tr><tr><td> Period 9 in Pre-Campaign Year (weeks 41–45)</td><td>1.00 (0.20–4.94)</td></tr><tr><td> Period 10 in Pre-Campaign Year (weeks 46–50)</td><td>Reference</td></tr><tr><td> Period 1 in Year 1 (weeks 1–5)</td><td>2.99 (0.81–11.1)</td></tr><tr><td> Period 2 in Year 1 (weeks 6–10)</td><td>1.34 (0.30–5.98)</td></tr><tr><td> Period 3 in Year 1 (weeks 11–15)</td><td>1.34 (0.30–6.00)</td></tr><tr><td> Period 4 in Year 1 (weeks 16–20)</td><td>7.09 (2.11–23.8)**</td></tr><tr><td> Period 5 in Year 1 (weeks 21–25)</td><td>13.6 (4.21–44.1)***</td></tr><tr><td> Period 6 in Year 1 (weeks 26–30)</td><td>4.27 (1.20–15.1)*</td></tr><tr><td> Period 7 in Year 1 (weeks 31–35)</td><td>3.23 (0.87–11.9)</td></tr><tr><td> Period 8 in Year 1 (weeks 36–40)</td><td>2.16 (0.54–8.66)</td></tr><tr><td> Period 9 in Year 1 (weeks 41–45)</td><td>1.45 (0.32–6.48)</td></tr><tr><td> Period 10 in Year 1 (weeks 46–50)</td><td>2.55 (0.66–9.86)</td></tr><tr><td> Period 1 in Year 2 (weeks 1–5)</td><td>2.91 (0.77–11.0)</td></tr><tr><td> Period 2 in Year 2 (weeks 6–10)</td><td>3.30 (0.89–12.2)</td></tr><tr><td> Period 3 in Year 2 (weeks 11–15)</td><td>1.84 (0.44–7.72)</td></tr><tr><td> Period 4 in Year 2 (weeks 16–20)</td><td>1.48 (0.33–6.62)</td></tr><tr><td> Period 5 in Year 2 (weeks 21–25)</td><td>1.49 (0.33–6.65)</td></tr><tr><td> Period 6 in Year 2 (weeks 26–30)</td><td>2.24 (0.56–8.97)</td></tr><tr><td> Period 7 in Year 2 (weeks 31–35)</td><td>1.50 (0.34–6.72)</td></tr><tr><td> Period 8 in Year 2 (weeks 36–40)</td><td>1.13 (0.23–5.60)</td></tr><tr><td> Period 9 in Year 2 (weeks 41–45)</td><td>1.89 (0.45–7.91)</td></tr><tr><td> Period 10 in Year 2 (weeks 46–50)</td><td>1.90 (0.45–7.95)</td></tr></table>
|
d81c0610c9e2748cf4e334d83f304ec9773b0c247d6de2b32b1356153410eb38.png
|
simple
|
<table><tr><td>Variable</td><td>G1 (n=15)</td><td>G2 (n=16)</td><td>G3 (n=16)</td><td>G4 (n=16)</td></tr><tr><td>25(OH)D (ng/mL)</td><td>14.0±3.3</td><td>19.5±2.3a</td><td>24.0±2.3b</td><td>36.7±7.7c</td></tr><tr><td>Age (years)</td><td>61.7±3.6</td><td>60.8±2.9</td><td>58.8±2.9</td><td>61.3±2.8</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>25.1±4.6</td><td>26.2±3.5</td><td>25.6±3.7</td><td>26.2±5.2</td></tr><tr><td>Ethnicity</td><td></td><td></td><td></td><td></td></tr><tr><td>White</td><td>10 (66.7%)</td><td>14 (87.5%)</td><td>15 (93.7%)</td><td>11 (68.7%)</td></tr><tr><td>Black</td><td>4 (26.7%)</td><td>2 (12.5%)</td><td>1 (6.3%)</td><td>4 (25%)</td></tr><tr><td>Other</td><td>1 (6.6%)</td><td>0 (0%)</td><td>0 (0%)</td><td>1 (6.3%)</td></tr><tr><td>Menopause (years)*</td><td>16.2±7.3</td><td>14.0±5.8</td><td>13.1±5.2</td><td>12.7±3.9</td></tr><tr><td>Smoking</td><td>2 (13.3%)</td><td>3 (18.7%)</td><td>1 (6.2%)</td><td>3 (18.7%)</td></tr><tr><td>HRT</td><td>6 (40%)</td><td>11 (68.7%)</td><td>9 (56.2%)</td><td>10 (66.7%)</td></tr><tr><td>Calcium supplementation</td><td>8 (53.3%)</td><td>8 (50%)</td><td>15 (93.7%)</td><td>6 (37.5%)</td></tr><tr><td>Bone mineral density (g/cm<sup>2</sup>)</td><td></td><td></td><td></td><td></td></tr><tr><td>Vertebral column</td><td>0.72±0.07</td><td>0.75±0.05</td><td>0.74±0.06</td><td>0.72±0.09</td></tr><tr><td>Femur</td><td>0.77±0.06</td><td>0.76±0.09</td><td>0.76±0.07</td><td>0.81±0.12</td></tr><tr><td>Femoral neck</td><td>0.69±0.06</td><td>0.71±0.08</td><td>0.70±0.05</td><td>0.76±0.09</td></tr></table>
|
6da1c6122361343dd61020338e6069bc445ddc8a6fa458bfcc3489dbee41d584.png
|
simple
|
<table><tr><td>Blood group</td><td>n (%)</td><td>5-year DFS (%)</td><td>5-year OS (%)</td></tr><tr><td>A</td><td>146 (37.4)</td><td>38.1</td><td>46.9</td></tr><tr><td>B</td><td>108 (27.7)</td><td>31.4</td><td>38.6</td></tr><tr><td>O</td><td>109 (27.9)</td><td>32.8</td><td>42.9</td></tr><tr><td>AB</td><td>27 (6.9)</td><td>23.8</td><td>30.3</td></tr><tr><td>Non-O</td><td>281 (72.1)</td><td>33.2</td><td>43.2</td></tr></table>
|
2d3432d5eb731337d4dbd0fdcc8f01904c22a0525102dfb8aafc52d78370492e.png
|
complex
|
<table><tr><td rowspan="2">Element</td><td rowspan="2">Extraction in H<sub>2</sub>O</td><td rowspan="2">Extraction in 0.1 mol L<sup>−1</sup>HCl</td><td rowspan="2">Extraction in DTPA–CaCl<sub>2</sub>–TEA</td><td colspan="4">Total contents</td></tr><tr><td>Copper mine environ (site 1)</td><td>Former iron mine environ (site 2)</td><td>Reference area (site 3)</td><td>Urban area (site 4)</td></tr><tr><td>Ag</td><td><0.01</td><td>0.02 ± 0.01</td><td><0.01</td><td>0.47</td><td>0.76</td><td>0.46</td><td>1.09</td></tr><tr><td>Al</td><td>23.9 ± 16.5</td><td>62.9 ± 46.2</td><td>0.78 ± 0.88</td><td>58992</td><td>61061</td><td>59467</td><td>59643</td></tr><tr><td>As</td><td><0.25</td><td><0.25</td><td><0.25</td><td>26.9</td><td>23.4</td><td>18.9</td><td>48.7</td></tr><tr><td>Ba</td><td>0.18 ± 0.05</td><td>10.9 ± 5.81</td><td>0.71 ± 0.40</td><td>311</td><td>403</td><td>343</td><td>437</td></tr><tr><td>Ca</td><td>104 ± 47.7</td><td>3421 ± 430</td><td>1222 ± 197</td><td>22677</td><td>20447</td><td>21954</td><td>35394</td></tr><tr><td>Cd</td><td>0.01 ± 0.001</td><td>0.05 ± 0.03</td><td>0.05 ± 0.03</td><td>1.06</td><td>0.96</td><td>0.86</td><td>0.59</td></tr><tr><td>Cr</td><td>0.04 ± 0.02</td><td>0.06 ± 0.03</td><td>0.01 ± 0.003</td><td>63.6</td><td>41.9</td><td>55.8</td><td>54.2</td></tr><tr><td>Cu</td><td>0.30 ± 0.06</td><td>1.57 ± 1.97</td><td>8.60 ± 6.65</td><td>100</td><td>63.7</td><td>34.3</td><td>79.0</td></tr><tr><td>Fe</td><td>27.9 ± 18.1</td><td>4.43 ± 4.84</td><td>28.0 ± 33.4</td><td>43025</td><td>32629</td><td>32646</td><td>31242</td></tr><tr><td>K</td><td>56.2 ± 15.6</td><td>155 ± 47.2</td><td>81.6 ± 26.6</td><td>23716</td><td>19805</td><td>16173</td><td>20290</td></tr><tr><td>Li</td><td>0.01 ± 0.004</td><td>0.04 ± 0.006</td><td>0.006 ± 0.005</td><td>7.79</td><td>5.70</td><td>7.74</td><td>9.81</td></tr><tr><td>Mg</td><td>21.7 ± 6.15</td><td>305 ± 79.6</td><td>103 ± 28.7</td><td>10676</td><td>6583</td><td>8956</td><td>8629</td></tr><tr><td>Mn</td><td>0.47 ± 0.31</td><td>44.4 ± 28.5</td><td>10.6 ± 2.82</td><td>521</td><td>577</td><td>575</td><td>567</td></tr><tr><td>Mo</td><td>0.04 ± 0.04</td><td>0.04 ± 0.02</td><td>0.03 ± 0.03</td><td>4.0</td><td>3.2</td><td>2.8</td><td>2.5</td></tr><tr><td>Na</td><td>6.91 ± 4.67</td><td>9.73 ± 5.94</td><td>6.06 ± 5.35</td><td>8582</td><td>9248</td><td>8506</td><td>7956</td></tr><tr><td>Ni</td><td>0.18 ± 0.05</td><td>0.84 ± 0.54</td><td>0.55 ± 0.22</td><td>19.6</td><td>39.0</td><td>23.9</td><td>34.0</td></tr><tr><td>P</td><td>16.6 ± 3.75</td><td>177 ± 24.8</td><td>5.19 ± 1.41</td><td>1385</td><td>931</td><td>995</td><td>2184</td></tr><tr><td>Pb</td><td>0.25 ± 0.07</td><td>0.38 ± 0.26</td><td>1.71 ± 1.15</td><td>24.4</td><td>44.8</td><td>36.8</td><td>83.9</td></tr><tr><td>V</td><td>0.08 ± 0.03</td><td>0.10 ± 0.08</td><td>0.06 ± 0.04</td><td>93.8</td><td>72.2</td><td>82.7</td><td>67.9</td></tr><tr><td>Zn</td><td>0.28 ± 0.11</td><td>6.02 ± 5.34</td><td>5.02 ± 5.10</td><td>78.8</td><td>72.9</td><td>73.2</td><td>181</td></tr></table>
|
ad346c03cb06daa620938525d29e4458248552ef05fa6559c81788f04f6bc7eb.png
|
simple
|
<table><tr><td>Concept given to justify why brain death is death</td><td>Neurologist responses (n = 192) [n (%; 95% confidence interval)]</td><td>Neurologists who agreed the conceptual basis makes brain death equivalent to death (n = 133) [n (%; 95% confidence interval)]</td></tr><tr><td>Higher brain concept</td><td>63 (33%; 27-40%)</td><td>52 (39%; 31-48%)</td></tr><tr><td> Loss of integration of body concept</td><td>15 (8%; 5-13%)</td><td>13 (10%; 6-16%)</td></tr><tr><td> Loss of integration alone</td><td>7 (4%; 2-7%)</td><td>7 (5%; 2-11%)</td></tr><tr><td> Loss of integration combined with higher brain concept</td><td>8 (4%; 2-8%)</td><td>6 (5%; 2-10%)</td></tr><tr><td>Prognosis concept</td><td>9 (5%; 2-9%)</td><td>5 (4%; 1-9%)</td></tr><tr><td> Prognosis of death certain</td><td>7 (4%; 2-7%)</td><td>3 (2%; 1-7%)</td></tr><tr><td> Quality of life statement</td><td>2 (1%; 0-4%)</td><td>2 (2%; 0-6%)</td></tr><tr><td>No concept given</td><td>96 (50%; 43-57%)</td><td>59 (44%; 36-53%)</td></tr><tr><td> Re-statement only: loss of brain function (the criterion)</td><td>32 (17%; 12-23%)</td><td>23 (17%; 12-25%)</td></tr><tr><td> No response (blank)</td><td>64 (33%; 27-40%)</td><td>36 (27%; 20-35%)</td></tr><tr><td>Vital work of organism concept<sup>a</sup></td><td>4 (2%; 1-5%)</td><td>0 (0%; 0-2%)</td></tr><tr><td>Other</td><td>9 (5%; 2-9%)</td><td>4 (3%; 1-8%)</td></tr></table>
|
040656651cc9d70b8a6d7cec880322c079ef3613e7bba61bbe2f7b1a5154d27c.png
|
simple
|
<table><tr><td>Sociocultural variables</td><td>C 1</td><td>C 2</td></tr><tr><td>NBI</td><td>0.103</td><td>-0.620</td></tr><tr><td>Tourism</td><td>-0.702</td><td>0.597</td></tr><tr><td>Food - Men</td><td>0.882</td><td>-0.096</td></tr><tr><td>Food - Women</td><td>0.798</td><td>0.357</td></tr><tr><td>Medicinal - Men</td><td>0.008</td><td>0.073</td></tr><tr><td>Medicinal - Women</td><td>-0.307</td><td>0.736</td></tr><tr><td>Food - <46</td><td>0.841</td><td>0.194</td></tr><tr><td>Food - > 45</td><td>0.941</td><td>0.180</td></tr><tr><td>Medicinal - <46</td><td>-0.577</td><td>0.223</td></tr><tr><td>Medicinal - >45</td><td>0.222</td><td>0.046</td></tr><tr><td>Food - Stable job</td><td>0.918</td><td>0.078</td></tr><tr><td>Food - Unstable job</td><td>0.845</td><td>0.386</td></tr><tr><td>Medicinal - Stable job</td><td>-0.151</td><td>0.730</td></tr><tr><td>Medicinal - Unstable job</td><td>-0.242</td><td>0.316</td></tr><tr><td>Food - 1a5 years of residence</td><td>0.531</td><td>-0.463</td></tr><tr><td>Food - 6a10 y o r</td><td>0.348</td><td>0.747</td></tr><tr><td>Food - 11a15 y o r</td><td>0.615</td><td>0.159</td></tr><tr><td>Food - 16 and+ y o r</td><td>0.798</td><td>0.359</td></tr><tr><td>Medicinal - 1a5 years of residence</td><td>0.176</td><td>-0.464</td></tr><tr><td>Medicinal - 6a10 y o r</td><td>-0.392</td><td>0.284</td></tr><tr><td>Medicinal - 11a15 y o r</td><td>0.080</td><td>-0.408</td></tr><tr><td>Medicinal - 16 and+ y o r</td><td>-0.016</td><td>0.760</td></tr></table>
|
1264997142de6e32fc431a7b3aa4632867cecedca10a1251fd2c2c0010569d13.png
|
complex
|
<table><tr><td>SNP</td><td>LVRS Response Phenotype</td><td colspan="2">All subjects(n = 203)</td><td colspan="2">Upper lobe, low exercise(n = 59)</td><td colspan="2">Upper lobe, high exercise(n = 84)</td><td colspan="2">Non-upper lobe, low exercise(n = 23)</td><td colspan="2">Non-upper lobe, high exercise(n = 37)</td></tr><tr><td></td><td></td><td>β</td><td>p</td><td>β</td><td>p</td><td>β</td><td>p</td><td>β</td><td>p</td><td>β</td><td>p</td></tr><tr><td>rs3753658</td><td>BODE</td><td>-0.8</td><td>0.008</td><td>-1.3</td><td>0.01</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>UCSD SOBQ</td><td>-7.7</td><td>0.02</td><td>-11.7</td><td>0.05</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>rs1877724</td><td>Post-BD FEV<sub>1</sub>, liters</td><td>-0.06</td><td>0.04</td><td>-0.13</td><td>0.01</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>rs2234922</td><td>BODE</td><td>0.5</td><td>0.02</td><td></td><td></td><td></td><td></td><td>1.6</td><td>0.02</td><td></td><td></td></tr><tr><td></td><td>Max work, watts</td><td>-3.7</td><td>0.05</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>rs1051741</td><td>Max work, watts</td><td>-5.9</td><td>0.01</td><td></td><td></td><td></td><td></td><td>-8.4</td><td>0.09</td><td>-10.2</td><td>0.09</td></tr><tr><td>rs2292558</td><td>Max work, watts</td><td>-5.1</td><td>0.03</td><td></td><td></td><td></td><td></td><td>-8.4</td><td>0.09</td><td>-10.2</td><td>0.09</td></tr></table>
|
7f1b4ebe06ab84438b34923b688287272b2bc626b50b5c3fe9c270c9bb73f940.png
|
complex
|
<table><tr><td colspan="2">Round 1</td></tr><tr><td rowspan="3">Communicating about symptoms and quality of life</td><td>(1) Tell us about a time when you told your doctor or nurse about a symptom that was bothering you—like trouble sleeping or being sick to your stomach. What was difficult or easy about this time?</td></tr><tr><td>(2) How do you usually let your doctor or nurse know about these things? How does speaking Spanish affect what you do or do not tell your doctor or nurse?</td></tr><tr><td>(3) Here is a list of symptoms and quality of life issues common for people during treatment for cancer. Is there anything missing? Is there anything on the list that is not easy to understand?</td></tr><tr><td rowspan="2">Using the Internet</td><td>(4) How often do you use the Internet, and how do you access it—for example, from a computer, your phone? Do you know how to access the Internet yourself, or does someone help you?</td></tr><tr><td>(5) Are there websites or applications that you use to learn about health information or to track your activities, like exercise? What do you like about these websites or applications?</td></tr><tr><td rowspan="3">Responding to Spanish ESRA-C mock website</td><td>(6) Why do you think this website would, or would not, be interesting or useful for you?</td></tr><tr><td>(7) Do you think most people can understand these questions clearly and give answers?</td></tr><tr><td>(8) What do you think patients and their families would find most helpful about this information? How can we make it better?</td></tr><tr><td colspan="2">Round 2</td></tr><tr><td rowspan="2">Review of new patient narration</td><td>(1) How well does this new version meet the ideas you had about hearing from a patient's point of view?</td></tr><tr><td>(2) What thoughts did you have about the patient shown in the pictures who was telling her story? How similar are her concerns to the ones that you thought about when you were going to start treatment?</td></tr><tr><td rowspan="2">Review of new website home page and introduction</td><td>(3) You saw the woman using the website to learn about getting help and then telling her nurse about problems she was having. How much does this encourage you to talk to your nurse or doctor?</td></tr><tr><td>(4) Did we explain well enough for you to understand that the answers you give on this website will go to your doctors and nurses?</td></tr><tr><td rowspan="2">Review of messages in revised patient education and communication coaching</td><td>(5) If you put these three messages in order from most to least important for new patients to hear, what order would you put them in? Why? </td></tr><tr><td>(6) Are there any words in the website that do not sound right to you, or do you think we could say better?</td></tr><tr><td>Working with interpreters</td><td>(7) If you have used professional interpreters, what have you learned about the process that you wish you had known before you started your treatment? If you have not, what would you like to know about using interpreters?</td></tr><tr><td rowspan="2">Emailing providers</td><td>(8) Have you had experience emailing your providers, and if so, how well did that work?</td></tr><tr><td>(9) How would you feel about being able to email a question in Spanish to a translator or bilingual provider who could ask your doctor or nurse and reply to you?</td></tr><tr><td>Prioritizing future revisions</td><td>(10) The last thing we want to show you is a list of things that people suggested should be added to the website. If you like any of these ideas, or another idea you have, which of these should we work on first?</td></tr></table>
|
6003349bafd3844b36a9345cf40f3edfaa9e76a093a25170a78c4556f5e26676.png
|
simple
|
<table><tr><td>Subjects</td><td>27</td></tr><tr><td>Sex</td><td>14 (51.8%) male</td></tr><tr><td>Age (years)</td><td>7.92 (±2.52)</td></tr><tr><td>Weight (kilograms)</td><td>34.89±14.89</td></tr><tr><td>Height (meters)</td><td>1.34±0.15</td></tr><tr><td>BMI (kg/m<sup>2</sup>), z-score</td><td>18.63±14.92, 0.09±1.88</td></tr><tr><td>Tonsil size</td><td>Grades 3 and 4</td></tr><tr><td>Tonsil volume, mean (cm<sup>3</sup>) ± standarddeviation</td><td>7.41±3.77</td></tr></table>
|
85da8c5102bce7527906e98a3eac7646b0eda59842d3794f9fd3a1e1872c1117.png
|
simple
|
<table><tr><td>Gene</td><td>Forward primer (5′ to 3′)</td><td>Reverse primer (5′ to 3′)</td></tr><tr><td><i>MeCWINV1</i></td><td>CGCGGATCCAAAATAGAGATGGAAGCAAT</td><td>CGCGTCGACATCATTTCTCAAACATACCC</td></tr><tr><td><i>MeCWINV2</i></td><td>CATGCCATGGTCTTCTTCATCTTCAGTC</td><td>CGGGTTACCTTTTATCTTTAGCTCAGC</td></tr><tr><td><i>MeCWINV3</i></td><td>TCAATCAAAGGAGCTATGGACA</td><td>GCACTGGCTTCTTTTATTTCATC</td></tr><tr><td><i>MeCWINV4</i></td><td>TATGGATCCCTCACCAGCATGGCTATCA</td><td>CATGTCGACTGTCAACCCTGGCTATTTCTCA</td></tr><tr><td><i>MeCWINV5</i></td><td>TCATCCCGCAAATTCAACATT</td><td>GCTTACTTCTTTTCCACCTTATTTTTT</td></tr><tr><td><i>MeCWINV6</i></td><td>CTCATTATCCCAAACAGATCAACC</td><td>ATTCTCACTTCTTTAAGCAGTCTCA</td></tr></table>
|
235e91e913853fa69bbbc93e2aa3e042b6d2e31f6ffc815f81f4d51383c9e848.png
|
complex
|
<table><tr><td></td><td>HRCT score</td><td colspan="5">MRI score</td></tr><tr><td></td><td></td><td>0</td><td>1</td><td>2</td><td>3</td><td>4</td></tr><tr><td>Consolidation</td><td>52</td><td></td><td></td><td></td><td></td><td>52</td></tr><tr><td>Alteration consistent with caseosis</td><td>undetermined</td><td></td><td></td><td></td><td></td><td>4</td></tr><tr><td>Cavitation</td><td>39</td><td></td><td></td><td></td><td></td><td>39</td></tr><tr><td>Ground glass</td><td>6</td><td></td><td></td><td>2</td><td>1</td><td>4</td></tr><tr><td>Nodule</td><td>43</td><td></td><td></td><td></td><td></td><td>43</td></tr><tr><td>Tree in bud</td><td>33</td><td></td><td></td><td></td><td></td><td>29</td></tr><tr><td>Interstitial changes</td><td>14</td><td></td><td></td><td>1</td><td>4</td><td>13</td></tr><tr><td>Lymph nodes</td><td>(Short axis > 10 mm) 38</td><td></td><td></td><td></td><td></td><td>56</td></tr><tr><td>Edema</td><td>undetermined</td><td></td><td></td><td></td><td></td><td>50</td></tr><tr><td>Alteration consistent with colliquative necrosis</td><td>undetermined</td><td></td><td></td><td></td><td></td><td>2</td></tr><tr><td>Alteration consistent with caseosis</td><td>undetermined</td><td></td><td></td><td></td><td></td><td>4</td></tr><tr><td>Pleural involvement</td><td>10</td><td></td><td></td><td></td><td></td><td>21</td></tr></table>
|
e369cdda5c954c3661e49456a195a91056d8de79bc7215caad5a1b7a542bdd34.png
|
simple
|
<table><tr><td>Time</td><td>Flow</td><td>%Phase C<sup>1</sup></td><td>%Phase A</td><td>Curve</td></tr><tr><td>0.0</td><td>0.20</td><td>10</td><td>90</td><td>6</td></tr><tr><td>1.0</td><td>0.20</td><td>10</td><td>90</td><td>6</td></tr><tr><td>40.0</td><td>0.20</td><td>100</td><td>0</td><td>6</td></tr><tr><td>45.0</td><td>0.30</td><td>100</td><td>0</td><td>6</td></tr><tr><td>50.0</td><td>0.20</td><td>10</td><td>90</td><td>3</td></tr><tr><td>58.0</td><td>0.20</td><td>10</td><td>90</td><td>6</td></tr><tr><td>59.0</td><td>0.20</td><td>10</td><td>90</td><td>6</td></tr><tr><td>78.0</td><td>0.20</td><td>100</td><td>0</td><td>6</td></tr></table>
|
941919aa0ea092ff7ef8e33a08d54c84e03f0792707dbb03d08af483cc1ee35f.png
|
simple
|
<table><tr><td>Term</td><td>Genes</td><td><i>p</i>-value</td></tr><tr><td>hsa05214:Glioma</td><td>CDKN1A, CDK6</td><td>0.018</td></tr><tr><td>hsa04115:p53 signaling pathway</td><td>CDKN1A, CDK6</td><td>0.019</td></tr><tr><td>hsa05218:Melanoma</td><td>CDKN1A, CDK6</td><td>0.02</td></tr><tr><td>hsa05220:Chronic myeloid leukemia</td><td>CDKN1A, CDK6</td><td>0.02</td></tr><tr><td>hsa04066:HIF-1 signaling pathway</td><td>CDKN1A, TFRC</td><td>0.028</td></tr><tr><td>hsa04110:Cell cycle</td><td>CDKN1A, CDK6</td><td>0.035</td></tr><tr><td>hsa05161:Hepatitis B</td><td>CDKN1A, CDK6</td><td>0.041</td></tr></table>
|
ca15d81c56679a1085a46260a3764faff5b5612778b9ddeaccd21aba18fe915f.png
|
simple
|
<table><tr><td></td><td>Model 1</td><td>Model 2</td><td>Model 3</td><td>Model 4</td></tr><tr><td>Independence</td><td>1076</td><td>1076</td><td>717</td><td>279</td></tr><tr><td>Chi-square</td><td>(378 df)</td><td>(378 df)</td><td>(171)</td><td>(55 df)</td></tr><tr><td>Average standardised residuals</td><td>0.11</td><td>0.09</td><td>0.09</td><td>0.09</td></tr><tr><td>Average off-diagonal st. residuals</td><td>0.12</td><td>0.10</td><td>0.10</td><td>0.11</td></tr><tr><td>Chi-squared fit</td><td>534.7</td><td>520</td><td>213</td><td>67.7</td></tr><tr><td>(df)s</td><td>(347 df)</td><td>(347 df)</td><td>(150 df)</td><td>(43)</td></tr><tr><td>P-value</td><td>0.00001</td><td>0.00001</td><td>0.001</td><td>0.01</td></tr><tr><td>Free parameters</td><td>59</td><td>57</td><td>40</td><td>23</td></tr><tr><td>Akaike's information criterion (AIC)</td><td>-193</td><td>-173</td><td>-87</td><td>-18</td></tr><tr><td>Bozodgan's version of AIC (C-AIC)</td><td>(-1437)</td><td>(-1424)</td><td>(-627)</td><td>(-173)</td></tr><tr><td>Comparative Fit Index (CFI)</td><td>0.73</td><td>0.75</td><td>0.89</td><td>0.90</td></tr><tr><td>Normed Fit Index (NFI)</td><td>0.50</td><td>0.52</td><td>0.70</td><td>0.76</td></tr><tr><td>Non-normed Fit Index (NNFI)</td><td>0.71</td><td>0.73</td><td>0.87</td><td>0.86</td></tr></table>
|
e014106f673018307bcd53170e3d50577f8d6709fd45feeddb0308a38bda87e0.png
|
simple
|
<table><tr><td></td><td><i>ρ</i> of TER</td><td><i>p</i> Value</td><td><i>ρ</i> of Delay Time</td><td><i>p</i> Value</td></tr><tr><td>upregulation</td><td>−0.084</td><td>0.43</td><td>0.37</td><td>2.7 × 10<sup>−4</sup></td></tr><tr><td>maximal FC</td><td>−0.17</td><td>0.10</td><td>0.416</td><td>7.2 × 10<sup>−6</sup></td></tr><tr><td>maximal RPKM</td><td>−0.10</td><td>0.36</td><td>0.05</td><td>0.61</td></tr><tr><td>GC content</td><td>−0.11</td><td>0.32</td><td>−0.04</td><td>0.73</td></tr><tr><td>CAI</td><td>−0.23</td><td>0.03</td><td>−0.10</td><td>0.35</td></tr><tr><td>ITE</td><td>−0.25</td><td>0.02</td><td>−0.15</td><td>0.14</td></tr><tr><td>RNA folding energy</td><td>0.17</td><td>0.10</td><td>0.12</td><td>0.25</td></tr><tr><td>regulated by Cra *</td><td>−0.03</td><td>0.75</td><td>−0.29</td><td>0.01</td></tr><tr><td>regulated by FNR *</td><td>−0.13</td><td>0.21</td><td>−0.21</td><td>0.04</td></tr><tr><td>regulated by Fur-Fe *</td><td>−0.12</td><td>0.28</td><td>0.22</td><td>0.04</td></tr><tr><td>controlled by sigma S</td><td>−0.15</td><td>0.15</td><td>−0.22</td><td>0.04</td></tr></table>
|
766df61b51582b88e2ce72799fb79fc7988044e2990e150ea17095b1355a1d23.png
|
simple
|
<table><tr><td>Themes</td><td>Categories</td><td>Definitions</td></tr><tr><td>Development of national maternal healthguidelines</td><td> · Development Process</td><td>· the steps taken to develop and produce guidelines</td></tr><tr><td></td><td> · Stakeholder participation</td><td>· level of involvement of stakeholders in guideline development</td></tr><tr><td></td><td> · National guidelines' relation to WHO recommendations</td><td>· how contents of national CPGs compare with WHO PCPNC guidelines</td></tr><tr><td>Health workers' access to guidelines</td><td>Perceived access barriers</td><td></td></tr><tr><td></td><td> · Distribution</td><td>· physical distribution of printed guidelines</td></tr><tr><td></td><td> · Staff mobility</td><td>· frequent changes of work-place displaces guidelines from health facilities</td></tr><tr><td></td><td> · Health workers' participation in training courses</td><td>· course curricula frequently used as CPGs, health workers dependent on courses to obtain up-to-date guidelines</td></tr><tr><td></td><td><underline>Perceived solutions to improve access:</underline></td><td></td></tr><tr><td></td><td> · Pocket sized guidelines</td><td>· personal portable guidelines for every health worker</td></tr><tr><td></td><td> · Wall posters</td><td>· guidelines in a poster format increases availability for everybody working in the health facility</td></tr><tr><td>Health workers' use of guidelines</td><td> · Low levels of guideline adherence</td><td>· perception among key informants of an overall low use of guidelines by front-line health workers</td></tr><tr><td></td><td><underline>Perceived reasons for low guideline adherence:</underline></td><td></td></tr><tr><td></td><td> · Attitudes towards continuing education</td><td>· health workers do not usually update their knowledge independently from organised training</td></tr><tr><td></td><td> · Effects of training</td><td>· limited change in clinical practice following courses</td></tr><tr><td></td><td> · Format of guidelines - lack of usability</td><td>· presence of flow-charts, algorithms etc.</td></tr><tr><td></td><td> · Negative beliefs about using guidelines during patient consultations</td><td>· perception that patients' trust will be undermined if health workers use CPGs during consultations</td></tr></table>
|
55e99b45a64fce0c2565e15229e77c6063a7b62e883884a85661e65868f19009.png
|
simple
|
<table><tr><td>Variables</td><td>Beta (OR)**</td><td>95% CI</td><td><i>P</i></td></tr><tr><td>Protein (g)</td><td>0.011</td><td>-0.04, 0.029</td><td>0.668</td></tr><tr><td>Carbohydrates (g)</td><td>0.129</td><td>0.012, 0.172</td><td>0.341</td></tr><tr><td>Iron (mg)</td><td>1.128</td><td>0.002, 0.161</td><td>0.031*</td></tr><tr><td>Thiamine (mg)</td><td>0.018</td><td>-0.040, 0.059</td><td>0.655</td></tr><tr><td>Zinc (mg)</td><td>0.029</td><td>-0.002, 0.004</td><td>0.089</td></tr></table>
|
c0d0ccc8f9310f2d67bafcc5b5f0bcefea69da14fde465037749b285fcfc720f.png
|
simple
|
<table><tr><td>Effect</td><td>Data structure</td><td>Type of test</td><td>Power</td><td>df (between)</td><td>df (within)</td><td><i>F</i></td><td>χ2</td><td><i>p</i></td></tr><tr><td>Pairwise discrimination phase (d)</td><td>Normally distributed</td><td>Two-factor repeated-measures ANOVA</td><td>0.96</td><td>1</td><td>9</td><td>17.58</td><td></td><td>0.002</td></tr><tr><td>Pairwise discrimination genotype (d)</td><td>Normally distributed</td><td>Two-factor repeated-measures ANOVA</td><td>0.41</td><td>1</td><td>9</td><td>3.78</td><td></td><td>0.08</td></tr><tr><td>Pairwise discrimination interaction (d)</td><td>Normally distributed</td><td>Two-factor repeated-measures ANOVA with <i>post hoc</i> Bonferroni correction</td><td>0.13</td><td>1</td><td>9</td><td>0.83</td><td></td><td>0.4</td></tr><tr><td>Pairwise discrimination phase (trials)</td><td>Normally distributed</td><td>Two-factor repeated-measures ANOVA</td><td>0.62</td><td>1</td><td>9</td><td>6.45</td><td></td><td>0.03</td></tr><tr><td>Pairwise discrimination genotype (trials)</td><td>Normally distributed</td><td>Two-factor repeated-measures ANOVA</td><td>0.16</td><td>1</td><td>9</td><td>1.10</td><td></td><td>0.3</td></tr><tr><td>Pairwise discrimination interaction (trials)</td><td>Normally distributed</td><td>Two-factor repeated-measures ANOVA</td><td>0.06</td><td>1</td><td>9</td><td>0.13</td><td></td><td>0.7</td></tr><tr><td>Pairwise discrimination (survival curve)</td><td>Normally distributed</td><td>Mantel–Cox test</td><td>0.06</td><td>1</td><td></td><td></td><td>0.53</td><td>0.5</td></tr><tr><td>Pairwise discrimination reversal (survival curve)</td><td>Normally distributed</td><td>Mantel–Cox test</td><td>0.07</td><td>1</td><td></td><td></td><td>0.48</td><td>0.5</td></tr></table>
|
05ba337f0dfd6ac724c6c63815e71c469d4702dbeb4be434bde6899df8df5f5b.png
|
simple
|
<table><tr><td>Authors/Year</td><td>Country</td><td>Design</td><td>Valable</td><td>OR (95% CI)</td></tr><tr><td>Chen 1995 [17]</td><td>England</td><td>Case–control</td><td>Severe life events</td><td>11.64 (3.10-43.66)</td></tr><tr><td>Protheroe 1999 [19]</td><td>Australia</td><td>Case–control</td><td>Severe life events</td><td>0.91 (0.47-1.81)</td></tr><tr><td>Kruk 2012 [20]</td><td>Poland</td><td>Case–control</td><td>Major life events</td><td>5.33 (4.01-8.21)</td></tr><tr><td>Helgesson 2003 [21]</td><td>Sweden</td><td>Prospective</td><td>Stressful events</td><td>2.1 (1.2-3.7)</td></tr><tr><td>Lillberg 2003 [22]</td><td>Finland</td><td>Prospective</td><td>Major life events</td><td>1.35 (1.09-1.67)</td></tr><tr><td>Michael2009 [23]</td><td>America</td><td>Prospective</td><td>≥4 life events</td><td>0.91 (0.77-1.08)</td></tr></table>
|
9710f6a7c1b82cecd07dc8af664c4974b7dfe1696dec4dd714c6cb6080d29397.png
|
simple
|
<table><tr><td></td><td>Grade 1</td><td>Grade 2</td><td>Grade 3</td><td>Grade 4</td><td>Grade 5</td></tr><tr><td>Pre CXL</td><td>0 (0 %)</td><td>0 (0 %)</td><td>3 (12.5 %)</td><td>8 (33.3%)</td><td>13 (64.2%)</td></tr><tr><td>Post CXL</td><td>16 (66.6%)</td><td>8 (33.3%)</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr></table>
|
459c054e4a357b447708be7472a1003272d9fbc684de664166cb7f80d119d2d1.png
|
simple
|
<table><tr><td>Adverse reactions and treatment</td><td>Ketotifen</td><td>Placebo</td></tr><tr><td>Total no. of doses of OIT, n</td><td>36</td><td>18</td></tr><tr><td>Total no. of patients reporting symptoms</td><td>3/4</td><td>2/2</td></tr><tr><td>Total no. of doses with symptoms, n (% of total OIT doses)</td><td>8/36 (22%)</td><td>12/18 (67%)</td></tr><tr><td>Anaphylaxis, n (% of total OIT doses)</td><td>-*</td><td>1 (5%)</td></tr><tr><td>Symptoms n, (% of OIT doses)</td><td>Ketotifen</td><td>Placebo</td></tr><tr><td>Gastrointestinal</td><td>6/36 (17%)</td><td>11/18 (61%)</td></tr><tr><td>Cutaneous</td><td>-</td><td>1/18 (6%)</td></tr><tr><td>Lower respiratory</td><td>2/36 (6%)</td><td>1/18 (6%)</td></tr><tr><td>Oropharyngeal</td><td>-</td><td>2/18 (11%)</td></tr><tr><td>Upper respiratory</td><td>-</td><td>-</td></tr><tr><td>Cardiovascular</td><td>-</td><td>-</td></tr><tr><td>Other<sup>A</sup></td><td>-</td><td>2/18 (11%)</td></tr><tr><td>Treatment n, (% of OIT doses)</td><td>Ketotifen</td><td>Placebo</td></tr><tr><td>Epinephrine</td><td>-</td><td>-</td></tr><tr><td>Diphenhydramine</td><td>-</td><td>-</td></tr><tr><td>Cetirizine or other**</td><td>-</td><td>1/18 (6%)</td></tr><tr><td>Prednisone</td><td>-</td><td>-</td></tr><tr><td>Salbutamol or other inhaled medication</td><td>-</td><td>1/18 (6%)</td></tr></table>
|
f9f90bf0e6fed28537c56d6e1a50ff9fa69c8db17c91da2b7a8a4c3d8ef47496.png
|
simple
|
<table><tr><td>Linear range</td><td>R<sup>2</sup></td><td>LOD (μg/kg)</td><td>RSD (%)</td><td>Recovery (%)</td></tr><tr><td>20~200 μg/L</td><td>0.9988</td><td>2.4</td><td>3.5</td><td>91~97</td></tr></table>
|
ee449812cc90b593153e5ed98f86d9a08ddbedfca5aabc7525066ec75f342bbd.png
|
simple
|
<table><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td></tr><tr><td>PTGI total score</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>PHQ-9 total score</td><td>0.12*</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>SAS total score</td><td>0.14*</td><td>0.66*</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Relating to others</td><td>0.89*</td><td>0.14*</td><td>0.13*</td><td>1</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>New Possibilities</td><td>0.91*</td><td>0.16*</td><td>0.14*</td><td>0.78*</td><td>1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Personal strength</td><td>0.82*</td><td>-0.03</td><td>0.03</td><td>0.62*</td><td>0.70*</td><td>1</td><td></td><td></td><td></td><td></td></tr><tr><td>Spiritual change</td><td>0.59*</td><td>0.14*</td><td>0.20*</td><td>0.50*</td><td>0.46*</td><td>0.34*</td><td>1</td><td></td><td></td><td></td></tr><tr><td>Appreciation of life</td><td>0.78*</td><td>0.09</td><td>0.15*</td><td>0.61*</td><td>0.64*</td><td>0.61*</td><td>0.43*</td><td>1</td><td></td><td></td></tr><tr><td>age</td><td>0.01</td><td>-0.02</td><td>-0.05</td><td>-0.06</td><td>0.06</td><td>-0.00</td><td>-0.02</td><td>0.04</td><td>1</td><td></td></tr></table>
|
dde787cafdea0674645424cc3316a9114c4fabbe56985ee0de4492222d4e662a.png
|
simple
|
<table><tr><td>Identified symptom</td><td>TotalN (%)</td><td>MaleN (%)</td><td>FemaleN (%)</td><td>X<sup>2</sup></td><td>p value</td></tr><tr><td>Fatigue</td><td>27 (9.8)</td><td>9 (6.3)</td><td>18 (13.6)</td><td>4.18*</td><td>0.041</td></tr><tr><td>Insomnia</td><td>47 (17.1)</td><td>23 (16.1)</td><td>24 (18.2)</td><td>0.21</td><td>0.644</td></tr><tr><td>Decreased appetite/weight loss</td><td>13 (4.7)</td><td>8 (5.6)</td><td>5 (3.8)</td><td>0.49</td><td>0.339</td></tr><tr><td>Diminished ability to think</td><td>37 (13.5)</td><td>14 (9.8)</td><td>23 (17.6)</td><td>3.53*</td><td>0.044</td></tr><tr><td>Diminished interest in activities</td><td>23 (8.4)</td><td>12 (4.4)</td><td>11 (4.0)</td><td>0.003</td><td>0.566</td></tr></table>
|
b870dd57e310584855157a2c295b10de6cb35bda6cd7d4afd7f917a894650d88.png
|
simple
|
<table><tr><td>Parameters(mean ± SD)</td><td>GDM(<i>n</i> = 45)</td><td>Non-GDM(<i>n</i> = 45)</td><td><i>p</i> value</td></tr><tr><td>Age (years)</td><td>29.27 ± 6.87</td><td>26.84 ± 6.99</td><td>0.101</td></tr><tr><td>Weight (Kg)</td><td>72.84 ± 8.79</td><td>70.84 ± 8.39</td><td>0.273</td></tr><tr><td>Height (cm)</td><td>158.42 ± 6.31</td><td>159.40 ± 5.15</td><td>0.423</td></tr><tr><td>BMI (Kg/m<sup>2</sup>)</td><td>30.73 ± 4.82</td><td>29.56 ± 3.66</td><td>0.198</td></tr><tr><td>SBP (mmHg)</td><td>121.64 ± 6.28</td><td>120.33 ± 6.25</td><td>0.324</td></tr><tr><td>DBP (mmHg)</td><td>73.42 ± 2.83</td><td>72.82 ± 2.57</td><td>0.295</td></tr><tr><td>Serum Cholesterol (mg/dl)</td><td>174.56 ± 12.71</td><td>158.71 ± 8.96</td><td>0.001</td></tr><tr><td>RBG (mg/dl)</td><td>93.24 ± 4.64</td><td>83.91 ± 4.12</td><td>0.001</td></tr></table>
|
f9328c5bfda60706d48dba6ea656a5ac59745bf9e94a0c901199fa35747342f1.png
|
simple
|
<table><tr><td>Explanatory variables</td><td>β<sup>a</sup></td><td>95% CI for β</td><td>P value</td></tr><tr><td>Waiting time</td><td></td><td></td><td></td></tr><tr><td> 0–3 months</td><td>Reference</td><td></td><td></td></tr><tr><td> > 3–6 months</td><td>0.013</td><td>-0.016, 0.043</td><td>0.381</td></tr><tr><td> > 6 months</td><td>0.017</td><td>-0.014, 0.047</td><td>0.286</td></tr><tr><td>BMI</td><td>-0.003</td><td>-0.005, -0.0004</td><td>0.020</td></tr><tr><td>Affected joint (0 = hip, 1 = knee)</td><td>0.013</td><td>-0.009, 0.035</td><td>0.232</td></tr><tr><td>15D score at baseline</td><td>0.752</td><td>0.637, 0.867</td><td><0.001</td></tr><tr><td>Gender (0 = female, 1 = male)</td><td>-0.008</td><td>-0.032, 0.015</td><td>0.479</td></tr><tr><td>Age</td><td>-0.0004</td><td>-0.002, 0.001</td><td>0.539</td></tr><tr><td>Professional education (0 = no, 1 = yes)</td><td>-0.0003</td><td>-0.023, 0.022</td><td>0.976</td></tr><tr><td>Housing (0 = living alone, 1 = living with someone)</td><td>0.009</td><td>-0.016, 0.034</td><td>0.469</td></tr><tr><td>Constant</td><td>0.301</td><td></td><td></td></tr><tr><td>R square</td><td>0.613</td><td></td><td></td></tr><tr><td>F</td><td>21.430***</td><td></td><td></td></tr><tr><td>n</td><td>133</td><td></td><td></td></tr></table>
|
3e2825eca1b99179843c1b0c3ccaad9127d001f18b1590a6f36f6f7ee34dd901.png
|
complex
|
<table><tr><td>Condition</td><td>Test</td><td>Absolute error (95% CI)</td><td>Symptomatic diagnosis-Tariff method with health care experience absolute error (95% CI)</td></tr><tr><td rowspan="3">Asthma</td><td>World Health Survey (WHS): Doctor (MD) diagnosis (Dx) [34]</td><td>0.023 (0.020, 0.025)</td><td rowspan="3">0.014 (0.012, 0.016)</td></tr><tr><td>WHS MD Dx OR asthma medications (Rx) [34]</td><td>0.023 (0.020, 0.025)</td></tr><tr><td>WHS MD Dx OR asthma Rx OR wheezing/whistling attacks [34]</td><td>0.092 (0.087, 0.095)</td></tr><tr><td>Angina pectoris</td><td>Rose questionnaire [35,36]</td><td>0.082 (0.073, 0.088)</td><td>0.020 (0.018, 0.022)</td></tr><tr><td>Depression</td><td>Composite international diagnostic interview questionnaire [37]</td><td>0.059 (0.054, 0.064)</td><td>0.016 (0.015, 0.017)</td></tr></table>
|
6472b6d43f7963d2fa7912f25cc6c9de0f63664fa1bc4fe5401ef9c28cbb0c55.png
|
complex
|
<table><tr><td></td><td>Topic</td></tr><tr><td colspan="2">Week 1</td></tr><tr><td>Day 1</td><td>An Overview of Maternal-Infant Care</td></tr><tr><td>Day 2</td><td>The Role of the Birth Attendant, Health Care Resources, and the Emergency Plan</td></tr><tr><td colspan="2">Week 2</td></tr><tr><td>Day 3</td><td>Sexual Organs, Sexual Desire, and Menstruation, Ovulation, and Fertilization</td></tr><tr><td>Day 4</td><td>The Natural Development of Pregnancy</td></tr><tr><td colspan="2">Week 3</td></tr><tr><td>Day 5</td><td>The Choice of Motherhood, The Importance of Prenatal Care—Part 1</td></tr><tr><td>Day 6</td><td>The Importance of Prenatal Care—Part 2</td></tr><tr><td colspan="2">Week 4</td></tr><tr><td>Day 7</td><td>Pregnancy Complications, Part 1</td></tr><tr><td>Day 8</td><td>Pregnancy Complications, Part 2</td></tr><tr><td colspan="2">Week 5</td></tr><tr><td>Day 9</td><td>Signs and Symptoms of Danger during Pregnancy</td></tr><tr><td>Day 10</td><td>Case Studies on Prenatal Care, Exam 1</td></tr><tr><td colspan="2">Week 6</td></tr><tr><td>Day 11</td><td>Review Exam 1</td></tr><tr><td>Day 12</td><td>Tetanus Vaccine, Introduction to Stages of Labor</td></tr><tr><td colspan="2">Week 7</td></tr><tr><td>Day 13</td><td>Uncomplicated Labor: Stage One and Two</td></tr><tr><td>Day 14</td><td>Uncomplicated Labor: Stage Two and Three</td></tr><tr><td colspan="2">Week 8</td></tr><tr><td>Day 15</td><td>Review of Stages of Labor, Basic Care of the Newborn</td></tr><tr><td>Day 16</td><td>Complications during Labor and Delivery</td></tr><tr><td colspan="2">Week 9</td></tr><tr><td>Day 17</td><td>When to Refer during Labor</td></tr><tr><td>Day 18</td><td>Neonatal Resuscitation, Immediate Post-Partum Care, Maternal Lactation</td></tr><tr><td colspan="2">Week 10</td></tr><tr><td>Day 19</td><td>Maternal Lactation Review, Post-Partum Care: Day 1 & 4</td></tr><tr><td>Day 20</td><td>Review of Normal and Complicated Labor, Exam 2</td></tr><tr><td colspan="2">Week 11</td></tr><tr><td>Day 21</td><td>Medicinal Plants, Sharing of Experiences during Labor</td></tr><tr><td>Day 22</td><td>Infection Prevention and Management, Sterilization of Birth Tools</td></tr><tr><td colspan="2">Week 12</td></tr><tr><td>Day 23</td><td>Family Planning Methods</td></tr><tr><td>Day 24</td><td>Case Studies: Family Planning, Self Breast Exam</td></tr><tr><td colspan="2">Week 13</td></tr><tr><td>Day 25</td><td>Vaginal Infections and STIs</td></tr><tr><td>Day 26</td><td>Nutrition and Malnutrition</td></tr><tr><td colspan="2">Week 14</td></tr><tr><td>Day 27</td><td>Complicated Labor</td></tr><tr><td>Day 28</td><td>Cumulative Review, Final Exam</td></tr></table>
|
1106daf0b16728b9db3451d61078675ee233450e53a6809aba9dac7f224484d0.png
|
complex
|
<table><tr><td colspan="5">Ergonomic problems</td></tr><tr><td>Categories</td><td>Working posture and type of examination</td><td>Equipment and physical factors</td><td>The patient’s physique and health</td><td>Work experience and knowledge</td></tr><tr><td>Subcategories</td><td>-Echocardiography-Vascular examinations-Bedside examination</td><td>-Ultrasonic device-Examination room including table and equipment to assist patients-Physical factors including light, noise and ventilation</td><td>-Patient constitution-Inpatients</td><td>-Lack of skills</td></tr></table>
|
c1041fe5722562603c9fc9598afe87c2f926265299ac5618e990aaf5d5338f63.png
|
complex
|
<table><tr><td>Variables</td><td>Chi Square</td><td>95% C.I.</td><td>Hazard Ratio</td><td><i>P </i>Value</td></tr><tr><td colspan="5">DFS</td></tr><tr><td>1. Cellular differentiation</td><td>10.51</td><td>4.20 – 463.30</td><td>0.3101</td><td>0.005*</td></tr><tr><td colspan="5">OS</td></tr><tr><td>1. Tumor Grade</td><td>6.08</td><td>1.41 – 3.07</td><td>0.2741</td><td>0.01*</td></tr></table>
|
9e96320c11a1a2f3a7fbd325de7a3b8217b2bec31509eed83f99b59bc8b7e292.png
|
simple
|
<table><tr><td> </td><td>Number of people</td><td>Percentage (%)</td></tr><tr><td>Before preferences learning</td><td>3</td><td>7.65%</td></tr><tr><td>After preferences learning</td><td>14</td><td>82.35%</td></tr><tr><td>Total number of people and percentage</td><td>17</td><td>100%</td></tr></table>
|
7e30cff0be3b9f6ca7d17aed4a25029f680a4773c85ee3789ebdbc81ea331438.png
|
simple
|
<table><tr><td></td><td>N</td><td>ATPIII 2001</td><td>ATPIII revised</td><td>WHO</td><td>IDF</td></tr><tr><td>NHANES 1988-1994 [143]</td><td>8,814</td><td>23.7%</td><td></td><td></td><td></td></tr><tr><td>NHANES 1988-1994 [144]</td><td>8,608</td><td>23.9%</td><td></td><td>25.1%</td><td></td></tr><tr><td>NHANES 1988-1994 [145]</td><td>6,436</td><td>24.1%</td><td>29.2%</td><td></td><td></td></tr><tr><td>NHANES 1999-2002 [145]</td><td>1,677</td><td>27.0%</td><td>32.3%</td><td></td><td></td></tr><tr><td>NHANES 1999-2002 [10]</td><td>3,601</td><td></td><td>34.6%</td><td></td><td>39.1%</td></tr><tr><td>NHANES 2003-2006 [13]</td><td>3,423</td><td></td><td>34%</td><td></td><td></td></tr></table>
|
f3460f36d126a350f164d71d7acb162bba563956e491910ad497c44c85865473.png
|
complex
|
<table><tr><td rowspan="2"> </td><td>All</td><td>Group 1</td><td>Group 2</td><td>Group 3</td><td>Group 4</td><td><i>P </i>- values</td></tr><tr><td>(N = 203)</td><td>(N = 46)</td><td>(N = 64)</td><td>(N = 64)</td><td>(N = 29)</td><td> </td></tr><tr><td>Age (years)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>0–1</td><td>15 (7%)</td><td>5 (11%)</td><td>7 (11%)</td><td>2 (3%)</td><td>1 (3%)</td><td rowspan="4">0.198</td></tr><tr><td>1–5</td><td>56 (28%)</td><td>15 (33%)</td><td>20 (31%)</td><td>13 (20%)</td><td>8 (28%)</td></tr><tr><td>5–10</td><td>98 (48%)</td><td>15 (33%)</td><td>28 (44%)</td><td>39 (61%)</td><td>16 (55%)</td></tr><tr><td>>10</td><td>34 (17%)</td><td>11 (23%)</td><td>9 (14%)</td><td>10 (16%)</td><td>4 (14%)</td></tr><tr><td>Gender male</td><td>132(65%)</td><td>27 (59%)</td><td>44 (69%)</td><td>45 (70%)</td><td>16 (55%)</td><td>0.358</td></tr><tr><td>Underlying medical conditions</td><td> </td><td> </td><td> </td><td> </td><td> </td><td rowspan="7">0.004</td></tr><tr><td>none</td><td>60 (30%)</td><td>13 (28%)</td><td>16 (25%)</td><td>24 (38%)</td><td>7 (24%)</td></tr><tr><td>asthma</td><td>57 (28%)</td><td>8 (17%)</td><td>20 (31%)</td><td>22 (34%)</td><td>7 (24%)</td></tr><tr><td>asthmatic diseases<sup>+</sup></td><td>29 (14%)</td><td>2 (5%)</td><td>10 (16%)</td><td>9 (14%)</td><td>8 (28%)</td></tr><tr><td>other respiratory problems<sup>++</sup></td><td>8 (4%)</td><td>3 (6%)</td><td>2 (3%)</td><td>2 (3%)</td><td>1 (4%)</td></tr><tr><td>immunocompromised *</td><td>4 (2%)</td><td>2 (5%)</td><td>0 (0%)</td><td>2 (3%)</td><td>0 (0%)</td></tr><tr><td>others**</td><td>45 (22%)</td><td>18 (39%)</td><td>16 (25%)</td><td>5 (8%)</td><td>6 (20%)</td></tr><tr><td>Heart Rate on admission</td><td>146</td><td>138</td><td>150</td><td>150</td><td>150</td><td rowspan="2">0.072</td></tr><tr><td>(bpm, median) IQR</td><td>133-160</td><td>100-175</td><td>128-172</td><td>121-179</td><td>128-172</td></tr><tr><td>Respiratory Rate on admission</td><td>37</td><td>24</td><td>40</td><td>38</td><td>40</td><td rowspan="2">< 0.001</td></tr><tr><td>(bpm, median) IQR</td><td>28-42</td><td>14-34</td><td>20-60</td><td>23-53</td><td>17-63</td></tr><tr><td>Body Temperature on admission</td><td>38.5</td><td>38.7</td><td>38.4</td><td>38.4</td><td>38.2</td><td rowspan="2">0.530</td></tr><tr><td>(°C, median) IQR</td><td>37.9-39.2</td><td>37.4-40.0</td><td>37.3-39.5</td><td>37.0-39.8</td><td>36.6-39.9</td></tr><tr><td>SpO<sub>2</sub> on admission</td><td>94</td><td>98</td><td>96</td><td>93</td><td>94</td><td rowspan="2">< 0.001</td></tr><tr><td>(%, median) IQR</td><td>93-98</td><td>95-100</td><td>91-100</td><td>88-98</td><td>88-100</td></tr><tr><td>O<sub>2</sub> demand on admission YES</td><td>39 (19%)</td><td>4 (9%)</td><td>9 (14%)</td><td>19 (30%)</td><td>7 (24%)</td><td>0.025</td></tr><tr><td>O<sub>2</sub> demand during admission YES</td><td>129 (64%)</td><td>10 (22%)</td><td>41 (64%)</td><td>53 (83%)</td><td>25 (86%)</td><td>0.002</td></tr><tr><td>Time from the onset of illness (hr)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>0–5</td><td>38 (19%)</td><td>11(23%)</td><td>14 (22%)</td><td>11 (17%)</td><td>2 (7%)</td><td rowspan="6">0.976</td></tr><tr><td>6–11</td><td>27 (13%)</td><td>1 (2%)</td><td>8 (12%)</td><td>13 (20%)</td><td>5 (17%)</td></tr><tr><td>12–23</td><td>61 (30%)</td><td>18 (41%)</td><td>14 (22%)</td><td>15 (23%)</td><td>14 (49%)</td></tr><tr><td>24–47</td><td>42 (21%)</td><td>11 (23%)</td><td>13 (20%)</td><td>11 (17%)</td><td>7 (24%)</td></tr><tr><td>48 -</td><td>20 (10%)</td><td>3 (7%)</td><td>8 (12%)</td><td>9 (14%)</td><td>0 (0%)</td></tr><tr><td>Unknown</td><td>15 (7%)</td><td>2 (4%)</td><td>7 (12%)</td><td>5 (9%)</td><td>1 (3%)</td></tr><tr><td>Systemic steroid use YES</td><td>84 (41%)</td><td>10 (22%)</td><td>24 (38%)</td><td>33 (52%)</td><td>17 (59%)</td><td>0.34</td></tr><tr><td>Antibiotics use YES</td><td>92 (45%)</td><td>5 (11%)</td><td>23 (36%)</td><td>51 (80%)</td><td>13 (45%)</td><td>0.10</td></tr><tr><td>Antiviral use YES</td><td>191 (94%)</td><td>42 (91%)</td><td>60 (94%)</td><td>62 (97%)</td><td>27 (93%)</td><td>0.994</td></tr></table>
|
ab357293b6b15b1078ab3761efc87e41954d79557d231ea5dd7a0a64c27136fd.png
|
simple
|
<table><tr><td></td><td></td><td>AOR single measure<sup>1</sup></td><td></td><td></td></tr><tr><td>Knowledge measure</td><td>Bivariate OR</td><td>Mozambique</td><td>4 Southern African countries<sup>2</sup></td><td>AOR all measures<sup>3</sup></td></tr><tr><td>Needles/razors</td><td>1.13 (0.70–1.83)</td><td>0.91 (0.55–1.49)</td><td>0.86 (0.71–1.04)</td><td>0.87 (0.52–1.45)</td></tr><tr><td>Blood contact</td><td>1.11 (0.82–1.51)</td><td>0.95 (0.70–1.30)</td><td>—</td><td>0.93 (0.67–1.30)</td></tr><tr><td>Vaginal sex</td><td>2.10 (1.16–3.80)</td><td>1.85 (0.99–3.45)</td><td>1.21 (1.07–1.37)</td><td>1.93 (1.02–3.64)</td></tr><tr><td>Anal sex</td><td>1.18 (0.92–1.51)</td><td>1.03 (0.79–1.34)</td><td>—</td><td>0.98 (0.75–1.28)</td></tr></table>
|
31cbdddf2f0eaac4cb2d03fc70b4b6ec110e77264bbf7ee1f6e28983e51e3326.png
|
complex
|
<table><tr><td rowspan="2"></td><td colspan="4">Stage</td></tr><tr><td>1</td><td>2</td><td>3</td><td><i>P</i> value</td></tr><tr><td>Number of patients</td><td>2</td><td>6</td><td>1</td><td></td></tr><tr><td>Location (%)</td><td></td><td></td><td></td><td>1</td></tr><tr><td> Mandible</td><td>2 (100)</td><td>5 (83.33)</td><td>1 (100)</td><td></td></tr><tr><td> Maxilla</td><td>0 (0)</td><td>1 (16.67)</td><td>0 (0)</td><td></td></tr><tr><td>Infection (%)</td><td></td><td></td><td></td><td>0.0476*</td></tr><tr><td> Yes</td><td>0 (0)</td><td>5 (83.33)</td><td>0 (0)</td><td></td></tr><tr><td> No</td><td>2 (100)</td><td>1 (16.67)</td><td>1 (100)</td><td></td></tr><tr><td>Etiology (%)</td><td></td><td></td><td></td><td>0.7222</td></tr><tr><td> Extraction</td><td>1 (50)</td><td>3 (50)</td><td>1 (100)</td><td></td></tr><tr><td> Prosthesis problem</td><td>0 (0)</td><td>2 (33.33)</td><td>0 (0)</td><td></td></tr><tr><td> Periodontal problem</td><td>0 (0)</td><td>1 (16.67)</td><td>0 (0)</td><td></td></tr><tr><td> Spontaneous</td><td>1 (50)</td><td>0 (0)</td><td>0 (0)</td><td></td></tr><tr><td>Bisphosphonate type (%)</td><td></td><td></td><td></td><td>0.25</td></tr><tr><td>Combination<sup>a</sup></td><td>2 (100)</td><td>5 (83.33)</td><td>0 (0)</td><td></td></tr><tr><td> Only zoledronate</td><td>0 (0)</td><td>1 (16.67)</td><td>0 (0)</td><td></td></tr><tr><td> Only pamidronate</td><td>0 (0)</td><td>0 (0)</td><td>1 (100)</td><td></td></tr><tr><td>Treatment<sup>b</sup> (%)</td><td></td><td></td><td></td><td>0.6429</td></tr><tr><td> Conservative</td><td>2 (100)</td><td>3 (50)</td><td>1 (100)</td><td></td></tr><tr><td> Invasive</td><td>0 (0)</td><td>3 (50)</td><td>0 (0)</td><td></td></tr><tr><td>Outcome (%)</td><td></td><td></td><td></td><td>1</td></tr><tr><td> 1</td><td>1 (100)</td><td>4 (80)</td><td>0 (0)</td><td></td></tr><tr><td> 2</td><td>0 (0)</td><td>1 (20)</td><td>0 (0)</td><td></td></tr><tr><td>Duration in months</td><td>21 (17–25)</td><td>19 (11–69)</td><td>9 (9–9)</td><td>0.2992</td></tr></table>
|
30e1b23119379ab9603aeea1269ad3285c5d0d0ca9bfce3e66d7dbe68817af04.png
|
complex
|
<table><tr><td rowspan="2" colspan="2">Virus</td><td colspan="3">% with HI titer ≥40</td></tr><tr><td>Serum wave 1 (n = 59)</td><td>Serum wave 2 (n = 32)</td><td>Serum wave 3 (n = 33)</td></tr><tr><td></td><td>CA/07</td><td>81.4 (48/59)</td><td>71.9 (23/32)</td><td>78.8 (26/33)</td></tr><tr><td rowspan="3">Thailand wave 1</td><td>Thai/104</td><td>100 (59/59)</td><td>100 (32/32)</td><td>100 (33/33)</td></tr><tr><td>CBI6</td><td>98.3 (58/59)</td><td>93.8 (30/32)</td><td>100 (33/33)</td></tr><tr><td>CBI10</td><td>91.5 (54/59)</td><td>96.9 (31/32)</td><td>100 (33/33)</td></tr><tr><td rowspan="3">Thailand wave 2</td><td>34002</td><td>100 (59/59)</td><td>90.6 (29/32)</td><td>97 (32/33)</td></tr><tr><td>34004</td><td>96.9 (57/59)</td><td>100 (32/32)</td><td>100 (33/33)</td></tr><tr><td>NMA1</td><td>100 (59/59)</td><td>93.8 (30/32)</td><td>93.3 (31/33)</td></tr><tr><td rowspan="2">Thailand wave 3</td><td>BKK1</td><td>71.2 (42/59)</td><td>81.3 (26/32)</td><td>100 (33/33)</td></tr><tr><td>BKK2</td><td>89.8 (53/59)</td><td>87.5 (28/32)</td><td>97 (32/33)</td></tr><tr><td rowspan="2">Thailand wave 4</td><td>BKK4</td><td>93.2 (55/59)</td><td>84.4 (27/32)</td><td>100 (33/33)</td></tr><tr><td>BKK5</td><td>98.3 (58/59)</td><td>100 (32/32)</td><td>100 (33/33)</td></tr></table>
|
b1997a1bc4e364362baa2c2c5c48cc8841eaf043ba1bbf9f9821e57be5f10b12.png
|
complex
|
<table><tr><td> </td><td>Patients (n)</td><td>HSR (n)</td><td>HSR (%)</td><td>p value<sup>1</sup></td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Female</td><td>113</td><td>16</td><td>14.2</td><td>0,0147</td></tr><tr><td>Male</td><td>78</td><td>1</td><td>1.3</td><td> </td></tr><tr><td colspan="2">Prior exposure to platinum salts</td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>45</td><td>8</td><td>17.8</td><td>0,0220</td></tr><tr><td>No</td><td>146</td><td>9</td><td>6.2</td><td> </td></tr><tr><td colspan="2">Atopic background</td><td> </td><td> </td><td> </td></tr><tr><td>Yes</td><td>32</td><td>4</td><td>12.5</td><td>0,4367</td></tr><tr><td>No</td><td>159</td><td>13</td><td>8.2</td><td> </td></tr></table>
|
faca1be2d8cbc34424612dd6198c7e2e26e45ef58d3dfabbf382b95c23e53580.png
|
complex
|
<table><tr><td></td><td colspan="2">Oromia</td><td colspan="2">SNNP</td><td colspan="2">All</td></tr><tr><td></td><td colspan="2">n = 57</td><td colspan="2">n = 73</td><td colspan="2">n = 130</td></tr><tr><td></td><td>n</td><td>%</td><td>n</td><td>%</td><td>n</td><td>%</td></tr><tr><td>Training Received by HEWs<sup>a</sup></td><td colspan="2">In past 3 years</td><td colspan="2">In past 3 years</td><td colspan="2">In past 3 years</td></tr><tr><td>Integrated refresher training</td><td>56</td><td>98%</td><td>67</td><td>92%</td><td>123</td><td>95%</td></tr><tr><td>Possible severe bacterial infections management</td><td>53</td><td>93%</td><td>66</td><td>90%</td><td>119</td><td>92%</td></tr><tr><td>Integrated community case management</td><td>56</td><td>98%</td><td>60</td><td>82%</td><td>116</td><td>89%</td></tr><tr><td>Maternal, newborn, and child health</td><td>52</td><td>91%</td><td>57</td><td>78%</td><td>109</td><td>84%</td></tr><tr><td>Health management information system</td><td>30</td><td>53%</td><td>72</td><td>99%</td><td>102</td><td>78%</td></tr><tr><td>Tuberculosis prevention and control</td><td>36</td><td>63%</td><td>62</td><td>85%</td><td>98</td><td>75%</td></tr><tr><td>Nutrition</td><td>41</td><td>72%</td><td>54</td><td>74%</td><td>95</td><td>73%</td></tr><tr><td>Family planning</td><td>36</td><td>63%</td><td>54</td><td>74%</td><td>90</td><td>69%</td></tr><tr><td>Malaria prevention and control</td><td>41</td><td>72%</td><td>31</td><td>42%</td><td>72</td><td>55%</td></tr><tr><td>HIV/AIDS and sexually transmitted infections</td><td>35</td><td>61%</td><td>31</td><td>42%</td><td>66</td><td>51%</td></tr><tr><td>Hygiene and environmental sanitation</td><td>32</td><td>56%</td><td>31</td><td>42%</td><td>63</td><td>48%</td></tr><tr><td>Immunization</td><td>32</td><td>56%</td><td>28</td><td>38%</td><td>60</td><td>46%</td></tr><tr><td>Adolescent reproductive health</td><td>24</td><td>42%</td><td>31</td><td>42%</td><td>55</td><td>42%</td></tr><tr><td>First aid</td><td>15</td><td>26%</td><td>9</td><td>12%</td><td>24</td><td>18%</td></tr><tr><td>Supervision and Technical Support Received</td><td colspan="2">In past 3 months</td><td colspan="2">In past 3 months</td><td colspan="2">In past 3 months</td></tr><tr><td>Any supervision or technical support<sup>b</sup></td><td>54</td><td>95%</td><td>73</td><td>100%</td><td>127</td><td>98%</td></tr><tr><td>By Primary Health Care Unit (PHCU)<sup>c</sup></td><td>53</td><td>93%</td><td>67</td><td>92%</td><td>120</td><td>92%</td></tr><tr><td>By Woreda Health Office (WoHO)<sup>d</sup></td><td>43</td><td>75%</td><td>58</td><td>79%</td><td>101</td><td>78%</td></tr><tr><td></td><td>Median</td><td>IQR</td><td>Median</td><td>IQR</td><td>Median</td><td>IQR</td></tr><tr><td>If supervised by PHCU, times in past 3 months</td><td>4.5</td><td>(2–8)</td><td>5</td><td>(3–8)</td><td>5</td><td>(2–8)</td></tr><tr><td>If supervised by WoHO, times in past 3 months</td><td>1</td><td>(1–2)</td><td>2</td><td>(1–2)</td><td>1</td><td>(1–2)</td></tr></table>
|
d4bf4fe361ddc57661f066cc679d7b6640a8801400588e36ee53fa0b6df0e81a.png
|
complex
|
<table><tr><td>Items</td><td>Mean age</td><td>Diagnosis</td><td>ACF</td><td>PIF + PD</td><td>One stage of ACF and PIF + PD</td></tr><tr><td rowspan="2">Present study</td><td rowspan="2">67.6 y/o</td><td rowspan="2">Degenerative cervical kyphosis with stenosis</td><td>ABL: 135.2 ± 85.2 ml</td><td>ABL: 307.7 ± 92.3 ml</td><td>ABL: 442.9 ± 236.0 ml</td></tr><tr><td>MST: 136.8 ± 52.3 min</td><td>MST: 139.3 ± 50.4 min</td><td>MST: 314.5 ± 51.2 min</td></tr><tr><td>Du et al. [2]</td><td>59.6 y/o</td><td>CSM/OPLL/cervical stenosis</td><td>None</td><td>ABL: 650 mL MST: 150 min</td><td>None</td></tr><tr><td rowspan="2">Epstein et al. [20]</td><td rowspan="2">54.0 y/o</td><td rowspan="2">OPLL</td><td rowspan="2">None</td><td rowspan="2">None</td><td>ABL: 500 ml</td></tr><tr><td>MST: 522 min</td></tr></table>
|
0fa625e9884a765dc2c4e640a8de5bff69aa66d4aab50989f0e5711f935dd983.png
|
simple
|
<table><tr><td>Characteristic</td><td>Cluster 1 Most Severe (n = 30)</td><td>Cluster 2 Intermediate (n = 67)</td><td>Cluster 3 Least Severe (n = 67)</td></tr><tr><td> SF-36 Scales (mean ± sd)</td><td></td><td></td><td></td></tr><tr><td>Physical function</td><td>49.5 ± 21.8</td><td>71.8 ± 20.1</td><td>91.0 ± 10.3</td></tr><tr><td>Role physical</td><td>12.5 ± 26.9</td><td>48.1 ± 36.0</td><td>92.5 ± 19.5</td></tr><tr><td>Bodily pain</td><td>39.5 ± 18.3</td><td>53.7 ± 16.5</td><td>79.4 ± 15.6</td></tr><tr><td>General health</td><td>45.4 ± 19.3</td><td>67.4 ± 13.8</td><td>85.3 ± 12.6</td></tr><tr><td>Vitality</td><td>14.3 ± 11.0</td><td>34.6 ± 15.8</td><td>69.6 ± 16.0</td></tr><tr><td>Social function</td><td>45.4 ± 24.0</td><td>67.9 ± 18.4</td><td>96.3 ± 8.7</td></tr><tr><td>Role emotional</td><td>47.8 ± 41.7</td><td>74.1 ± 35.2</td><td>96.0 ± 13.6</td></tr><tr><td>Mental health</td><td>61.5 ± 19.5</td><td>74.4 ± 13.5</td><td>86.9 ± 9.1</td></tr><tr><td> MFI Scales (mean ± sd)</td><td></td><td></td><td></td></tr><tr><td>General fatigue</td><td>18.4 ± 1.4</td><td>15.1 ± 2.7</td><td>8.7 ± 3.2</td></tr><tr><td>Physical fatigue</td><td>15.4 ± 2.7</td><td>11.6 ± 2.8</td><td>6.7 ± 2.1</td></tr><tr><td>Mental fatigue</td><td>15.9 ± 3.5</td><td>10.3 ± 3.9</td><td>6.6 ± 2.7</td></tr><tr><td>Reduced motivation</td><td>13.4 ± 4.0</td><td>10.3 ± 3.0</td><td>6.2 ± 2.0</td></tr><tr><td>Reduced activity</td><td>15.8 ± 3.3</td><td>11.9 ± 3.5</td><td>5.9 ± 2.0</td></tr><tr><td>Symptom Inventory (mean ± sd)</td><td>52.2 ± 24.8</td><td>21.6 ± 12.6</td><td>7.0 ± 8.5</td></tr></table>
|
f79e802b11e68cd2944d0cbd0dedbc4e3bfb2a76afd77d6ebcde50c0584cb615.png
|
simple
|
<table><tr><td>Class</td><td>Biophysical Features</td><td>Geographical Regions</td></tr><tr><td>1</td><td>lowest temperature and high chlorophyll a</td><td>south side of Bali, Sumbawa, Fores and Sumba</td></tr><tr><td>2</td><td>moderate biophysical conditions</td><td>Savu Sea (in the west) and Arafura Sea (in the east)</td></tr><tr><td>3</td><td>high chlorophyll a and high salinity</td><td>Van Dieman Gulf and Beagle Gulf (out of the SBS)</td></tr><tr><td>4</td><td>low chlorophyll a and high salinity</td><td>Timor Sea</td></tr><tr><td>5</td><td>the lowest chlorophyll a and the highest currents</td><td>Banda Sea, Molucca Sea (to the north), Ceram Sea (to the east), Flores Sea (to the southwest).</td></tr><tr><td>6</td><td>low chlorophyll a and medium currents</td><td>Bali Sea, Flores Sea and Gulf of Boni</td></tr><tr><td>7</td><td>the second highest overall temperature</td><td>Halmahera Sea and Molucca Sea</td></tr><tr><td>8</td><td>highest overall temperature</td><td>Gulf of Tomini and Makassar Strait (northeast of the SBS, south to the Equator)</td></tr><tr><td>9</td><td>high chlorophyll a and low salinity</td><td>Java Sea</td></tr></table>
|
c8f95992c3936d437a38ca665bb893ef55e0a2019a0dcdf8592e7addcecf77af.png
|
simple
|
<table><tr><td>Scenario</td><td>WI ORCF</td><td>GA BRCF</td><td>GA ARCF</td><td>RA BRCF</td><td>RA ARCF</td><td>TA ORCF</td></tr><tr><td>1</td><td>29.2727</td><td>5.8364</td><td>6.3186</td><td>9.3091</td><td>9.3363</td><td>8.7455</td></tr><tr><td>2</td><td>109.3333</td><td>20.0000</td><td>23.7894</td><td>31.3333</td><td>31.3333</td><td>24.6667</td></tr><tr><td>3</td><td>383.2625</td><td>227.4618</td><td>229.1624</td><td>217.495</td><td>218.1787</td><td>295.495</td></tr><tr><td>4</td><td>217.3091</td><td>20.0364</td><td>21.6105</td><td>18.4364</td><td>18.5327</td><td>23.3455</td></tr><tr><td>5</td><td>250.8222</td><td>22.7778</td><td>24.6070</td><td>20.1778</td><td>20.5511</td><td>23.7778</td></tr><tr><td>6</td><td>557.3333</td><td>141.3333</td><td>150.0000</td><td>112.6667</td><td>117.7333</td><td>114.0000</td></tr><tr><td>7</td><td>2778.2573</td><td>2550.3018</td><td>2550.3139</td><td>2557.0901</td><td>2557.0901</td><td>2550.3018</td></tr><tr><td>8</td><td>898.7805</td><td>244.3707</td><td>249.9034</td><td>206.7951</td><td>209.8641</td><td>522.9854</td></tr></table>
|
fd4b775f5720e5e8d38ba125b9260179829b42e54c7b77ee6d677c5cff1a47ae.png
|
simple
|
<table><tr><td>Gene name</td><td>Primers</td><td>Annealing temperature</td></tr><tr><td><i>hHSF4F</i></td><td>CCCCCTCAAGAAAGTGTGGAA</td><td>60°C</td></tr><tr><td><i>hHSF4R</i></td><td>GAACCAAGGGCTGCATCAAG</td><td>60°C</td></tr><tr><td><i>mHSF4F</i></td><td>GGCACCAGCTTCCTCGTAAG</td><td>60°C</td></tr><tr><td><i>mHSF4R</i></td><td>CCTTCCGAAAACCATACATGTTG</td><td>60°C</td></tr><tr><td><i>hCrygsF</i></td><td>CCCAACTTTGCTGGGTACATG</td><td>60°C</td></tr><tr><td><i>hCrygsR</i></td><td>GGCCTCCACTAGGCAGATGA</td><td>60°C</td></tr><tr><td><i>mCrygsF</i></td><td>AGCGTTGGATGGGCCTTAAT</td><td>60°C</td></tr><tr><td><i>mCrygsR</i></td><td>GTTTCGTACATCTGACCGTTGAAG</td><td>60°C</td></tr><tr><td><i>hBFSP1F</i></td><td>TTCAGTGGGAGAGAGATGTTGAAA</td><td>60°C</td></tr><tr><td><i>hBFSP1R</i></td><td>CTCCTGGGTCTGGGACATGT</td><td>60°C</td></tr><tr><td><i>mBfsp1F</i></td><td>AGACGCCCATCTCTCTGATCA</td><td>60°C</td></tr><tr><td><i>mBfsp1R</i></td><td>AGGGCCTTCTGTCTCGGTTT</td><td>60°C</td></tr><tr><td><i>hBFSP2F</i></td><td>TTCAGTGGGAGAGAGATGTTGAAA</td><td>60°C</td></tr><tr><td><i>hBFSP2R</i></td><td>CTCCTGGGTCTGGGACATGT</td><td>60°C</td></tr><tr><td><i>mBfsp2F</i></td><td>GCACCGGTCTGGATGATGTC</td><td>60°C</td></tr><tr><td><i>mBfsp2R</i></td><td>ACGTGGACCACCTCTGTCTG T</td><td>60°C</td></tr><tr><td><i>mLp82F</i></td><td>ATTGGCTTCGCCATCTACGA</td><td>60°C</td></tr><tr><td><i>mLp82R</i></td><td>CCCGCATGTTGATGTAGGTTT</td><td>60°C</td></tr><tr><td><i>mCalpain2F</i></td><td>ATGCGGAAAGCACTGGAAGA</td><td>60°C</td></tr><tr><td><i>mCalpain2R</i></td><td>CCAAACACCGCACAAAATTG</td><td>60°C</td></tr></table>
|
ab2b67eda0b7f514c1badd784b5afc7eeeb4f467705913a9f4c91e816bfe4afb.png
|
complex
|
<table><tr><td>Animal models</td><td>Polyurethane scaffolds</td><td>Major conclusions</td><td>Reference</td></tr><tr><td rowspan="4">Iliac crest (sheep)</td><td rowspan="4">Porous scaffolds synthesized from HMDI, PEO-PPO-PEO, and PCL at various ratios. Pore size, 300 to 2,000 μm; porosity, 85%</td><td>At 18 and 25 months, all the defects in the ilium implanted with polyurethane bone substitutes had healed with new bone.</td><td rowspan="4">Gogolewski and Gorna ([2007]), Gogolewski et al. ([2006])</td></tr><tr><td>The extent of bone healing depended on the chemical composition of the polymer from which the implant was made.</td></tr><tr><td>The implants from polymers with the incorporated calcium-complexing additive were the most effective promoters of bone healing, followed by those with vitamin D and polysaccharide-containing polymer.</td></tr><tr><td>There was no bone healing in the control defects.</td></tr><tr><td>Bone marrow stromal cells</td><td>BDI with PCL films</td><td>Bone marrow stromal cells were cultured on rigid polymer films under osteogenic conditions for up to 21 days. This study demonstrated the suitability of this family of PEUUs for bone tissue engineering applications.</td><td>Kavlock et al. ([2007])</td></tr><tr><td>Femoral condyle</td><td>LTI with PCL-co-PGA-co-PDLLA</td><td>Extensive cellular infiltration deep to the implant and new bone formation at 6 weeks</td><td>Dumas et al. ([2010])</td></tr><tr><td>Chondrocytes</td><td>Porous scaffolds synthesized from HMDI with PCL and ISO</td><td>Although the covalent incorporation of the isoprenoid molecule into the polyurethane chain modified the surface chemistry of the polymer, it did not affect the viability of attached chondrocytes.</td><td>Eglin et al. ([2010])</td></tr><tr><td></td><td></td><td>The change of surface characteristics and the more open pore structure of the scaffolds produced from the isoprenoid-modified polyurethane are beneficial for the seeding efficiency and the homogeneity of the tissue-engineered constructs.</td><td></td></tr></table>
|
0fd0d567d2b8cb6ccbbeef48460fe9ce242c20901862fac3103e2c74c2e87e1e.png
|
complex
|
<table><tr><td></td><td>SPATA2 7–219</td><td>HOIP 5–180 + SPATA2 334–344</td></tr><tr><td colspan="3">Data Collection</td></tr><tr><td>Beamline</td><td>Diamond I02</td><td>Diamond I02</td></tr><tr><td>Space group</td><td><i>P 2</i><sub><i>1</i></sub></td><td><i>P 4</i><sub><i>3</i></sub></td></tr><tr><td><i>a</i>, <i>b</i>, <i>c</i> (Å)</td><td>43.48, 51.14, 56.29</td><td>89.04, 89.04, 53.56</td></tr><tr><td>α, β, γ (°)</td><td>90.00, 105.97, 90.00</td><td>90.00, 90.00, 90.00</td></tr><tr><td>Wavelength</td><td>0.9794</td><td>0.9795</td></tr><tr><td>Resolution (Å)</td><td>54.12–1.45 (1.48–1.45)</td><td>62.96–2.70 (2.83–2.70)</td></tr><tr><td><i>R</i><sub>merge</sub></td><td>3.7 (32.7)</td><td>7.2 (67.9)</td></tr><tr><td><i>< I</i> / σ<i>I ></i></td><td>12.1 (2.2)</td><td>9.5 (2.0)</td></tr><tr><td>CC(1/2)</td><td>0.99 (0.91)</td><td>0.99 (0.61)</td></tr><tr><td>Completeness (%)</td><td>90.2 (81.2)</td><td>97.7 (99.7)</td></tr><tr><td>Redundancy</td><td>3.0 (2.9)</td><td>2.7 (2.7)</td></tr><tr><td colspan="3">Refinement</td></tr><tr><td>Resolution (Å)</td><td>54.11–1.45</td><td>62.96–2.70</td></tr><tr><td>No. reflections</td><td>37,458</td><td>11,425</td></tr><tr><td><i>R</i><sub>work</sub> / <i>R</i><sub>free</sub></td><td>18.2/22.5</td><td>23.3/28.1</td></tr><tr><td colspan="3">No. Atoms</td></tr><tr><td>Protein</td><td>1,722</td><td>2,695</td></tr><tr><td>Ligand/ion</td><td>12</td><td>15</td></tr><tr><td>Water</td><td>308</td><td>–</td></tr><tr><td colspan="3">B Factors</td></tr><tr><td>Wilson B</td><td>15.73</td><td>57.1</td></tr><tr><td>Protein</td><td>25.1</td><td>61.3</td></tr><tr><td>Ligand/ion</td><td>21.8</td><td>85.0</td></tr><tr><td>Water</td><td>38.0</td><td>–</td></tr><tr><td colspan="3">RMSDs</td></tr><tr><td>Bond lengths (Å)</td><td>0.005</td><td>0.002</td></tr><tr><td>Bond angles (°)</td><td>0.772</td><td>0.526</td></tr><tr><td>Ramachandran statistics (outliers, allowed, favored)</td><td>0.0, 1.4, 98.6</td><td>0.0, 2.6, 97.4</td></tr></table>
|
9d03a300d2ebf682c2bba45add3e91cbea4d7bebc604d92e4839175e850e34a7.png
|
complex
|
<table><tr><td>Sex and Age Groups</td><td colspan="3">Unintentional Injury Code</td><td colspan="3">Any Maltreatment Code</td></tr><tr><td> </td><td>Mean</td><td>SD</td><td>% with any risk documented</td><td>Mean</td><td>SD</td><td>% with any risk documented</td></tr><tr><td colspan="7">Males</td></tr><tr><td> <1</td><td>.67</td><td>1.00</td><td>44.4</td><td>3.00</td><td>2.13</td><td>85.7</td></tr><tr><td> 1-5</td><td>.10</td><td>.43</td><td>7.2</td><td>2.61</td><td>1.72</td><td>89.1</td></tr><tr><td> 6-9</td><td>.05</td><td>.23</td><td>5.3</td><td>2.71</td><td>1.61</td><td>100.0</td></tr><tr><td> 10-14</td><td>.19</td><td>.69</td><td>10.6</td><td>3.74</td><td>1.64</td><td>100.0</td></tr><tr><td> 15-17</td><td>.23</td><td>.65</td><td>14.3</td><td>4.50</td><td>2.01</td><td>100.0</td></tr><tr><td> Total</td><td>.17</td><td>.58</td><td>10.8</td><td>3.11</td><td>1.91</td><td>92.3</td></tr><tr><td colspan="7">Females</td></tr><tr><td> <1</td><td>.22</td><td>.44</td><td>22.2</td><td>2.79</td><td>1.88</td><td>89.7</td></tr><tr><td> 1-5</td><td>.25</td><td>1.02</td><td>7.8</td><td>2.82</td><td>1.91</td><td>90.1</td></tr><tr><td> 6-9</td><td>.03</td><td>.16</td><td>2.6</td><td>3.11</td><td>1.77</td><td>96.4</td></tr><tr><td> 10-14</td><td>.03</td><td>.19</td><td>3.4</td><td>3.90</td><td>2.19</td><td>92.7</td></tr><tr><td> 15-17</td><td>.75</td><td>1.29</td><td>35.7</td><td>4.30</td><td>2.35</td><td>98.2</td></tr><tr><td> Total</td><td>.24</td><td>.85</td><td>11.5</td><td>3.47</td><td>2.15</td><td>93.1</td></tr><tr><td colspan="7">Total</td></tr><tr><td> <1</td><td>.44</td><td>.78</td><td>33.3</td><td>2.91</td><td>2.02</td><td>87.5</td></tr><tr><td> 1-5</td><td>.17</td><td>.74</td><td>7.5</td><td>2.74</td><td>1.83</td><td>89.7</td></tr><tr><td> 6-9</td><td>.04</td><td>.20</td><td>4.2</td><td>2.96</td><td>1.71</td><td>97.8</td></tr><tr><td> 10-14</td><td>.15</td><td>.61</td><td>8.9</td><td>3.85</td><td>2.04</td><td>94.8</td></tr><tr><td> 15-17</td><td>.37</td><td>.89</td><td>20.0</td><td>4.33</td><td>2.29</td><td>98.5</td></tr><tr><td> Total</td><td>.19</td><td>.68</td><td>11.0</td><td>3.34</td><td>2.07</td><td>92.8</td></tr></table>
|
b9323303cdee95535cb5086a2960aef856c7245cbf23509a7c1a55f1a4a5d6ff.png
|
complex
|
<table><tr><td><i>Variables</i></td><td><i>All (</i>n<i>=704)</i></td><td><i>Presence of NHS-EMH (</i>n<i>=40)</i></td><td><i>Absence of NHS-EMH (</i>n<i>=664)</i></td><td>P<i>-value univariate</i></td><td>P-<i>value multivariate</i></td></tr><tr><td>Age at referall in years median (range)</td><td>64 (22–90)</td><td>62.5 (38–79)</td><td>64 (22–90)</td><td>0.1</td><td> </td></tr><tr><td>Male (%)</td><td>454 (64%)</td><td>25 (63%)</td><td>429 (65%)</td><td>0.8</td><td> </td></tr><tr><td>Hemoglobin, g/dl median (range)</td><td>10.5 (5.8–16.7)</td><td>10.9 (7.5–13.8)</td><td>10.4 (5.8–16.7)</td><td>0.4</td><td> </td></tr><tr><td>Hemoglobin <10 g/dl, <i>n</i> (%)</td><td>331 (47%)</td><td>14 (35%)</td><td>317 (48%)</td><td>0.1</td><td> </td></tr><tr><td>Leukocytes, x10<sup>9</sup>/l median (range)</td><td>9.0 (0.8–236.1)</td><td>12.6 (1.1–105.9)</td><td>9 (0.8–236.1)</td><td>0.01</td><td>0.8</td></tr><tr><td>Leukocytes >11x10<sup>9</sup>/l, <i>n</i> (%)</td><td>279 (40%)</td><td>23 (58%)</td><td>256 (39%)</td><td>0.02</td><td>0.009</td></tr><tr><td>Leukocytes >25 x10<sup>9</sup>/l, <i>n</i> (%)</td><td>101 (14%)</td><td>7 (18%)</td><td>94 (14%)</td><td>0.6</td><td> </td></tr><tr><td>Platelets, x 10<sup>9</sup>/l median (range)</td><td>210.0 (10.0–2466.0)</td><td>229.5 (13.0–1164.0)</td><td>208.5 (10.0–2466.0)</td><td>0.9</td><td> </td></tr><tr><td>Platelets<450x10<sup>9</sup>/l, <i>n</i> (%)</td><td>595 (85%)</td><td>34 (85%)</td><td>561 (84%)</td><td>0.9</td><td> </td></tr><tr><td>Platelets <1000 x10<sup>9</sup>/l, <i>n</i> (%)</td><td>689 (98%)</td><td>39 (98%)</td><td>650 (98%)</td><td>0.9</td><td> </td></tr><tr><td>Circulating blasts % median (range)</td><td>1 (0–15)</td><td>0.5 (0–9)</td><td>1 (0–15)</td><td>0.3</td><td> </td></tr><tr><td>Presence of constitutional symptoms, <i>n</i> (%)</td><td>203 (29%)</td><td>10 (25%)</td><td>193 (29%)</td><td>0.6</td><td> </td></tr><tr><td>Presence of palpable splenomegaly <i>N</i> evaluable=680, <i>n</i> (%)</td><td>509 (75%)</td><td>29 (81%)</td><td>480 (75%)</td><td>0.4</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>DIPSS-plus risk N evaluable=685</i></td><td> </td><td> </td><td> </td><td>0.2</td><td> </td></tr><tr><td> Low</td><td>93 (14%)</td><td>6 (15%)</td><td>87 (13%)</td><td> </td><td> </td></tr><tr><td> Intermediate-1</td><td>113 (16%)</td><td>10 (25%)</td><td>103 (16%)</td><td> </td><td> </td></tr><tr><td> Intermediate-2</td><td>252 (37%)</td><td>16 (40%)</td><td>236 (37%)</td><td> </td><td> </td></tr><tr><td> High</td><td>227 (33%)</td><td>8 (20%)</td><td>219 (34%)</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>Driver mutations</i></td><td> </td><td> </td><td> </td><td>0.045</td><td> </td></tr><tr><td><i> JAK2</i> mutated, <i>n</i> (%)</td><td>463 (66%)</td><td>20 (50%)</td><td>443 (67%)</td><td> </td><td> </td></tr><tr><td><i> CALR</i> type 1/type 1-like, <i>n</i> (%)</td><td>112 (16%)</td><td>12 (30%)</td><td>100 (15%)</td><td> </td><td> </td></tr><tr><td><i> CALR</i> type 2/type 2-like, <i>n</i> (%)</td><td>22 (3%)</td><td>3 (8%)</td><td>19 (3%)</td><td> </td><td> </td></tr><tr><td><i> MPL</i> mutated, <i>n</i> (%)</td><td>38 (5%)</td><td>2 (5%)</td><td>36 (5%)</td><td> </td><td> </td></tr><tr><td> Triple negative, <i>n</i> (%)</td><td>69 (10%)</td><td>3 (8%)</td><td>66 (10%)</td><td> </td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>CALR</i> mutated, <i>n</i> (%)</td><td>134 (19%)</td><td>15 (38%)</td><td>119 (18%)</td><td> </td><td> </td></tr><tr><td>Mutated versus unmutated</td><td> </td><td> </td><td> </td><td>0.002</td><td>0.0008</td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td colspan="6"><i>Cytogenetic categories N evaluable=685</i></td></tr><tr><td colspan="6"> Normal</td></tr><tr><td> Normal versus Abnormal</td><td>417 (61%)</td><td>26 (65%)</td><td>391 (61%)</td><td>0.6</td><td> </td></tr><tr><td> Favorable</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Favorable versus unfavorable*</td><td>605 (88%)</td><td>38 (95%)</td><td>567 (88%)</td><td>0.2</td><td> </td></tr><tr><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td><i>ASXL1,</i><i>N</i> evaluable=467</td><td>178 (38%)</td><td>14 (39%)</td><td>164 (38%)</td><td>0.9</td><td> </td></tr><tr><td><i>SF3B1</i>, <i>N</i> evaluable=401</td><td>35 (9%)</td><td>4 (13%)</td><td>31 (8%)</td><td>0.4</td><td> </td></tr><tr><td><i>U2AF1</i>, <i>N</i> evaluable=445</td><td>71 (16%)</td><td>2 (6%)</td><td>69 (17%)</td><td>0.1</td><td> </td></tr><tr><td><i>SRSF2</i>, <i>N</i> evaluable=461</td><td>70 (15%)</td><td>7 (19%)</td><td>63 (15%)</td><td>0.5</td><td> </td></tr><tr><td><i>TET2</i>, <i>N</i> evaluable=179</td><td>32 (18%)</td><td>3 (21%)</td><td>29 (18%)</td><td>0.7</td><td> </td></tr><tr><td><i>EZH2</i>, <i>N</i> evaluable=363</td><td>16 (4%)</td><td>2 (7%)</td><td>14 (4%)</td><td>0.5</td><td> </td></tr><tr><td><i>ZRSR2</i>, <i>N</i> evaluable=179</td><td>19 (11%)</td><td>2 (14%)</td><td>17 (10%)</td><td>0.6</td><td> </td></tr><tr><td><i>IDH1</i>, <i>N</i> evaluable=185</td><td>8 (4%)</td><td>0 (0%)</td><td>8 (5%)</td><td>0.4</td><td> </td></tr><tr><td><i>IDH2</i>, <i>N</i> evaluable=186</td><td>14 (8%)</td><td>2 (13%)</td><td>12 (7%)</td><td>0.4</td><td> </td></tr></table>
|
e4d55d4c6833837e6ed37f45ef3303ec789048893bc8fc9a8568e02accd03867.png
|
complex
|
<table><tr><td colspan="5">Central cardiologist</td></tr><tr><td> </td><td> </td><td>No RV dysfunction (n)</td><td>RV dysfunction (n)</td><td>Total (n)</td></tr><tr><td rowspan="3">Local cardiologist</td><td>No RV dysfunction (n)</td><td>55</td><td>4</td><td>59</td></tr><tr><td>RV dysfunction (n)</td><td>3</td><td>11</td><td>14</td></tr><tr><td>Total (n)</td><td>58</td><td>15</td><td>73</td></tr></table>
|
3f667da1be81734c56bbf2165e36a43af02dbf8e2ada02ceebf6bf261d70e736.png
|
simple
|
<table><tr><td></td><td></td><td>Before peritonitis</td><td>12 hours peritonitis</td><td>18 hours peritonitis</td><td>24 hours peritonitis</td></tr><tr><td>Exhaled NO (pmol/kg/min)</td><td>Control</td><td>6 (3 to 47)</td><td>22 (6 to 72)<sup>b</sup></td><td>27 (11 to 98)<sup>b</sup></td><td>15 (14 to 141)<sup>b</sup></td></tr><tr><td></td><td>AVP</td><td>5 (4 to 9)</td><td>14 (7 to 17)<sup>b</sup></td><td>12 (9 to 16)<sup>b</sup></td><td>8 (6 to 10)<sup>a</sup></td></tr><tr><td>Arterial NO<sub>3</sub><sup>-</sup>+NO<sub>2</sub><sup>- </sup>(μmol/g<sub>protein</sub>)</td><td>Control</td><td>0.5 (0.4 to 1.6)</td><td>1.5 (0.6 to 2.1)<sup>b</sup></td><td>1.8 (0.9 to 2.6)<sup>b</sup></td><td>1.8 (1.3 to 2.7)<sup>b</sup></td></tr><tr><td></td><td>AVP</td><td>1.0 (0.6 to 1.3)</td><td>1.4 (1.0 to 2.2)<sup>b</sup></td><td>1.3 (1.0 to 2.4)<sup>b</sup></td><td>1.2 (1.0 to 2.3)<sup>b</sup></td></tr><tr><td>Tumor necrosis factor-α (μmol/g<sub>protein</sub>)</td><td>Control</td><td>3 (2 to 3)</td><td>10 (8 to 16)<sup>b</sup></td><td>20 (12 to 25)<sup>b</sup></td><td>27 (15 to 55)<sup>b</sup></td></tr><tr><td></td><td>AVP</td><td>2 (2 to 3)</td><td>8 (7 to 11)<sup>b</sup></td><td>14 (12 to 19)<sup>b</sup></td><td>18 (15 to 29)<sup>b</sup></td></tr><tr><td>Interleukin 6 (μmol/g<sub>protein</sub>)</td><td>Control</td><td>1 (1 to 1)</td><td>125 (56 to 286)<sup>b</sup></td><td>549 (252 to 1624)<sup>b</sup></td><td>753 (559 to 3443)<sup>b</sup></td></tr><tr><td></td><td>AVP</td><td>1 (0 to 3)</td><td>83 (51 to 150)<sup>b</sup></td><td>216 (119 to 365)<sup>a, b</sup></td><td>354 (140 to 677)<sup>a, b</sup></td></tr></table>
|
b3ba653ab599848ea060c25c4ccacb7018c3576b915197de13da8728334923ad.png
|
complex
|
<table><tr><td>Label</td><td>Predicted function</td><td>Activity present in the following species</td><td>Activity suspected in <i>T. maritimum</i></td></tr><tr><td colspan="4">Iron uptake</td></tr><tr><td><i>MARIT_0169-0174</i></td><td>Siderophore biosynthesis system, Tbs</td><td>Deep sea metagenome (Fujita et al., 2012)</td><td>Avendaño-Herrera et al., 2005b</td></tr><tr><td><i>MARIT_1312-1313</i></td><td>Heme uptake mechanism, HmuYR</td><td><i>Porphyromonas gingivalis</i> (Olczak et al., 2008; Wójtowicz et al., 2009)</td><td>Avendaño-Herrera et al., 2005b</td></tr><tr><td><i>MARIT_0141 – 0142</i></td><td>Fe<sup>2+</sup> uptake system, FeoAB</td><td><i>Porphyromonas gingivalis</i> (Lau et al., 2016)</td><td>Avendaño-Herrera et al., 2005b</td></tr><tr><td><i>MARIT_1664</i></td><td>Iron acquisition, uptake or storage, imelysin family protein</td><td><i>Synechococcus elongatus</i> (Xu et al., 2011)</td><td>Avendaño-Herrera et al., 2005b</td></tr><tr><td><i>MARIT_1661</i></td><td>Iron acquisition, uptake or storage, imelysin family protein</td><td><i>Synechococcus elongatus</i> (Xu et al., 2011)</td><td>Avendaño-Herrera et al., 2005b</td></tr><tr><td colspan="4">Stress resistance</td></tr><tr><td><i>MARIT_3105</i></td><td>Superoxide dismutase [Mn/Fe], SodA</td><td><i>Staphylococcus carnosus</i> (Barrière et al., 2001)</td><td>Suzuki et al., 2001</td></tr><tr><td><i>MARIT_1670</i></td><td>Superoxide dismutase [Fe], SodB</td><td><i>Legionella pneumophila</i> (Amemura-Maekawa et al., 1996)</td><td>Suzuki et al., 2001</td></tr><tr><td><i>MARIT_1821</i></td><td>Superoxide dismutase [Cu–Zn], SodC</td><td><i>Schistosoma mansoni</i> (da Silva et al., 1992)</td><td>Suzuki et al., 2001</td></tr><tr><td><i>MARIT_0946</i></td><td>KatG catalase</td><td><i>Geobacillus stearothermophilus</i> (Singh et al., 2008)</td><td>Suzuki et al., 2001</td></tr><tr><td><i>MARIT_2408</i></td><td>KatA catalase</td><td><i>Pseudomonas aeruginosa</i> (Brown et al., 1995)</td><td>Suzuki et al., 2001</td></tr><tr><td colspan="4">Toxins</td></tr><tr><td><i>MARIT_0124</i></td><td>Cholesterol-dependent cytolysin</td><td><i>Capnocytophaga canimorsus</i> (Gilbert, 2010)</td><td>Baxa et al., 1988</td></tr><tr><td><i>MARIT_1085</i></td><td>Collagenase</td><td><i>Cytophaga</i> sp. (Sasagawa et al., 1995)</td><td>Baxa et al., 1988</td></tr><tr><td><i>MARIT_1748</i></td><td>Sphingomyelinase</td><td><i>Bacillus cereus</i> (Oda et al., 2010)</td><td></td></tr><tr><td><i>MARIT_2033</i></td><td>Ceramidase</td><td><i>Pseudomonas aeruginosa</i> (Ito et al., 2014)</td><td></td></tr><tr><td><i>MARIT_2107</i></td><td>Chondroitin AC lyase</td><td><i>Flavobacterium columnare</i> (Suomalainen et al., 2006)</td><td>Rahman et al., 2014</td></tr><tr><td><i>MARIT_2328</i></td><td>Streptopain family protease</td><td><i>Streptococcus pyogenes</i> (Nelson et al., 2011)</td><td>Wakabayashi et al., 1986; Baxa et al., 1988</td></tr><tr><td><i>MARIT_2678 - 2687</i></td><td>Sialoglycan degradation and uptake</td><td><i>Capnocytophaga canimorsus</i> (Mally et al., 2008)</td><td></td></tr></table>
|
99b1c169700d82d43fb12bc9231eb896ebe74a5f6d76292af17fc25c8645c9e9.png
|
simple
|
<table><tr><td>Sample items</td><td>%Agree</td></tr><tr><td>I am worried that other people might realize that I am HIV + if they see me taking my HIV medications.</td><td>52</td></tr><tr><td>I get frustrated taking my HIV medications because I have to plan my life around them.</td><td>40</td></tr><tr><td>I don’t like taking my HIV medications because they remind me that I am HIV + .</td><td>40</td></tr><tr><td>I feel that my healthcare provider takes my needs into account when making recommendations about which HIV medications to take.</td><td>84</td></tr><tr><td>Most people who are important to me who know I’m HIV positive support me in taking my HIV medications.</td><td>88</td></tr><tr><td>My healthcare provider doesn’t give me enough support when it comes to taking my medications as prescribed.</td><td>24</td></tr><tr><td>It frustrates me to think that I will have to take these HIV medications every day for the rest of my life.</td><td>44</td></tr><tr><td>I am worried that the HIV medications I have been prescribed will hurt my health.</td><td>56</td></tr><tr><td>It upsets me that the HIV medications I have been prescribed can affect the way I look.</td><td>52</td></tr><tr><td>It upsets me that the HIV medications I have been prescribed can cause side effects.</td><td>64</td></tr></table>
|
28ec9107447124a89e34ade5de90ee6277b5669cba567b93012c92f4bbf3b29f.png
|
simple
|
<table><tr><td>Smoking habit</td><td>Frequency among patients</td><td>Percentage</td><td>95% Confidence interval</td></tr><tr><td>No</td><td>106</td><td>77.9</td><td>70.1-84.2</td></tr><tr><td>Yes</td><td>27</td><td>19.9</td><td>13.9-27.5</td></tr><tr><td>Unknown</td><td>3</td><td>2.2</td><td>0.7-6.7</td></tr></table>
|
ba0a2a75ba0bdd89d6e8e641bac4cfd2e9ff655808ab1dd79cdcb015f94b59eb.png
|
complex
|
<table><tr><td> </td><td> </td><td>No/minimal impairment(independent)</td><td>Moderate impairment(independent/unilateral support)</td><td>Severe impairment(bilateral support/wheelchair)</td><td><i>p</i> value</td></tr><tr><td colspan="6"><i>Peroneal nerve</i></td></tr><tr><td rowspan="2">Motor CV (m/sec)</td><td>CIDP</td><td>40.4 ± 1.3</td><td>26.7 ± 14.7<sup>a</sup></td><td>21.0 ± 13.4</td><td>0.006</td></tr><tr><td>MMN</td><td>40.7 ± 6.8</td><td>37.2 ± 5.5</td><td>33.9 ± 3.1</td><td>0.099</td></tr><tr><td rowspan="2">CMAP amplitude (mV)</td><td>CIDP</td><td>4.4 ± 3.0</td><td>1.7 ± 1.4<sup>a</sup></td><td>0.1 ± 0.2</td><td>0.016</td></tr><tr><td>MMN</td><td>3.1 ± 2.1</td><td>2.8 ± 1.8</td><td>1.1 ± 1.2</td><td>0.110</td></tr><tr><td rowspan="2">CSA popliteal fossa (mm<sup>2</sup>)</td><td>CIDP</td><td>12.2 ± 3.1</td><td>17.9 ± 3.5<sup>a</sup></td><td>16.7 ± 2.0</td><td>0.045</td></tr><tr><td>MMN</td><td>10.5 ± 1.5</td><td>17.3 ± 4.3</td><td>14.0 ± 1.9</td><td>0.114</td></tr><tr><td rowspan="2">CSA fibular head (mm<sup>2</sup>)</td><td>CIDP</td><td>8.8 ± 1.7</td><td>11.5 ± 3.0</td><td>11 ± 1.3</td><td>0.227</td></tr><tr><td>MMN</td><td>7.8 ± 1.5</td><td>10.5 ± 2.3</td><td>9.3 ± 2.3</td><td>0.112</td></tr><tr><td colspan="6"><i>Tibial nerve</i></td></tr><tr><td rowspan="2">Motor CV (m/sec)</td><td>CIDP</td><td>39.4 ± 6.6</td><td>32.7 ± 12.5</td><td>33.9 ± 0.9</td><td>0.121</td></tr><tr><td>MMN</td><td>37.4 ± 3.6</td><td>34.6 ± 4.5</td><td>35.9 ± 4.0</td><td>0.234</td></tr><tr><td rowspan="2">CMAP amplitude (mV)</td><td>CIDP</td><td>3.9 ± 2.1</td><td>1.7 ± 2.4<sup>b</sup></td><td>0.3 ± 0.1</td><td>0.036</td></tr><tr><td>MMN</td><td>3.8 ± 1.1</td><td>2.3 ± 1.3</td><td>2.2 ± 2.7</td><td>0.048</td></tr><tr><td rowspan="2">CSA popliteal fossa (mm<sup>2</sup>)</td><td>CIDP</td><td>15.9 ± 3.8</td><td>26.7 ± 4.1</td><td>19.7 ± 3.9</td><td>0.037</td></tr><tr><td>MMN</td><td>15.4 ± 3.9</td><td>23.8 ± 4.8</td><td>17.8 ± 2.2</td><td>0.241</td></tr><tr><td rowspan="2">CSA ankle (mm<sup>2</sup>)</td><td>CIDP</td><td>12.6 ± 2.1</td><td>15.7 ± 3.8</td><td>11.8 ± 2.5</td><td>0.254</td></tr><tr><td>MMN</td><td>12.1 ± 2.4</td><td>14.5 ± 3.5<sup>b</sup></td><td>8.7 ± 2.0</td><td>0.032</td></tr><tr><td colspan="6"><i>Sural nerve</i></td></tr><tr><td rowspan="2">Sensory CV (m/sec)</td><td>CIDP</td><td>51.7 ± 3.3</td><td>25.1 ± 18.7</td><td>20.3 ± 18.3</td><td>0.255</td></tr><tr><td>MMN</td><td>48.8 ± 7.8</td><td>45.4 ± 1.6</td><td>44.4 ± 4.3</td><td>0.441</td></tr><tr><td rowspan="2">SNAP amplitude (<i>μ</i>V)</td><td>CIDP</td><td>4.5 ± 2.3</td><td>3.4 ± 3.7</td><td>1.7 ± 2.9</td><td>0.111</td></tr><tr><td>MMN</td><td>10.3 ± 6.1</td><td>9.9 ± 4.8</td><td>11.3 ± 5.4</td><td>0.638</td></tr><tr><td rowspan="2">CSA ankle (mm<sup>2</sup>)</td><td>CIDP</td><td>3.3 ± 0.3</td><td>3.7 ± 0.8</td><td>3.3 ± 0.2</td><td>0.928</td></tr><tr><td>MMN</td><td>3.0 ± 1.1</td><td>2.7 ± 0.4</td><td>2.7 ± 0.5</td><td>0.958</td></tr></table>
|
ac664df4a5255b8ed1f70dbf9e25dc97bc9d48af6544e9c22fe0bd6395e1345b.png
|
simple
|
<table><tr><td></td><td>Mean (standard deviation)</td><td>Min value</td><td>Max value</td></tr><tr><td>CGI-S</td><td>4.16 (0.92)</td><td>2</td><td>6</td></tr><tr><td>PANSS total score</td><td>79.4 (16.34)</td><td>45</td><td>140</td></tr><tr><td>PANSS positive score</td><td>16.46 (5.15)</td><td>7</td><td>33</td></tr><tr><td>PANSS negative score</td><td>23.19 (5.68)</td><td>10</td><td>43</td></tr><tr><td>PANSS general score</td><td>39.75 (9.77)</td><td>18</td><td>76</td></tr><tr><td>V-SIR</td><td>24.32 (7.82)</td><td>9.4</td><td>49.19</td></tr><tr><td>SCD total score</td><td>7.6 (4.1)</td><td>0</td><td>18</td></tr></table>
|
94e9e9c91cf85bbacd05931b858bde11aa3b600b5f074caa3fca73c5cf4b008e.png
|
complex
|
<table><tr><td rowspan="2">Features</td><td colspan="2">Patients</td></tr><tr><td><i>n</i></td><td>Frequency %</td></tr><tr><td>Gender</td><td> </td><td> </td></tr><tr><td> Males</td><td>344</td><td>82.3</td></tr><tr><td> Females</td><td>74</td><td>17.7</td></tr><tr><td>Age (years)</td><td> </td><td> </td></tr><tr><td> Min</td><td>31</td><td> </td></tr><tr><td> Max</td><td>93</td><td> </td></tr><tr><td> Mean ± SD</td><td> </td><td>66.7 ± 10.9</td></tr><tr><td> Median</td><td>67</td><td> </td></tr><tr><td>Smoking</td><td> </td><td> </td></tr><tr><td> Smokers</td><td>283</td><td>67.7</td></tr><tr><td> Nonsmokers</td><td>117</td><td>28.0</td></tr><tr><td> Not specified</td><td>18</td><td>4.3</td></tr><tr><td>Tumor stages</td><td> </td><td> </td></tr><tr><td> TIS</td><td>1</td><td>0.2</td></tr><tr><td> Ta</td><td>91</td><td>21.8</td></tr><tr><td> T1</td><td>198</td><td>47.4</td></tr><tr><td> T2</td><td>72</td><td>17.2</td></tr><tr><td> T3</td><td>27</td><td>6.5</td></tr><tr><td> T4</td><td>27</td><td>6.5</td></tr><tr><td> Not specified</td><td>2</td><td>0.4</td></tr><tr><td>Tumor grades</td><td> </td><td> </td></tr><tr><td> 1973</td><td> </td><td> </td></tr><tr><td>CIS</td><td>1</td><td>0.2</td></tr><tr><td>G1</td><td>139</td><td>33.3</td></tr><tr><td>G2</td><td>186</td><td>44.5</td></tr><tr><td>G3</td><td>86</td><td>20.6</td></tr><tr><td>Not specified</td><td>6</td><td>1.4</td></tr><tr><td> 2004</td><td> </td><td> </td></tr><tr><td>PUNLMP</td><td>11</td><td>2.6</td></tr><tr><td>CIS</td><td>1</td><td>0.2</td></tr><tr><td>Low</td><td>241</td><td>57.7</td></tr><tr><td>High</td><td>156</td><td>37.3</td></tr><tr><td>Not specified</td><td>9</td><td>2.2</td></tr><tr><td>Recurrence</td><td> </td><td> </td></tr><tr><td> No</td><td>268</td><td>64.1</td></tr><tr><td> Yes</td><td>150</td><td>35.9</td></tr></table>
|
32121112102c3f7cafea47345907f81a153be5af03be5f3e00f337df687661a9.png
|
complex
|
<table><tr><td rowspan="2">Groups</td><td colspan="2"> Ovarian weight</td></tr><tr><td>mg</td><td>mg/g body weight</td></tr><tr><td>Control</td><td>22.79 ± 4.87</td><td>1.26 ± 0.29</td></tr><tr><td>X-ray</td><td>12.54 ± 8.06<sup><i>∗∗</i></sup></td><td>0.71 ± 1.28<sup><i>∗∗</i></sup></td></tr><tr><td>NAC</td><td>23.96 ± 5.46<sup>##</sup></td><td>1.19 ± 0.89<sup>##</sup></td></tr><tr><td>NAC/X-ray</td><td>20.79 ± 4.01<sup>##</sup></td><td>1.20 ± 0.28<sup>##</sup></td></tr></table>
|
5e1d8f29059794368c1c85389fbbcab52c51796982a99537345d3d853f46aefd.png
|
complex
|
<table><tr><td></td><td colspan="4">Final grade</td></tr><tr><td></td><td><i>Grade</i></td><td><i>1</i></td><td><i>2</i></td><td><i>3</i></td></tr><tr><td>Predicted grade</td><td><i>1</i></td><td>21</td><td>0</td><td>0</td></tr><tr><td></td><td><i>2</i></td><td>5</td><td>35</td><td>9</td></tr><tr><td></td><td><i>3</i></td><td>1</td><td>6</td><td>7</td></tr><tr><td></td><td><i>1 or 2</i></td><td>7</td><td>1</td><td>1</td></tr><tr><td></td><td><i>2 or 3</i></td><td>0</td><td>2</td><td>8</td></tr><tr><td></td><td><i>Not predicted</i></td><td>1</td><td>1</td><td>0</td></tr></table>
|
8c6d9821d134328f74c2fd81450d9d92ac5bae9b8f67e78baf7fecf61f9a8b01.png
|
complex
|
<table><tr><td></td><td>Nurse/midwives <i>n</i> = 13</td><td>Doctors <i>n</i> = 05</td><td>Administrators <i>n</i> = 06</td></tr><tr><td colspan="4">Age (years)</td></tr><tr><td><30</td><td>6</td><td>1</td><td>0</td></tr><tr><td>30-39</td><td>3</td><td>3</td><td>0</td></tr><tr><td>40-49</td><td>2</td><td>0</td><td>1</td></tr><tr><td>≥50</td><td>2</td><td>1</td><td>5</td></tr><tr><td colspan="4">Marital status</td></tr><tr><td>Single</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Married</td><td>12</td><td>5</td><td>6</td></tr><tr><td>Widowed</td><td>0</td><td>0</td><td>0</td></tr><tr><td colspan="4">Gender</td></tr><tr><td>Female</td><td>13</td><td>0</td><td>0</td></tr><tr><td>Male</td><td>0</td><td>5</td><td>6</td></tr><tr><td colspan="4">Years of experience</td></tr><tr><td>0-4</td><td>5</td><td>2</td><td>1</td></tr><tr><td>5-9</td><td>5</td><td>2</td><td>0</td></tr><tr><td>10-15</td><td>1</td><td>0</td><td>0</td></tr><tr><td>15+</td><td>2</td><td>1</td><td>5</td></tr><tr><td colspan="4">Hospital location</td></tr><tr><td>Urban</td><td>8</td><td>4</td><td>3</td></tr><tr><td>Peri-urban</td><td>5</td><td>1</td><td>3</td></tr></table>
|
36e64375e176789fb8260750dafb829a69d39921fcb7b29710d5e53ddd2349b7.png
|
complex
|
<table><tr><td rowspan="2"> </td><td colspan="2">Healthy sample</td><td colspan="2">Overall sample</td></tr><tr><td>male</td><td>female</td><td>male</td><td>female</td></tr><tr><td>N</td><td>342</td><td>859</td><td>1275</td><td>1577</td></tr><tr><td>Age , years</td><td>46.2 ± 15.4</td><td>46.7 ± 13.8</td><td>52.5 ± 12.7</td><td>54.0 ± 14.9</td></tr><tr><td>BaPWV, cm/s</td><td>1339.3 ± 224.8</td><td>1294.8 ± 241.9</td><td>1524.8 ± 355.7</td><td>1578.6 ± 463.6</td></tr><tr><td>BMI, kg/m<sup>2</sup></td><td>23.8 ± 2.9</td><td>22.8 ± 2.9</td><td>24.7 ± 3.2</td><td>23.9 ± 3.4</td></tr><tr><td>MAP, mmHg</td><td>89.8 ± 7.3</td><td>85.3 ± 8.8</td><td>97.9 ± 18.8</td><td>94.7 ± 13.3</td></tr><tr><td>SBP, mmHg</td><td>123.9 ± 13.2</td><td>120.6 ± 12.1</td><td>131.8 ± 17.9</td><td>130.9 ± 20.9</td></tr><tr><td>DBP, mmHg</td><td>74.4 ± 7.5</td><td>70.2 ± 8.4</td><td>80.9 ± 24.1</td><td>76.6 ± 10.9</td></tr><tr><td>Pulse pressure, mmHg</td><td>46.0 ± 7.9</td><td>45.3 ± 9.1</td><td>50.9 ± 24.9</td><td>54.5 ± 14.9</td></tr><tr><td>HR, beats/min</td><td>70.8 ± 9.4</td><td>71.4 ± 9.4</td><td>70.9 ± 10.2</td><td>71.6 ± 10.1</td></tr><tr><td>TC, mmol/L</td><td>4.57 ± 0.81</td><td>4.75 ± 0.94</td><td>4.73 ± 0.94</td><td>5.09 ± 1.06</td></tr><tr><td>HDL-C, mmol/L</td><td>1.37 ± 0.29</td><td>1.44 ± 0.33</td><td>1.29 ± 0.29</td><td>1.39 ± 0.33</td></tr><tr><td>LDL-C, mmol/L</td><td>2.67 ± 0.62</td><td>2.75 ± 0.83</td><td>2.81 ± 0.76</td><td>3.02 ± 0.91</td></tr><tr><td>TG, mmol/L</td><td>1.53 ± 1.04</td><td>1.31 ± 0.87</td><td>1.80 ± 1.27</td><td>1.59 ± 0.99</td></tr><tr><td>Fasting glucose, mmol/L</td><td>4.9 ± 0.6</td><td>4.9 ± 0.5</td><td>5.4 ± 1.4</td><td>5.4 ± 1.6</td></tr><tr><td>Hypertension, %</td><td>0</td><td>0</td><td>50.3</td><td>47.8</td></tr><tr><td>Diabetes, %</td><td>0</td><td>0</td><td>23.7</td><td>21.1</td></tr><tr><td>Smoking, %</td><td>0</td><td>0</td><td>50.2</td><td>3.7</td></tr><tr><td>Stroke, %</td><td>0</td><td>0</td><td>7.2%</td><td>6.5%</td></tr><tr><td>Ischemic heart disease, %</td><td>0</td><td>0</td><td>10.9</td><td>7.1</td></tr><tr><td>Medication</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>ACEIs/ARBs, %</td><td>0</td><td>0</td><td>9.9</td><td>8.9</td></tr><tr><td>Statins, %</td><td>0</td><td>0</td><td>6.6</td><td>4.9</td></tr><tr><td>CCBs, %</td><td>0</td><td>0</td><td>15.3</td><td>14.5</td></tr></table>
|
5c41ce888c1d30040546b63e00f4595b28a34df720b08923cf519f22b4574fc9.png
|
complex
|
<table><tr><td>Transcript ID</td><td>LG</td><td>Start position</td><td colspan="4">Median reads per million (RPM) ± S.D.</td><td>Zebrafish homolog</td></tr><tr><td> </td><td> </td><td> </td><td>Pacific Ocean males</td><td>Pacific Ocean females</td><td>Japan Sea males</td><td>Japan Sea females</td><td> </td></tr><tr><td>ENSGACT00000029029</td><td>I</td><td>7684495</td><td>2852.3 (227.8)</td><td>4343.0 (1716.7)</td><td>10218.3 (1270.0)</td><td>4026.2 (860.8)</td><td><i>mir22a</i>-<i>1</i></td></tr><tr><td>ENSGACT00000028961</td><td>III</td><td>7312510</td><td>563.3 (78.4)</td><td>1250.9 (684.9)</td><td>3683.1 (408.8)</td><td>1115.0 (176.9)</td><td><i>mir7a</i>-<i>3</i></td></tr><tr><td>ENSGACT00000028970</td><td>VI</td><td>4231011</td><td>2465.3 (127.5)</td><td>2270.1 (62.9)</td><td>1858.6 (244.0)</td><td>1966.8 (141.3)</td><td><i>mir30c</i></td></tr><tr><td>ENSGACT00000029035</td><td>XI</td><td>1952924</td><td>9700.4 (165.6)</td><td>11004.3 (1503.8)</td><td>14871.2 (475.2)</td><td>12259.0 (332.2)</td><td><i>mir152</i></td></tr><tr><td>ENSGACT00000028984</td><td>XIII</td><td>7256736</td><td>609.2 (80.5)</td><td>1294.3 (679.4)</td><td>3601.1 (393.0)</td><td>1134.8 (168.2)</td><td><i>mir7b</i></td></tr><tr><td>ENSGACT00000029072</td><td>XIX</td><td>2936579</td><td>547.6 (75.4)</td><td>1228.1 (681.4)</td><td>3503.5 (381.2)</td><td>1073.8 (169.6)</td><td><i>mir7a</i>-<i>1</i></td></tr><tr><td>ENSGACT00000029039</td><td>XX</td><td>15698389</td><td>568.3 (73.6)</td><td>1245.5 (680.7)</td><td>3560.3 (396.7)</td><td>1099.6 (167.8)</td><td><i>mir7a</i>-<i>2</i></td></tr></table>
|
b6b1dda9f63506bdfcd29d581d654d6255fd958246786b0c92aba60411b7c2c6.png
|
complex
|
<table><tr><td></td><td colspan="3">If Rval<sup>a</sup> ≤ value</td><td colspan="3">If Rval ≥ value</td><td></td></tr><tr><td>Study</td><td>Value</td><td>Intercept 1</td><td>X1<sup>b</sup></td><td>Value</td><td>Intercept 2</td><td>X2<sup>b</sup></td><td>R<sup>2</sup></td></tr><tr><td> GNHIES98</td><td>73.2698</td><td>−0.2256</td><td>1.2197</td><td>73.2698</td><td>49.0336</td><td>0.5474</td><td>0.94</td></tr><tr><td> DEGS1</td><td>121.9968</td><td>14.5310</td><td>0.7715</td><td>121.9968</td><td>102.1919</td><td>0.0530</td><td>0.79</td></tr><tr><td> KiGGS</td><td>60.5211</td><td>9.4005</td><td>1.0225</td><td>60.5211</td><td>52.4099</td><td>0.3119</td><td>0.81</td></tr></table>
|
234bf7b3f9dd44a5d2239e248bed2d4623cb0ea3c8ef92772ca6bd24525cd189.png
|
simple
|
<table><tr><td>Cardiovascular risk indicators</td><td>20 – 39 years</td><td>40 – 59 years</td><td>≥ 60 years</td><td>Total</td><td>p-value*</td></tr><tr><td>Total cholesterol (mg/dl)</td><td> </td><td> </td><td> </td><td> </td><td>0.871</td></tr><tr><td>Normal</td><td>238 (91.2)</td><td>100 (90.9)</td><td>78 (92.9)</td><td>416 (91.4)</td><td> </td></tr><tr><td>Risk</td><td>23 (8.8)</td><td>10 (9.1)</td><td>6 (7.1)</td><td>39 (8.6)</td><td> </td></tr><tr><td>HDL-cholesterol (mg/dl)</td><td> </td><td> </td><td> </td><td> </td><td>0.035</td></tr><tr><td>Normal</td><td>78 (29.9)</td><td>38 (34.5)</td><td>38 (45.2)</td><td>154 (33.8)</td><td> </td></tr><tr><td>Risk</td><td>183 (70.1)</td><td>72 (65.5)</td><td>46 (54.8)</td><td>301 (66.2)</td><td> </td></tr><tr><td>LDL-cholesterol (mg/dl)</td><td> </td><td> </td><td> </td><td> </td><td>0.448</td></tr><tr><td>Normal</td><td>242 (98.8)</td><td>93 (96.9)</td><td>77 (98.7)</td><td>412 (98.3)</td><td> </td></tr><tr><td>Risk</td><td>3 (1.2)</td><td>3 (3.1)</td><td>1 (1.3)</td><td>7 (1.7)</td><td> </td></tr><tr><td>Triglycerides (mg/dl)</td><td> </td><td> </td><td> </td><td> </td><td>0.003</td></tr><tr><td>Normal</td><td>120 (46.0)</td><td>41 (37.3)</td><td>52 (61.9)</td><td>213 (46.8)</td><td> </td></tr><tr><td>Risk</td><td>141 (54.0)</td><td>69 (62.7)</td><td>32 (38.1)</td><td>242 (53.2)</td><td> </td></tr><tr><td>Castelli index I</td><td> </td><td> </td><td> </td><td> </td><td>0.128</td></tr><tr><td>Normal</td><td>225 (86.2)</td><td>94 (85.5)</td><td>79 (94.)</td><td>398 (87.5)</td><td> </td></tr><tr><td>Risk</td><td>36 (13.8)</td><td>16 (14.5)</td><td>5 (6.0)</td><td>57 (12.5)</td><td> </td></tr><tr><td>Castelli index II</td><td> </td><td> </td><td> </td><td> </td><td>0.033</td></tr><tr><td>Normal</td><td>227 (92.7)</td><td>94 (97.9)</td><td>77 (98.7)</td><td>398 (95.0)</td><td> </td></tr><tr><td>Risk</td><td>18 (7.3)</td><td>2 (2.1)</td><td>1 (1.3)</td><td>21 (5.0)</td><td> </td></tr><tr><td>TG/HDL-C ratio</td><td> </td><td> </td><td> </td><td> </td><td>< 0.001</td></tr><tr><td>Normal</td><td>98 (37.5)</td><td>35 (31.8)</td><td>49 (58.3)</td><td>182 (40.0)</td><td> </td></tr><tr><td>Risk</td><td>163 (62.5)</td><td>75 (68.2)</td><td>35 (41.7)</td><td>274 (60.0)</td><td> </td></tr><tr><td>ApoB/ApoA1 ratio</td><td> </td><td> </td><td> </td><td> </td><td>0.128</td></tr><tr><td>Normal</td><td>229 (88.4)</td><td>102 (92.7)</td><td>79 (95.2)</td><td>410 (90.7)</td><td> </td></tr><tr><td>Risk</td><td>30 (11.6)</td><td>8 (7.3)</td><td>4 (4.8)</td><td>42 (9.3)</td><td> </td></tr><tr><td>Framingham</td><td> </td><td> </td><td> </td><td> </td><td>< 0.001</td></tr><tr><td>Low risk</td><td>261 (100.0)</td><td>79 (71.8)</td><td>1 (1.2)</td><td>34 (74.9)</td><td> </td></tr><tr><td>Intermediate risk</td><td>0 (0.0)</td><td>24 (21.8)</td><td>21 (25.0)</td><td>45 (9.9)</td><td> </td></tr><tr><td>High risk</td><td>0 (0.0)</td><td>7 (6.4)</td><td>62 (73.8)</td><td>69 (15.2)</td><td> </td></tr><tr><td>Hs-CRP (mg/L)</td><td> </td><td> </td><td> </td><td> </td><td>0.867</td></tr><tr><td>Low risk</td><td>47 (18.0)</td><td>19 (17.3)</td><td>17 (20.5)</td><td>83 (18.3)</td><td> </td></tr><tr><td>Intermediate risk</td><td>102 (39.1)</td><td>42 (38.2)</td><td>27 (32.5)</td><td>171 (37.7)</td><td> </td></tr><tr><td>High risk</td><td>112 (42.9)</td><td>49 (44.5)</td><td>39 (47.0)</td><td>200 (44.1)</td><td> </td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td> </td><td> </td><td> </td><td> </td><td>< 0.001</td></tr><tr><td>Normal</td><td>33 (12.6)</td><td>10 (9.1)</td><td>42 (50.0)</td><td>85 (18.7)</td><td> </td></tr><tr><td>Risk</td><td>228 (87.4)</td><td>100 (90.9)</td><td>42 (50.0)</td><td>370 (81.3)</td><td> </td></tr><tr><td>Waist circumference (cm)</td><td> </td><td> </td><td> </td><td> </td><td>< 0.001</td></tr><tr><td>Normal</td><td>118 (45.2)</td><td>27 (24.5)</td><td>41 (48.8)</td><td>186 (40.9)</td><td> </td></tr><tr><td>Risk</td><td>143 (54.8)</td><td>83 (75.5)</td><td>43 (51.2)</td><td>269 (59.1)</td><td> </td></tr><tr><td>Hypertriglyceridemic waist</td><td> </td><td> </td><td> </td><td> </td><td>0.001</td></tr><tr><td>Normal</td><td>164 (62.8)</td><td>54 (49.1)</td><td>64 (76.2)</td><td>282 (62.0)</td><td> </td></tr><tr><td>Risk</td><td>97 (37.2)</td><td>56 (50.9)</td><td>20 (23.8)</td><td>173 (38.0)</td><td> </td></tr><tr><td>Glycemia (mg/dL)</td><td> </td><td> </td><td> </td><td> </td><td>< 0.001</td></tr><tr><td>Low risk</td><td>160 (61.3)</td><td>46 (41.8)</td><td>36 (42.9)</td><td>242 (53.2)</td><td> </td></tr><tr><td>High risk</td><td>101 (38.7)</td><td>64 (58.2)</td><td>48 (57.1)</td><td>213 (46.8)</td><td> </td></tr><tr><td>Blood pressure (mm/Hg)</td><td> </td><td> </td><td> </td><td> </td><td>< 0.001</td></tr><tr><td>Low risk</td><td>236 (90.4)</td><td>86 (78.2)</td><td>51 (60.7)</td><td>373 (82.0)</td><td> </td></tr><tr><td>High risk</td><td>25 (9.6)</td><td>24 (21.8)</td><td>33 (39.3)</td><td>82 (18.0)</td><td> </td></tr></table>
|
eea66b442ad0487bf0d50db6e97047ec3ffa0a746340efd8d9abec89c2ad4b4c.png
|
simple
|
<table><tr><td></td><td>Total</td><td>N/100 orders</td><td>N/100 admissions</td><td>N/1000 patient-days</td></tr><tr><td>Orders</td><td>4942</td><td>NA*</td><td>7844</td><td>9709</td></tr><tr><td>Medication error</td><td>492</td><td>10</td><td>780</td><td>967</td></tr><tr><td>Adverse drug events</td><td>8</td><td>0.16</td><td>12.6</td><td>15.7</td></tr><tr><td>Potential adverse drug events</td><td>113</td><td>2.28</td><td>179.3</td><td>222</td></tr></table>
|
1da2b821b08a1f15d814a01e671f3a74418a9ed4ffd49f3c27eda43a41283423.png
|
simple
|
<table><tr><td>Parameters</td><td>Value</td></tr><tr><td>Plant life</td><td>30 years</td></tr><tr><td>Discount rate</td><td>10%</td></tr><tr><td>Financing</td><td>40% equity</td></tr><tr><td>Loan terms</td><td>10-year loan at 8% APR</td></tr><tr><td>General plant depreciation</td><td>200% declining balance<sup>a</sup></td></tr><tr><td>General plant recovery period</td><td>7 years</td></tr><tr><td>Steam plant depreciation</td><td>150% declining balance</td></tr><tr><td>Steam plant recovery period</td><td>20 years</td></tr><tr><td>Construction period</td><td>3 years</td></tr><tr><td>0-12 months</td><td>8% of project cost</td></tr><tr><td>12-24 months</td><td>60% of project cost</td></tr><tr><td>24-36 months</td><td>32% of project cost</td></tr><tr><td>Working capital</td><td>5% of fixed capital investment</td></tr><tr><td>Start-up time</td><td>3 months</td></tr><tr><td>Revenues during start-up</td><td>50%</td></tr><tr><td>Variable costs incurred during start-up</td><td>75%</td></tr><tr><td>Fixed costs incurred during start-up</td><td>100%</td></tr></table>
|
56a3681775c2a27cabc1227eae38c0cdd0a81337c76dafee09aac189c3a3843c.png
|
simple
|
<table><tr><td> Patient characteristics</td><td></td></tr><tr><td>Male/female</td><td>49 (63.6%)/28 (36.4%)</td></tr><tr><td>Birth weight (gr)</td><td>2930 ± 485 (range 4300-1800)</td></tr><tr><td>Gestational age at delivery (wk)</td><td>37 ± 2 (range 42–32)</td></tr><tr><td>Term/preterm delivery</td><td>40 (52%)/37 (48%)</td></tr><tr><td>Left/right side</td><td>67 (87%)/10 (13%)</td></tr><tr><td>Inborn/outborn</td><td>71 (92.2%)/6 (7.8%)</td></tr><tr><td>Prenatal diagnosis</td><td>68 (88.3%)</td></tr><tr><td>Associated anomalies</td><td>18 (23.4%)</td></tr><tr><td>Associated congenital heart diseases</td><td>4 (5.2%)</td></tr></table>
|
2cae2be0109b44a20b8e593e4a5bff2855742867d65d9eb0e36b9c2e313d0aa7.png
|
simple
|
<table><tr><td>date (day of chth)</td><td></td><td></td></tr><tr><td>(I day)</td><td>1.</td><td>Doxorubicin 80 mg i.v.</td></tr><tr><td></td><td>2.</td><td>Cis-Platinium 40 mg i.v.</td></tr><tr><td></td><td>3.</td><td>5-FU 800 mg i.v.</td></tr><tr><td></td><td>4.</td><td>Roferon 9 MU</td></tr><tr><td>(II day)</td><td>1.</td><td>Cis-Platinium 40 mg i.v.</td></tr><tr><td></td><td>2.</td><td>5-FU 800 mg i.v.</td></tr><tr><td></td><td>3.</td><td>Roferon 9 M U</td></tr><tr><td>(III day)</td><td>1.</td><td>Cis-Platinium 40 mg i.v.</td></tr><tr><td></td><td>2.</td><td>5-FU 800 mg i.v.</td></tr><tr><td></td><td>3.</td><td>Roferon 9 M U</td></tr><tr><td>(IV day)</td><td>1.</td><td>Cis-Platinium 40 mg i.v.</td></tr><tr><td></td><td>2.</td><td>5-FU 800 mg i.v.</td></tr><tr><td></td><td>3.</td><td>Roferon 9 M U</td></tr></table>
|
37a43c46082c223b73773b6560852eb315fb041db7181d114b0885643d20a704.png
|
complex
|
<table><tr><td rowspan="2">Characteristics</td><td colspan="3">mRNA profiling</td><td colspan="3">microRNA profiling</td><td colspan="3">Total subjects</td></tr><tr><td>Trisomy 21 (<i>n</i> = 3)</td><td>Normal (<i>n</i> = 5)</td><td><i>P</i> value</td><td>Trisomy 21 (<i>n</i> = 4)</td><td>Normal (n = 5)</td><td><i>P</i> value</td><td>Trisomy 21 (<i>n</i> = 7)</td><td>Normal (<i>n</i> = 10)</td><td><i>P</i> value</td></tr><tr><td>Maternal Age (years)</td><td>34.6 ± 3.8</td><td>37.4 ± 3.9</td><td>0.853</td><td>30.3 ± 2.2</td><td>34.2 ± 3.1</td><td>0.628</td><td>32.1 ± 3.6</td><td>35.8 ± 3.7</td><td>0.062</td></tr><tr><td>Gestational age (weeks)</td><td>12.0 ± 0.0</td><td>12.2 ± 0.4</td><td>0.092</td><td>12.2 ± 0.4</td><td>12.4 ± 0.7</td><td>0.071</td><td>12.1 ± 0.4</td><td>12.3 ± 0.6</td><td>0.454</td></tr><tr><td>Body mass index (kg/m<sup>2</sup>)</td><td>22.3 ± 3.7</td><td>24.4 ± 6.2</td><td>0.545</td><td>21.8 ± 3.3</td><td>21.5 ± 1.2.2</td><td>0.874</td><td>22.0 ± 3.2</td><td>22.9 ± 4.7</td><td>0.659</td></tr><tr><td>Gravidity</td><td>2.7 ± 1.2</td><td>2.8 ± 0.8</td><td>0.446</td><td>1.8 ± 1.0</td><td>3.0 ± 1.6</td><td>0.210</td><td>2.1 ± 1.1</td><td>2.9 ± 1.2</td><td>0.201</td></tr><tr><td>Nuchal translucency (mm)</td><td>3.7 ± 1.4</td><td>4.9 ± 1.9</td><td>0.402</td><td>4.2 ± 0.8</td><td>3.3 ± 1.5</td><td>0.377</td><td>4.0 ± 1.0</td><td>4.1 ± 1.8</td><td>0.862</td></tr><tr><td>Nullipara</td><td>2</td><td>1</td><td>0.146</td><td>2</td><td>1</td><td>0.524</td><td>4</td><td>2</td><td>0.162</td></tr><tr><td>Gender-ratio (female:male)</td><td>1:2</td><td>1:4</td><td>1.000</td><td>1:3</td><td>1:4</td><td>1.000</td><td>2:5</td><td>2:8</td><td>1.000</td></tr></table>
|
4bf136c9ae8c3fe0378c5838b25581081d8b352968e1ea87cd3f5db01f91d013.png
|
simple
|
<table><tr><td>Characteristics</td><td>Patients</td></tr><tr><td>Median age (y) (range)</td><td>52 (36–76)</td></tr><tr><td>Median parity (range)</td><td>3 (0–9)</td></tr><tr><td>Median BMI (range)</td><td>31.2 (21.4–41.5)</td></tr><tr><td>Prior surgery for prolapse including hysterectomy (<i>n</i>, %) </td><td>3 (15)</td></tr><tr><td>Prior hysterectomy for benign tumor (<i>n</i>, %)</td><td>4 (20)</td></tr><tr><td>Stage of prolapse </td><td></td></tr><tr><td><i> </i><i> </i>Stage II (<i>n</i>, %)</td><td>6 (30)</td></tr><tr><td><i> </i><i> </i>Stage III (<i>n</i>, %)</td><td>12 (60)</td></tr><tr><td><i> </i><i> </i>Stage IV (<i>n</i>, %)</td><td>2 (10)</td></tr><tr><td>Urinary incontinence (<i>n</i>, %)</td><td>16 (80)</td></tr></table>
|
6b60305e9446d2d8cc6c62b31b5cd3c94d75b5847f0995d15b38813d1f523415.png
|
simple
|
<table><tr><td>Sources of Attrition</td><td>N (%)</td><td>AA<sup>a</sup> (%)</td><td>EA<sup>a</sup> (%)</td><td><i>p</i>-value<sup>c,d</sup></td></tr><tr><td>Deceased</td><td>118 (26)</td><td>59 (50)</td><td>59 (50)</td><td>1.000</td></tr><tr><td>Frail</td><td>23 (5)</td><td>13 (57)</td><td>10 (44)</td><td>0.532</td></tr><tr><td>Lost to Follow-Up</td><td>87 (19)</td><td>69 (79)</td><td>18 (21)</td><td>< 0.001</td></tr><tr><td>Passive Refusal</td><td>29 (6)</td><td>22 (76)</td><td>7 (24)</td><td>0.005</td></tr><tr><td>Active Refusal<sup>e</sup></td><td>206 (45)</td><td>103 (50)</td><td>103 (50)</td><td>1.000</td></tr><tr><td>Total</td><td>463 (100)</td><td>266 (58)</td><td>197 (43)</td><td>0.001</td></tr></table>
|
1bdf5f2c05169f90689d19091ca0f54da1056cd9f90a2e8ab910ff93522e0b3a.png
|
complex
|
<table><tr><td rowspan="2"></td><td colspan="3">Univariate analysis</td><td colspan="3">Mulivariate analysis</td></tr><tr><td>β</td><td>95% CI</td><td>p</td><td>βadj</td><td>95% CI</td><td>p</td></tr><tr><td>Age of mother</td><td>−0.03</td><td>(− 0.08,0.02)</td><td>0.25</td><td>0.05</td><td>(0.03,0.08)</td><td>< 0.0001</td></tr><tr><td>Age of mother at birth of the first children</td><td>- 0.05</td><td>(−0.02,-0.13)</td><td>0.02</td><td>−0.01</td><td>(−0.04,0.01)</td><td>0.39</td></tr><tr><td>NUMBER OF CHILDERN</td><td>−0.23</td><td>(−0.52,0.06)</td><td>0.12</td><td>0.09</td><td>(−0.20,0.42)</td><td>0.50</td></tr><tr><td colspan="7">Mother’s Educational level</td></tr><tr><td> None</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td> 1 to 5 years</td><td>−1.04</td><td>(−1.38,-0.70)</td><td>< 0.001</td><td>0.49</td><td>(0.07,0.92)</td><td>0.02</td></tr><tr><td> 6 to 12</td><td>−0.74</td><td>(−1.13,-0.37)</td><td>< 0.001</td><td>1.18</td><td>(0.79,1.58)</td><td>< 0.001</td></tr><tr><td> University</td><td>1.11</td><td>(0.56,1.65)</td><td>< 0.001</td><td>2.07</td><td>(1.43,2.71)</td><td>< 0.001</td></tr><tr><td>Mother’s employment status, working<sup>a</sup></td><td>1.42</td><td>(0.34,2.50)</td><td>0.01</td><td>1.70</td><td>(0.69,2.8)</td><td>0.003</td></tr><tr><td>Children health status, chronic illness<sup>b</sup></td><td>−0.07</td><td>(−0.45,0.30)</td><td>0.70</td><td></td><td></td><td></td></tr><tr><td colspan="7">Family income</td></tr><tr><td> Low</td><td>1</td><td></td><td></td><td>1</td><td></td><td></td></tr><tr><td> Medium</td><td>0.60</td><td>(0.22, 0.99)</td><td>0.002</td><td>0.38</td><td>(0.01,0.76)</td><td>0.04</td></tr><tr><td> High</td><td>- 1.20</td><td>(−0.32,-2.09)</td><td>0.007</td><td>0.45</td><td>(− 0.43,1.33)</td><td>0.31</td></tr></table>
|
8532965a7f50f3df5219a5811299ab78afe171f2b262f033e834d3225e89534c.png
|
complex
|
<table><tr><td>Activities</td><td>Advantages</td><td>Specific challenges</td><td>Response</td></tr><tr><td rowspan="4">School meetings</td><td>• Easy to organize</td><td>• Low attendance</td><td>• Follow-up school meetings organized</td></tr><tr><td>• Resource and time efficient</td><td>• Consenting decisions may be influenced by other parents</td><td>• Meetings held outside classrooms to minimize disruption</td></tr><tr><td>• Follow-up consent meetings allowed time for consultations</td><td>• Disruption to school schedules</td><td>• Insistence on parental consent</td></tr><tr><td> </td><td>• Danger of proxy consent from relatives</td><td>• Household visits</td></tr><tr><td rowspan="4">Household visits</td><td>• Allows for more in-depth and one-on-one discussions of the study</td><td>• Difficulties in tracking households</td><td>• Use of village elders/community health workers to track parents</td></tr><tr><td>• Eliminates pressure and influence associated with school meetings</td><td>• Unavailability of parents at home</td><td>• Field workers sent to households early in the morning or late in the evening</td></tr><tr><td>• Can allow joint decision-making to participate in research</td><td>• Time consuming</td><td> </td></tr><tr><td> </td><td>• Resource intensive</td><td> </td></tr></table>
|
aa82c7e98f2c80e8d6df8b502ace41157b5e34c3106c0b3d4dbf6ef134081290.png
|
simple
|
<table><tr><td>Fluorescent real-time PCR</td><td>Orientation</td><td>Sequence<sup>a </sup>(5'---3')</td><td>Amplicon length (bp)</td></tr><tr><td>TaqMan</td><td>Sense</td><td>CCGCCTTTGAGTGAGCTGATA</td><td>210</td></tr><tr><td></td><td>Anti-sense</td><td>TGTAGACAACATCCCCTCCCC</td><td></td></tr><tr><td></td><td>Probe</td><td>FAM CGCCGCAGCCGAACGACCGAG TAMRA</td><td></td></tr><tr><td></td><td>Sense</td><td>GTATTACCGCCTTTGAGTGAGCT</td><td>510</td></tr><tr><td></td><td>Anti-sense</td><td>ATGACAATCAGCTACTTCACTGTTG</td><td></td></tr><tr><td></td><td>Probe</td><td>FAM CGCCGCAGCCGAACGACCGAG TAMRA</td><td></td></tr><tr><td></td><td>Sense</td><td>CCGCCTTTGAGTGAGCTGATA</td><td>992</td></tr><tr><td></td><td>Anti-sense</td><td>CTCCGCTGGTCCGATTGAAC</td><td></td></tr><tr><td></td><td>Probe</td><td>FAM CGCCGCAGCCGAACGACCGAG TAMRA</td><td></td></tr><tr><td></td><td>Sense</td><td>CCGCCTTTGAGTGAGCTGATA</td><td>1596</td></tr><tr><td></td><td>Anti-sense</td><td>AATGGTTTCTGACGTATGTGCTTAG</td><td></td></tr><tr><td></td><td>Probe</td><td>FAM CGCCGCAGCCGAACGACCGAG TAMRA</td><td></td></tr><tr><td>UT<sup>a</sup></td><td>Sense</td><td>taggaacaggcggcgacga<i>ATACAA </i>CATCCGCTTGCCCTCATC</td><td>195</td></tr><tr><td></td><td>Anti-sense</td><td>TGCCAAAGGGTTCGTGTAG</td><td></td></tr><tr><td></td><td>Sense</td><td>taggaacaggcggcgacga <i>ATACAA </i>CATCCGCTTGCCCTCATC</td><td>546</td></tr><tr><td></td><td>Anti-sense</td><td>GGGATAACGCAGGAAAGAACAT</td><td></td></tr><tr><td></td><td>Sense</td><td>CAGACGTGAAACCCAACATACC</td><td>1032</td></tr><tr><td></td><td>Anti-sense</td><td>Taggaacaggcggcgacga <i>ATACAA </i>CCCAATAGCAGCCAGTCCCT</td><td></td></tr><tr><td></td><td>Sense</td><td>taggaacaggcggcgacga <i>ATACAA </i>TCTGCTGTAGTGAGTGGGTTGC</td><td>1630</td></tr><tr><td></td><td>Anti-sense</td><td>GCCGATTGTCTGTTGTGCC</td><td></td></tr><tr><td></td><td>UT probe</td><td>FAM TCGTCGCCGCCTGTTCCTA TAMRA</td><td></td></tr><tr><td>AUDP probe<sup>b</sup></td><td>Sense</td><td>taggaacaggcggcgacgagcgtgggacata<i>AA</i>ACTCCATCCGCTTGCCCTCATC</td><td>195</td></tr><tr><td></td><td>Anti-sense</td><td>TGCCAAAGGGTTCGTGTAG</td><td></td></tr><tr><td></td><td>Sense</td><td>taggaacaggcggcgacgagcgtgggacata<i>AAACTC</i>CATCCGCTTGCCCTCATC</td><td>546</td></tr><tr><td></td><td>Anti-sense</td><td>GGGATAACGCAGGAAAGAACAT</td><td></td></tr><tr><td></td><td>Sense</td><td>CAGACGTGAAACCCAACATACC</td><td>1032</td></tr><tr><td></td><td>Anti-sense</td><td>taggaacaggcggcgacgagcgtgggacata<i>AAACTC</i>CCCAATAGCAGCCAGTCCCT</td><td></td></tr><tr><td></td><td>Sense</td><td>taggaacaggcggcgacgagcgtgggacata<i>AAACCTC</i>TCTGCTGTAGTGAGTGGGTTGC</td><td>1630</td></tr><tr><td></td><td>Anti-sense</td><td>GCCGATTGTCTGTTGTGCC</td><td></td></tr><tr><td></td><td>FP</td><td>FAM TAGGAACAGGCGGCGACGAGCGTGGGACATA</td><td></td></tr><tr><td></td><td>QP</td><td>AGTCGTCGCCGCCTGTTCCTA Dabcyl</td><td></td></tr></table>
|
32b3ea32eef47a265a857f7444f91ea7ed8702d0264003807be8b5c7c1141f85.png
|
complex
|
<table><tr><td colspan="10">Compounds</td></tr><tr><td>C</td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td></tr><tr><td>1</td><td>38.7</td><td>38.3<sup>a</sup></td><td>32.9</td><td>37.5</td><td>155.3</td><td>37.4</td><td>158.6</td><td>155.1</td><td>155.0</td></tr><tr><td>2</td><td>38.2</td><td>32.1</td><td>30.6</td><td>34.2</td><td>127.7</td><td>34.1</td><td>125.1</td><td>127.8</td><td>127.8</td></tr><tr><td>3</td><td>211.8</td><td>71.8</td><td>67.2</td><td>200.3</td><td>186.3</td><td>199.9</td><td>186.7</td><td>186.2</td><td>186.2</td></tr><tr><td>4</td><td>44.5</td><td>38.9</td><td>36.7</td><td>124.6</td><td>124.2</td><td>124.8</td><td>124.8</td><td>124.3</td><td>124.2</td></tr><tr><td>5</td><td>46.8</td><td>46.3</td><td>40.4</td><td>170.9</td><td>168.3</td><td>170.1</td><td>167.4</td><td>167.9</td><td>167.9</td></tr><tr><td>6</td><td>28.9</td><td>29.9</td><td>29.6</td><td>33.6</td><td>32.5</td><td>33.3</td><td>32.8</td><td>32.5</td><td>32.4</td></tr><tr><td>7</td><td>31.3</td><td>32.9</td><td>33.5</td><td>31.1</td><td>32.3</td><td>30.3</td><td>32.1</td><td>33.4</td><td>31.9</td></tr><tr><td>8</td><td>35.6</td><td>36.9</td><td>36.9</td><td>35.3</td><td>35.1</td><td>34.6</td><td>33.9</td><td>34.4</td><td>35.0</td></tr><tr><td>9</td><td>53.8</td><td>56.0</td><td>56.1</td><td>59.2</td><td>52.2</td><td>59.2</td><td>60.4</td><td>52.1</td><td>51.9</td></tr><tr><td>10</td><td>35.8</td><td>36.7</td><td>37.2</td><td>39.9</td><td>43.4</td><td>40.0</td><td>43.9</td><td>43.4</td><td>43.3</td></tr><tr><td>11</td><td>21.0</td><td>21.9</td><td>21.5</td><td>68.9</td><td>22.1</td><td>68.7</td><td>67.7</td><td>36.1</td><td>21.7</td></tr><tr><td>12</td><td>36.8</td><td>38.1<sup>a</sup></td><td>38.1</td><td>48.5</td><td>31.1</td><td>42.9</td><td>42.3</td><td>86.0</td><td>30.9</td></tr><tr><td>13</td><td>43.1</td><td>44.1</td><td>44.1</td><td>43.7</td><td>47.7</td><td>47.9</td><td>47.8</td><td>42.7</td><td>38.7</td></tr><tr><td>14</td><td>50.9</td><td>52.4</td><td>52.5</td><td>49.8</td><td>50.4</td><td>50.0</td><td>49.6</td><td>44.1</td><td>47.3</td></tr><tr><td>15</td><td>23.5</td><td>24.3</td><td>24.3</td><td>23.3</td><td>21.9</td><td>21.7</td><td>21.8</td><td>22.2</td><td>30.6</td></tr><tr><td>16</td><td>30.6</td><td>30.6</td><td>29.7</td><td>30.6</td><td>35.6</td><td>35.7</td><td>35.8</td><td>35.5</td><td>71.1</td></tr><tr><td>17</td><td>81.9</td><td>82.5</td><td>82.6</td><td>81.0</td><td>220.1</td><td>218.4</td><td>218.3</td><td>216.2</td><td>218.3</td></tr><tr><td>18</td><td>11.1</td><td>11.7</td><td>11.7</td><td>12.3</td><td>13.8</td><td>14.6</td><td>14.6</td><td>11.5</td><td>14.1</td></tr><tr><td>19</td><td>11.5</td><td>12.8</td><td>11.6</td><td>18.4</td><td>18.7</td><td>18.3</td><td>18.7</td><td>18.7</td><td>18.7</td></tr></table>
|
ffbb697875bdd85b7b287694a0b1765480a0bc7a9d23544d6f12927798a3cb36.png
|
complex
|
<table><tr><td rowspan="2">Variables</td><td colspan="3">Univariate analysis</td></tr><tr><td>HR</td><td>95% CI</td><td>P</td></tr><tr><td>Age (< 65 vs. ≥65)</td><td>1.47</td><td>0.68–3.17</td><td>NS</td></tr><tr><td>Gender (female vs. male)</td><td>0.74</td><td>0.29–1.84</td><td>NS</td></tr><tr><td>Stage (I vs. II vs. III)</td><td>1.64</td><td>1.00–2.69</td><td>0.049</td></tr><tr><td>Histology (adeno vs. other)</td><td>1.50</td><td>0.69–3.27</td><td>NS</td></tr><tr><td>Lymph node status (negative vs. positive)</td><td>2.09</td><td>0.95–4.60</td><td>NS</td></tr><tr><td>pT status (pT1a-2b vs. pT3–4)</td><td>2.65</td><td>1.25–5.62</td><td>0.011</td></tr><tr><td>Differentiation (poor vs. well-moderate)</td><td>0.80</td><td>0.37–1.75</td><td>NS</td></tr><tr><td>Smoking (smokers vs. nonsmokers)</td><td>0.48</td><td>0.18–1.23</td><td>NS</td></tr><tr><td>COPD (present vs. absent)</td><td>1.17</td><td>0.54–2.55</td><td>NS</td></tr><tr><td>M1 macrophages in islets (high vs. low)</td><td>2.83</td><td>1.20–6.68</td><td>0.017</td></tr><tr><td>M1 macrophages in stroma (high vs. low)</td><td>1.91</td><td>0.86–4.25</td><td>NS</td></tr><tr><td>Total M1 macrophages (high vs. low)</td><td>1.43</td><td>0.63–3.21</td><td>NS</td></tr><tr><td>M2 macrophages in islets (high vs. low)</td><td>1.43</td><td>0.66–1.43</td><td>NS</td></tr><tr><td>M2 macrophages in stroma (high vs. low)</td><td>1.00</td><td>0.73–1.37</td><td>NS</td></tr><tr><td>Total M2 macrophages (high vs. low)</td><td>0.31</td><td>0.13–0.75</td><td>0.009</td></tr><tr><td>IL-10</td><td>0.74</td><td>0.35–1.55</td><td>NS</td></tr><tr><td>TNF-α</td><td>1.16</td><td>0.55–2.45</td><td>NS</td></tr><tr><td>IFN-γ</td><td>0.67</td><td>0.31–1.43</td><td>NS</td></tr></table>
|
d83bc4a7a826ba888f76e21f831421dfa1e4fa5add94bd58993eede811eafcef.png
|
simple
|
<table><tr><td></td><td></td><td>HR (OS)</td><td>lower CI (95%)</td><td>upper CI (95%)</td><td><i>p</i>-value</td></tr><tr><td>Gender</td><td><i>male</i></td><td>1.000</td><td></td><td></td><td><i>0.026</i></td></tr><tr><td></td><td><i>female</i></td><td>0.518</td><td>0.290</td><td>0.925</td><td></td></tr><tr><td>Age</td><td><i>per year</i></td><td>1.022</td><td>0.994</td><td>1.051</td><td><i>0.121</i></td></tr><tr><td>pT</td><td><i>1</i></td><td>1.000</td><td></td><td></td><td><i><0.001</i></td></tr><tr><td></td><td><i>2</i></td><td>3.345</td><td>1.918</td><td>5.834</td><td></td></tr><tr><td></td><td><i>3</i></td><td>1.693</td><td>0.875</td><td>3.276</td><td></td></tr><tr><td></td><td><i>4</i></td><td>2.068</td><td>0.223</td><td>19.211</td><td></td></tr><tr><td>pN</td><td><i>0</i></td><td>1.000</td><td></td><td></td><td><i>0.038</i></td></tr><tr><td></td><td><i>1</i></td><td>1.441</td><td>0.879</td><td>2.361</td><td></td></tr><tr><td></td><td><i>2</i></td><td>0.554</td><td>0.149</td><td>2.057</td><td></td></tr><tr><td></td><td><i>3</i></td><td>6.048</td><td>1.288</td><td>28.387</td><td></td></tr><tr><td>CD3i</td><td><i>high</i></td><td>1.000</td><td></td><td></td><td><i>0.011</i></td></tr><tr><td></td><td><i>low</i></td><td>1.925</td><td>1.159</td><td>3.200</td><td></td></tr><tr><td></td><td></td><td>HR (OS)</td><td>lower CI (95%)</td><td>upper CI (95%)</td><td>p-value</td></tr><tr><td>Gender</td><td><i>male</i></td><td>1.000</td><td></td><td></td><td><i>0.044</i></td></tr><tr><td></td><td><i>female</i></td><td>0.551</td><td>0.308</td><td>0.985</td><td></td></tr><tr><td>Age</td><td><i>per year</i></td><td>1.026</td><td>0.997</td><td>1.056</td><td><i>0.077</i></td></tr><tr><td>pT</td><td><i>1</i></td><td>1.000</td><td></td><td></td><td><i>0.001</i></td></tr><tr><td></td><td><i>2</i></td><td>3.025</td><td>1.736</td><td>5.272</td><td></td></tr><tr><td></td><td><i>3</i></td><td>1.723</td><td>0.893</td><td>3.325</td><td></td></tr><tr><td></td><td><i>4</i></td><td>2.962</td><td>0.343</td><td>25.556</td><td></td></tr><tr><td>pN</td><td><i>0</i></td><td>1.000</td><td></td><td></td><td><i>0.040</i></td></tr><tr><td></td><td><i>1</i></td><td>1.471</td><td>0.892</td><td>2.426</td><td></td></tr><tr><td></td><td><i>2</i></td><td>0.602</td><td>0.168</td><td>2.163</td><td></td></tr><tr><td></td><td><i>3</i></td><td></td><td>5.952</td><td>1.269</td><td><i>27.904</i></td></tr><tr><td>CD3i</td><td><i>diffuse</i></td><td>1.000</td><td></td><td></td><td><i>0.010</i></td></tr><tr><td>Distribution</td><td><i>focal</i></td><td>1.941</td><td>1.173</td><td>3.210</td><td></td></tr><tr><td></td><td></td><td>HR (OS)</td><td>lower CI (95%)</td><td>upper CI (95%)</td><td>p-value</td></tr><tr><td>Gender</td><td><i>male</i></td><td>1.000</td><td></td><td></td><td><i>0.088</i></td></tr><tr><td></td><td><i>female</i></td><td>0.597</td><td>0.329</td><td>1.080</td><td></td></tr><tr><td>Age</td><td><i>per year</i></td><td>1.022</td><td>0.995</td><td>1.049</td><td><i>0.112</i></td></tr><tr><td>pT</td><td><i>1</i></td><td>1.000</td><td></td><td></td><td><i><0.001</i></td></tr><tr><td></td><td><i>2</i></td><td>3.415</td><td>1.978</td><td>5.895</td><td></td></tr><tr><td></td><td><i>3</i></td><td>1.956</td><td>1.013</td><td>3.777</td><td></td></tr><tr><td></td><td><i>4</i></td><td>5.081</td><td>0.529</td><td>48.760</td><td></td></tr><tr><td>pN</td><td><i>0</i></td><td>1.000</td><td></td><td></td><td><i>0.048</i></td></tr><tr><td></td><td><i>1</i></td><td>1.248</td><td>0.773</td><td>2.014</td><td></td></tr><tr><td></td><td><i>2</i></td><td>0.388</td><td>0.105</td><td>1.432</td><td></td></tr><tr><td></td><td><i>3</i></td><td>5.210</td><td>1.110</td><td>24.457</td><td></td></tr><tr><td>PD-L1 TCs</td><td><i>high</i></td><td>1.000</td><td></td><td></td><td><i>0.026</i></td></tr><tr><td></td><td><i>low</i></td><td>1.801</td><td>1.074</td><td>3.021</td><td></td></tr></table>
|
20b1e4b02958a67d0a527bf67802df7dcc9f8860fce7127f76b20590e21cd54a.png
|
simple
|
<table><tr><td>Characteristics (Total <i>n</i> = 126)</td><td></td></tr><tr><td>Maternal</td><td></td></tr><tr><td>Age, year</td><td>32.8 ± 5.0</td></tr><tr><td>Ethnicity</td><td></td></tr><tr><td>European</td><td>104 (83%)</td></tr><tr><td>Maori</td><td>8 (6%)</td></tr><tr><td>Pacific</td><td>1 (1%)</td></tr><tr><td>Other</td><td>13 (10%)</td></tr><tr><td>Skin color <sup>2</sup></td><td></td></tr><tr><td>Very light</td><td>67 (53%)</td></tr><tr><td>Light</td><td>51 (41%)</td></tr><tr><td>Intermediate</td><td>5 (4%)</td></tr><tr><td>Dark</td><td>3 (2%)</td></tr><tr><td>Primiparous</td><td>37 (29%)</td></tr><tr><td>Tertiary education <sup>3</sup></td><td>90 (71%)</td></tr><tr><td>Pre-pregnancy BMI, kg/m<sup>2</sup> Primiparous</td><td>25.0 ± 6.2</td></tr><tr><td>Smoker</td><td>9 (7%)</td></tr><tr><td>Antenatal vitamin D supplement use <sup>4</sup></td><td>35 (28%)</td></tr><tr><td>Supplement intake IU/day <sup>4</sup></td><td></td></tr><tr><td>Consumers only</td><td>339 ± 269</td></tr><tr><td>Infant</td><td></td></tr><tr><td>Gestation, week</td><td>39.3 ± 1.1</td></tr><tr><td>Gender, male</td><td>61 (48%)</td></tr><tr><td>Birth weight, g</td><td>3506 ± 495</td></tr><tr><td>Birth Season</td><td></td></tr><tr><td>Spring</td><td>30 (24%)</td></tr><tr><td>Summer</td><td>28 (22%)</td></tr><tr><td>Autumn</td><td>28 (22%)</td></tr><tr><td>Winter</td><td>40 (32%)</td></tr><tr><td>Skin color <sup>2</sup></td><td></td></tr><tr><td>Very light</td><td>2 (2%)</td></tr><tr><td>Light</td><td>64 (50%)</td></tr><tr><td>Intermediate</td><td>51 (40%)</td></tr><tr><td>Dark</td><td>9 (7%)</td></tr><tr><td>Exclusive breast feeding <sup>5</sup></td><td>90 (71%)</td></tr><tr><td>Breastfeeding at week 20</td><td>110 (87%)</td></tr><tr><td>Infant vitamin D intake, <sup>6</sup> IU/day</td><td></td></tr><tr><td>Consumers only</td><td>96 ± 146</td></tr></table>
|
46ac0b0fd9a1a6dd4ca7bc05d300092b3e6022569b5ac5603d3104de156f5825.png
|
complex
|
<table><tr><td>Primer</td><td>Sequence (5' - 3')</td><td>Product size</td><td>Position in coding sequence</td><td>Reference</td></tr><tr><td>erm(A)-F</td><td>CCCGAAAAATACGCAAAATTTCAT</td><td>590</td><td>15-38</td><td>[23]</td></tr><tr><td>erm(A)-R</td><td>CCCTGTTTACCCATTTATAAACG</td><td></td><td>604-582</td><td></td></tr><tr><td>erm(B)-F</td><td>TGGTATTCCAAATGCGTAATG</td><td>745</td><td>203-183</td><td></td></tr><tr><td>erm(B)-R</td><td>CTGTGGTATGGCGGGTAAGT</td><td></td><td>541-522</td><td></td></tr><tr><td>mef(A)-F*</td><td>CAATATGGGCAGGGCAAG</td><td>317</td><td>38-55</td><td></td></tr><tr><td>mef(A)-R*</td><td>AAGCTGTTCCAATGCTACGG</td><td></td><td>352-333</td><td></td></tr><tr><td>tet(M)-F</td><td>GTGGACAAAGGTACAACGAG</td><td>406</td><td>106-125</td><td></td></tr><tr><td>tet(M)-R</td><td>CGGTAAAGTTCGTCACACAC</td><td></td><td>511-492</td><td></td></tr><tr><td>tet(O)- F</td><td>AACTTAGGCATTCTGGCTCAC</td><td>515</td><td>13-43</td><td></td></tr><tr><td>tet(O)- R</td><td>TCCCACTGTTCCATATCGTCA</td><td></td><td>527-507</td><td></td></tr><tr><td>tet(K)-F</td><td>GATCAATTGTAGCTTTAGGTGAAGG</td><td>155</td><td>344-368</td><td></td></tr><tr><td>tet(K)-R</td><td>TTTTGTTGATTTACCAGGTACCATT</td><td></td><td>498-474</td><td></td></tr><tr><td>tet(L)-F</td><td>TGGTGGAATGATAGCCCATT</td><td>229</td><td>384-403</td><td></td></tr><tr><td>tet(L)-R</td><td>CAGGAATGACAGCACGCTAA</td><td></td><td>612-593</td><td></td></tr><tr><td>16S-rDNA-F</td><td>GAGTACGACCGCAAGGTTGA</td><td>100</td><td>886-905</td><td></td></tr><tr><td>16S-rDNA -R</td><td>CTGGTAAGGTTCTTCGCGTTG</td><td></td><td>985-964</td><td></td></tr><tr><td>ss-Tn<i>916</i>-1</td><td>GCCATGACCTATCTTATA</td><td>476</td><td>16083-16100</td><td>[24]</td></tr><tr><td>ss-Tn<i>916</i>-2</td><td>CTAGATTGCGTCCAA</td><td></td><td>16559-16545</td><td></td></tr><tr><td>tet(32)For</td><td>GAACCAGATGCTGCTCTT</td><td>620</td><td>619-637</td><td>[28]</td></tr><tr><td>Tet(32)Rev</td><td>CATAGCCACGCCCACATGAT</td><td></td><td>1239-1220</td><td></td></tr><tr><td>SScps2J-F</td><td>CAAACGCAAGGAATTACGGTATC</td><td>236</td><td>209-231</td><td>[29,30]</td></tr><tr><td>SScps2J-R</td><td>CATTTCCTAAGTCTCGCACC</td><td></td><td>445-426</td><td></td></tr><tr><td>tet(L)Ng-F</td><td>TCGTTAGCGTGCTGTCATTC</td><td>698</td><td>680-700</td><td>[31]</td></tr><tr><td>tet(L)-R-pDG364</td><td>CTTAGAAATCCCTTTGAGAAT</td><td></td><td>1378-1358</td><td>This study</td></tr><tr><td>tet(W)- F</td><td>TTGGAATTCTTGCCCATGTAGACGC</td><td>1872</td><td>18-42</td><td>This study</td></tr><tr><td>tet(W)- R</td><td>TTGTCCAGGCGGTTGTTTGGAC</td><td></td><td>1889-1868</td><td></td></tr><tr><td>tet(W)-F-HN</td><td>GGTGCAGTTGGAGGTTGTTT</td><td>410</td><td>1179-1198</td><td></td></tr><tr><td>tet(W)-R-HN</td><td>CCTTCAATGCCTGTTCCAAT</td><td></td><td>1569-1588</td><td></td></tr><tr><td>tet(O)-F-pDG364</td><td>ATGAAAATAATTAACTTAGG</td><td>1920</td><td>1-19</td><td></td></tr><tr><td>tet(O)-R-pDG364</td><td>TTAAGCTAACTTGTGGAACA</td><td></td><td>1920-1901</td><td></td></tr><tr><td>ss-tet(M)-whole-F</td><td>ACAGACAAAGAACTATCCTTAATG</td><td>2500</td><td>419-396</td><td></td></tr><tr><td>ss-tet(M)-whole-R</td><td>GTACCCAGTTTAAGAATACCTTTATC</td><td></td><td>161-136</td><td></td></tr><tr><td colspan="5">Additional primers used for sequencing</td></tr><tr><td>tet(O)-2-F</td><td>TTCAAGACGCCTCCCTGTTC</td><td></td><td>679-698</td><td>This study</td></tr><tr><td>tet(O)-2-R</td><td>ATTTGGCGGGACTTCTATGTGG</td><td></td><td>1318-1296</td><td></td></tr><tr><td>ss-tet(M)-Fseq1</td><td>GTTAAATCACTACGATAT</td><td></td><td>1763-1745</td><td></td></tr><tr><td>ss-tet(M)-Rseq1</td><td>ATAGTGTTCTTGGAGATA</td><td></td><td>906-929</td><td></td></tr><tr><td>ss-tet(M)-Fseq2</td><td>GTATAATTTCATGTGTCG</td><td></td><td>1162-1144</td><td></td></tr><tr><td>ss-tet(M)-Rseq2</td><td>AGATGGCGTACAAGCACA</td><td></td><td>305-323</td><td></td></tr><tr><td>ss-PAI-P8-tet(M)-R</td><td>GCCCTTTTGGGTTTTTGAAT</td><td></td><td>-33- -14</td><td></td></tr><tr><td>ss-PAItetM-P9over F</td><td>GGGAATCCCCATTTTCCTAA</td><td></td><td>366-347</td><td></td></tr></table>
|
43c5c1b168f38796d1e0eb2488a314b366873a759169d6ab5e39b1fc8358c050.png
|
complex
|
<table><tr><td> </td><td>theoretical</td><td colspan="2">measured</td></tr><tr><td> </td><td>mass content</td><td>mass content</td><td>molar composition</td></tr><tr><td>C</td><td>53.0 ± 0.9%</td><td>47.3 ± 0.1%</td><td>1</td></tr><tr><td>H</td><td>6.6 ± 0.1%</td><td>6.83 ± 0.04%</td><td>1.733</td></tr><tr><td>O</td><td>23.2 ± 0.7%</td><td>32.0 ± 0.8%</td><td>0.508</td></tr><tr><td>N</td><td>16.7 ± 0.2%</td><td>12.7 ± 0.5%</td><td>0.23</td></tr><tr><td>S</td><td>1.6 ± 0.5%</td><td>1.00 ± 0.05%</td><td>0.008</td></tr><tr><td>Total</td><td>100.1 ± 2.4%</td><td>99.7 ± 0.6%</td><td> </td></tr></table>
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.